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Background: Myeloma causes profound immunodeficiency and recurrent serious infections. There are
approximately 5500 new UK cases of myeloma per annum, and one-quarter of patients will have a serious
infection within 3 months of diagnosis. Newly diagnosed patients may benefit from antibiotic prophylaxis
to prevent infection. However, the use of prophylaxis has not been established in myeloma and may be
associated with health-care-associated infections (HCAIs), such as Clostridium difficile. There is a need to
assess the benefits and cost-effectiveness of the use of antibacterial prophylaxis against any risks in a
double-blind, placebo-controlled, randomised clinical trial.
Objectives: To assess the risks, benefits and cost-effectiveness of prophylactic levofloxacin in newly
diagnosed symptomatic myeloma patients.
Design: Multicentre, randomised, double-blind, placebo-controlled trial. A central telephone
randomisation service used a minimisation computer algorithm to allocate treatments in a 1 : 1 ratio.
Setting: A total of 93 NHS hospitals throughout England, Northern Ireland and Wales.
Participants: A total of 977 patients with newly diagnosed symptomatic myeloma.
Intervention: Patients were randomised to receive levofloxacin or placebo tablets for 12 weeks at the
start of antimyeloma treatment. Treatment allocation was blinded and balanced by centre, estimated
glomerular filtration rate and intention to give high-dose chemotherapy with autologous stem cell
transplantation. Follow-up was at 4-week intervals up to 16 weeks, with a further follow-up at 1 year.
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Main outcome measures: The primary outcome was to assess the number of febrile episodes (or deaths)
in the first 12 weeks from randomisation. Secondary outcomes included number of deaths and infection-
related deaths, days in hospital, carriage and invasive infections, response to antimyeloma treatment and
its relation to infection, quality of life and overall survival within the first 12 weeks and beyond.
Results: In total, 977 patients were randomised (levofloxacin, n = 489; placebo, n = 488). A total of 134
(27%) events (febrile episodes, n = 119; deaths, n = 15) occurred in the placebo arm and 95 (19%) events
(febrile episodes, n = 91; deaths, n = 4) occurred in the levofloxacin arm; the hazard ratio for time to first
event (febrile episode or death) within the first 12 weeks was 0.66 (95% confidence interval 0.51 to 0.86;
p = 0.002). Levofloxacin also reduced other infections (144 infections from 116 patients) compared with
placebo (179 infections from 133 patients; p-trend of 0.06). There was no difference in new acquisitions
of C. difficile, methicillin-resistant Staphylococcus aureus and extended-spectrum beta-lactamase Gram-
negative organisms when assessed up to 16 weeks. Levofloxacin produced slightly higher quality-adjusted
life-year gains over 16 weeks, but had associated higher costs for health resource use. With a median
follow-up of 52 weeks, there was no significant difference in overall survival (p = 0.94).
Limitations: Short duration of prophylactic antibiotics and cost-effectiveness.
Conclusions: During the 12 weeks from new diagnosis, the addition of prophylactic levofloxacin to active
myeloma treatment significantly reduced febrile episodes and deaths without increasing HCAIs or carriage.
Future work should aim to establish the optimal duration of antibiotic prophylaxis and should involve the
laboratory investigation of immunity, inflammation and disease activity on stored samples funded by the
TEAMM (Tackling Early Morbidity and Mortality in Myeloma) National Institute for Health Research Efficacy
and Mechanism Evaluation grant (reference number 14/24/04).
Trial registration: Current Controlled Trials ISRCTN51731976.
Funding details: This project was funded by the NIHR Health Technology Assessment programme and will
be published in full in Health Technology Assessment; Vol. 23, No. 62. See the NIHR Journals Library
website for further project information.
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Plain English summary
What is the problem?
Myeloma is a type of cancer that develops from cells in the bone marrow, called plasma cells, which are
part of the immune system. Because myeloma affects the immune system, people who have it are at
greater risk of picking up infections. This risk is higher at the start of antimyeloma therapy when the
myeloma is active.
What did the study do?
The trial looked to see if the risk of getting an infection can be reduced, rather than waiting to see if an
infection developed and then treating it. An antibiotic already used all over the world, called levofloxacin
was tested. Half of the patients (n = 489) took levofloxacin for 12 weeks and the other half (n = 488) were
given a dummy tablet (placebo). The aim was to see if taking levofloxacin at the start of antimyeloma
therapy reduced the risk of getting an infection. Alongside this, we evaluated three important groups of
antibiotic-resistant bacteria to see whether or not the use of preventative levofloxacin increased the
number of these resistant bacteria living in the body.
In addition, the overall survival, economic impacts and the impact of using preventative antibiotics on
patients’ quality of life and response to antimyeloma treatment were evaluated.
What did the study find?
During the 12 weeks from new diagnosis of myeloma, the addition of prophylactic levofloxacin to active
myeloma treatment significantly reduced the number of febrile episodes and deaths [134 (febrile episodes
alone, n = 112; febrile episodes plus death, n = 7; deaths alone, n = 15) out of 488 (27%) placebo patients
vs. 95 (febrile episodes alone, n = 87; febrile episodes plus death, n = 4; deaths alone, n = 4) out of 489
(19%) levofloxacin patients; p = 0.002] without increasing antibiotic-resistant bacteria.
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Scientific summary
Background
Myeloma is a cancer of bone marrow plasma cells that causes profound immunosuppression. There is a
high early-death rate, with the biggest single cause being infection. Recent improvements in overall
survival in myeloma mean that prevention of early death has become more pressing, especially as early
death affects all prognosis groups.
Antibiotic prophylaxis is likely to be the single most effective measure to prevent early death in myeloma
patients. Treatment with antibiotics once an infection is established is probably not sufficient, as the
early-death rate in older patients has remained constant over a 20-year period, despite improvements in
supportive care. The use of antibiotic prophylaxis is evidence-based established practice in some areas of
medicine (e.g. neutropenia, human immunodeficiency virus) but the recent rise in health care-associated
infections (HCAIs) has raised concern about the risks of antibiotic prophylaxis. Although the benefits are
well established, there is concern that clinicians are withholding antibiotic prophylaxis because of fears of
HCAI. Extrapolating from current data, the benefits of prophylaxis are likely to outweigh the risks of HCAI.
However, there has not been a large trial looking at the benefits of antibiotic prophylaxis compared with
the risks of HCAI. Examination of the organisms causing infection in myeloma suggests that levofloxacin,
given for the first 12 weeks, is the best antibiotic for prophylaxis.
Reducing infection in the first 3 months from diagnosis may increase the myeloma response rate primarily by
reducing the number of interruptions of antimyeloma treatment. There is also some evidence for a role for
infections driving myeloma pathogenesis directly, although further proof is required to confirm this effect in vivo.
Objectives
To assess the risks, benefits and cost-effectiveness of levofloxacin in newly diagnosed symptomatic
myeloma by means of a prospective, multicentre, randomised, double-blind, placebo-controlled trial.
End points
Primary outcome from start of trial treatment to 12 weeks
l Time to first febrile episode or death.
A febrile episode is identified and counted by a single oral temperature of ≥ 38 °C (recorded either by a
health-care professional or by the patient/carer, provided that the patient/carer has been trained and
assessed as being competent in temperature taking) and by that patient then being given anti-infectives.
Secondary outcomes from start of trial treatment to 12 weeks
l Number of deaths and infection-related deaths.
l Number of days in hospital.
l Number of days in hospital on anti-infectives.
l Carriage and invasive infections with Staphylococcus aureus, Clostridium difficile and extended-
spectrum beta-lactamase (ESBL) coliforms.
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l Patient characteristics, steroid use and indices of immunocompetence and their relation to colonisation
by, and development of, infection with S. aureus, C. difficile and ESBL coliforms, non-HCAIs and Eastern
Cooperative Oncology Group (ECOG) performance status.
l Number of clinically documented total infections, episodes of severe sepsis (Common Terminology
Criteria for Adverse Events grade 3 or 4) and suspected infections (defined as any episode in which the
patient was given anti-infective treatment for a suspected infection and any recorded temperature of
< 38 °C).
l Incidence of microbiologically proven infections, the pathogens and their susceptibility to antibacterials.
l Number of days on anti-infective therapy for treatment of infection.
l Response to antimyeloma therapy and its relationship to infection.
Secondary outcomes from start of trial treatment to beyond 12 weeks
l Carriage and invasive infections with S. aureus, C. difficile and ESBL coliforms between 12 and 16 weeks
to assess for delayed effects from the intervention, which is stopped at 12 weeks.
l Response to antimyeloma therapy at 16 weeks.
l Quality of life (QoL).
l Health economics.
l Overall survival.
Trial design and methodology
Multicentre, randomised, double-blind, placebo-controlled trial.
Patients were randomised to receive levofloxacin or placebo tablets for 12 weeks at the start of
antimyeloma treatment. Treatment allocation was blinded and balanced by centre, estimated glomerular
filtration rate (eGFR) and intention to give high-dose chemotherapy with autologous stem cell transplant.
A central randomisation telephone service used a minimisation algorithm to generate a trial number and a
drug pack number for each patient and allocate treatments in a 1 : 1 ratio. All investigators, patients and
trial co-ordination staff were blinded to the treatment allocation. The levofloxacin and placebo tablets
were packaged in coded, but otherwise identical, blister packs. Neither the patient nor the clinical team
responsible for the patient’s care could break the treatment code. The treatment code could be broken
only by the Emergency Scientific and Medical Services team at Guy’s and St Thomas’ Hospital.
Treatment and investigations
In the experimental arm, patients were given 500 mg of levofloxacin orally, once daily, for 12 weeks
(dose reduced in patients with renal impairment).
In the control arm, patients were given placebo orally, once daily, for 12 weeks (dose reduced in patients
with renal impairment).
All patients received antimyeloma treatment and supportive care including bisphosphonates as per
standard practice. If it was intended to give patients high-dose chemotherapy with autologous stem cell
transplant, this information was collected at randomisation and taken into account during stratification.
When patients were within 14 days either side of starting a programme of antimyeloma treatment,
they received two levofloxacin (dose of 250 mg) or placebo tablets daily for 12 weeks. The start of the
antimyeloma treatment was determined as the start of high-dose steroids or chemotherapy, whichever
came first.
Estimated glomerular filtration rate provided locally, where possible, was assessed at baseline and
reassessed at each scheduled trial visit to identify changes in renal function that would necessitate a
change in dose of levofloxacin. It is recommended that eGFR was assessed within the 7- to 14-day period
SCIENTIFIC SUMMARY
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prior to randomisation. Those patients with an eGFR of > 50 ml/minute/1.73 m2 took two tablets once per
day (dose of 500 mg), patients with an eGFR of 20–50 ml/minute/1.73 m2 took one tablet daily (dose of
250 mg) and patients with an eGFR of < 20 ml/minute/1.73 m2 took half a tablet daily (dose of 125 mg).
Both the active and placebo tablets were identical in breakable form. Dose reductions were recorded on
the front of the patient diary, which was provided at each trial visit in conjunction with a review of eGFR.
At entry and at 4, 8, 12 and 16 weeks, central laboratory analysis of stool samples and nasal swabs for
microbiology, blood and urine for paraprotein response and immune function were collected. QoL [is
assessed via the EuroQoL-5 Dimensions (EQ-5D), European Organization for Research and Treatment of
Cancer Quality of Life Questionnaire-C30 and the Hospital Anxiety and Depression Scale] and health
economics data were collected via the patient diaries.
Sample size determination
The final number of patients recruited was 977 (randomised to levofloxacin, n = 489; randomised to
placebo, n = 488). The primary outcome measure was time to first febrile episode or death from all causes,
using a Kaplan–Meier survival curve and log-rank analysis. Assuming that the proportion of patients
experiencing a febrile episode or death is 30% in the first 3 months and that prophylactic antibacterials
would reduce that rate to 20%, then recruiting 800 patients into the trial (400 patients in each arm)
would allow differences in excess of 10% to be detected with 90% power using a two-sided test at the
5% level of significance. Recruiting 1000 patients into the trial (500 in each arm) would allow differences
in excess of 8% to be detected with a 90% power using a two-sided test at the 5% level of significance.
Recruiting 1000 patients would also allow detection of a levofloxacin-induced threefold increase in the rate
of C. difficile-positive stools from 5% to 15% from entry to the trial to 12 weeks, with a 95% power and
a 5% level of significance (two-sided test).
Other analyses included the incidence of suspected infections by site, severity and therapy; response to
antimyeloma therapy and its relationship to infection; patient characteristics and indices of immunocompetence
(blood leucocyte subset enumeration and antibacterial antibody titres) as prognostic markers for colonisation
and invasive infection by antibiotic-resistant organisms; health economics; and QoL (by daily diary card and
4-weekly EQ-5D up to 16 weeks). With 1000 patients, reliable estimates can be reported for these secondary
outcomes.
Follow-up
Patients were followed up at 4-weekly intervals up to 16 weeks, with a further follow-up at 1 year.
Long-term follow-up will be collected for patients until the end of the trial by flagging with the Office for
National Statistics and requesting copies of death certificates.
Key inclusion criteria
Patients were eligible for this trial if:
l they were aged ≥ 21 years and able to give informed consent
l they had newly diagnosed symptomatic myeloma based on internationally agreed criteria
l there was an intention to treat their myeloma actively
l they were within 14 days of starting, and no more than 14 days into, a programme of
antimyeloma treatment
l they were able to provide written informed consent.
Key exclusion criteria
Patients were ineligible for this trial if they:
l had a contraindication to levofloxacin
l were women of childbearing age who were not willing to use appropriate methods of contraception to
prevent pregnancy or women who were breastfeeding
l were thought to have a mandatory requirement for antibacterial prophylaxis.
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l had received previous treatment for myeloma, except for the following –
¢ local radiotherapy to relieve bone pain or spinal cord compression
¢ prior bisphosphonate treatment
¢ previous (< 5 years since diagnosis) or concurrent active malignancies except surgically removed
basal or squamous cell carcinoma of the skin, treated carcinoma in situ of the breast or cervix, or
incidental histological finding of prostate cancer (tumour, node, metastasis stage of T1a or T1b)
[patients with remote histories (> 5 years) of other cured malignancies could be entered].
SCIENTIFIC SUMMARY
Results
Tackling Early Morbidity and Mortality in Myeloma (TEAMM) recruited 977 patients between August 2012 
and April 2016 from 93 centres in the UK. The median age of participants was 67 years, 63% were 
male, 76% had an eGFR of > 50 ml/minute/1.73 m2, 54% had planned high-dose chemotherapy with 
autologous stem cell transplantation, 76% had ECOG performance status 0 or 1 and 71% presented with 
bone disease. In total, 977 patients were randomised (levofloxacin, n = 489; placebo, n = 488); 24 patients 
withdrew before their first assessment and were censored at their date of withdrawal for the primary 
outcome.
A total of 134 (27%) events (febrile episode alone, n = 112; febrile episodes plus death, n = 7; deaths 
alone, n = 15) occurred in the placebo arm and 95 (19%) events (febrile episode alone, n = 87; febrile 
episodes plus death, n = 4; deaths alone, n = 4) occurred in the levofloxacin arm. The hazard ratio (HR) for 
time to first event (febrile episode or death) within the first 12 weeks was 0.66 [95% confidence interval 
(CI) 0.51 to 0.86; p = 0.002]. Cox regression models adjusting for slight imbalances between baseline 
factors did not identify any significant independent prognostic factors in the presence of treatment
(adjusted HR 0.73, 95% CI 0.53 to 0.99; p = 0.04) in favour of levofloxacin.
Levofloxacin also reduced other infections (144 infections from 116 patients) compared with placebo
(179 infections from 133 patients) (p-trend of 0.06). There was no difference in new acquisitions of C. 
difficile, methicillin-resistant S. aureus and ESBL Gram-negative organisms when assessed up to 16 weeks. 
Levofloxacin produced slightly higher quality-adjusted life-year gains over 16 weeks compared to placebo but 
had associated higher costs for health resource use. With a median follow-up of 52 weeks, there was no 
significant difference in overall survival (p = 0.94).
Conclusions
During the 12 weeks from new diagnosis, the addition of prophylactic levofloxacin to active myeloma 
treatment significantly reduced febrile episodes and deaths without increasing HCAIs or carriage.
Trial registration
This trial is registered as ISRCTN51731976.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National 
Institute for Health Research.
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Chapter 1 Introduction
Background
Myeloma is a cancer of bone marrow plasma cells that causes anaemia, skeletal fractures, renal failure and
profound immunodeficiency. There are approximately 5500 new cases of myeloma in the UK per annum.1
However, the overall prevalence is increasing, given the improved survival rates over the past four decades.2
The median age at presentation is approximately 70 years and only 15% of patients are aged < 60 years.
Myeloma has a higher incidence in African-Caribbean ethnic groups than in Caucasians, but there are few
other distinctive epidemiological features.3 The majority of cases present de novo, but it is now recognised
that this is preceded by an asymptomatic monoclonal gammopathy of undetermined significance phase in
virtually all patients.4
Myeloma causes profound immunodeficiency and recurrent serious infections. One-quarter of patients will
have a serious infection within 3 months of diagnosis. Ten per cent of patients die within the first 60 days
of diagnosis, with bacterial infection directly causing 45% of these deaths.5 Recent advances in antimyeloma
treatment have improved overall survival significantly, yet this high early-death rate remains little changed,
affecting all prognostic groups. Patients who may have survived long term with current antimyeloma
treatment are dying soon after diagnosis, with the biggest single cause being bacterial infection. Therefore,
newly diagnosed myeloma patients may benefit from antibacterial prophylaxis to prevent infection, hospital
admission and early death. Reducing infection may also improve response to antimyeloma treatment by
reducing interruptions of antimyeloma treatment and reducing immune responses to infection that promote
myeloma cell survival and growth. In patients with other causes of immunodeficiency, such as neutropenia,
asplenia, human immunodeficiency virus infection or reflux nephropathy, the importance of prophylactic
antibiotics to prevent infection is well established and the administration of prophyactic antibiotics is
common practice in the NHS. However, their usefulness in myeloma has not been established. Furthermore,
some of the studies that established the use of antibacterial prophylaxis in other conditions predate the
current rise in health care-associated infections (HCAIs), such as Clostridium difficile. The data from these
older trials may not reflect current risks associated with antibiotic prophylaxis and so there is a need to
reassess the effect of antibiotic prophylaxis on HCAI.
Existing research
Large studies in Europe and North America have identified a high mortality rate (8–20%) in the first
3 months following a diagnosis of myeloma, with bacterial infection being the single biggest identifiable
cause.5–8 Analysis of 3107 myeloma patients registered into UK Medical Research Council (MRC) trials from
1980 to 2002 showed that 10% of patients died within 60 days of trial entry and that 45% of these
deaths were directly attributable to bacterial infection.5
In the ‘MRC myeloma 9’ trial,9 which recruited between 2003 and 2008, overall incidence of infection in
non-intensively treated patients was 214 out of 692 (30.9%), with a median time to infection from first
diagnosis of myeloma of 43 days. Recent advances in antimyeloma treatment have improved survival
significantly, yet this high early-death rate has remained unchanged for > 30 years and affects all
prognostic groups. This suggests that current supportive care strategies, including the treatment of an
infection once established, may be insufficient. Streptococcus pneumoniae, Staphylococcus aureus and
Escherichia coli are the most frequent types of bacterial infection in myeloma patients.10–15 The risk of these
infections is associated with myeloma disease activity and abates as the disease is brought under control
with antimyeloma treatment.
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The mechanism by which the risk of infection is increased in the presence of active myeloma disease is not
well understood. Over 90% of 3218 MRC myeloma trial patients had reduced levels of normal antibodies,16
and these patients’ susceptibility to bacterial chest infections is characteristic of antibody deficiency. However,
a previous MRC trial (MacLennan ICM, Chapman C, Hazelwood M, North J. University of Birmingham, 1993)
of immunoglobulin G (IgG) replacement treatment (double-blind, randomised, placebo-controlled trial of
203 patients) did not significantly reduce mortality or morbidity from infection in the first 3 months after
diagnosis, despite effectively increasing total serum IgG levels and titres against specific bacterial pathogens.
Myeloma patients are not usually neutropenic at presentation, and, in one study, only 11 out of 135 myeloma
patients dying of infection within 60 days of diagnosis had a neutrophil count of < 2.0 × 109/l.5 Other factors
associated with active myeloma disease that might increase the risk of infection include low serum complement
component 4 (C4) levels, increased transforming growth factor beta and increased interleukin 10.17
Antibacterial prophylaxis is an obvious strategy to prevent infection, hospital admission and early death in
these patients. Of the only two trials18,19 of prophylactic antibiotics in early myeloma, one prospective
randomised study18 was with co-trimoxazole in the early 1990s. This showed a reduction in bacterial
infections with prophylactic co-trimoxazole (2/28 treated vs. 11/26 control patients) but the sample size was
too small to detect reduced mortality. A recent trial19 of 212 patients given ciprofloxacin, co-trimoxazole
and placebo found no difference in the rate of infection. This study19 was, again, underpowered to show
differences in infection and mortality. The low incidence of all infections (22%) in this study raises the
question whether or not the patients were representative of the normal myeloma clinic population. A
retrospective analysis20 of infections in 202 patients on new therapies found that 40% of patients had an
infection within 6 months, with 80% of severe infections (16% of patients) occurring in the first cycle of
treatment. Antibiotic prophylaxis was effective in preventing infections in those patients with surrogate
markers of high tumour burden (monoclonal band of > 3 g/dl, platelet count of < 130 × 109/l), but not in
those without these parameters.
Antibiotic prophylaxis should be active against the bacteria commonly causing infections in the patients
treated, should be given as ideally oral, once-daily medication to maximise adherence and efficacy, and
should have few side effects. For all of the above reasons, the quinolones, particularly ciprofloxacin and
levofloxacin, are now the most commonly used antibiotics for chemoprophylaxis.
Although less than one-tenth of myeloma patients dying of infection are neutropenic, the immunosuppressed
state in both neutropenic and early myeloma patients leads to bacterial infection.5 The common organisms causing
infection in myeloma are E. coli, S. pneumoniae, Klebsiella spp., S. aureus, Pseudomonas spp., Haemophilus spp.
and Proteus spp. These are similar to those organisms seen in neutropenic infections, although Gram-negative
infections are more common in neutropenia. Thus, studies on the use of prophylactic antibiotics active against
the common pathogens that cause infection in neutropenia are pertinent to myeloma patients.
A large meta-analysis21 including 162 studies with 12,599 neutropenic patients found that all antibiotic
prophylaxis significantly reduced the risk of death compared with placebo or no treatment [relative risk (RR)
0.66, 95% confidence interval (CI) 0.55 to 0.79]. Fluoroquinolone prophylaxis was the most effective
and reduced the risk of all-cause mortality (RR 0.52, 95% CI 0.37 to 0.74), as well as of infection-related
mortality, fever, clinically documented infection and microbiologically documented infections. Fluoroquinolone
prophylaxis increased the risk of adverse events (AEs) (RR 1.52, 95% CI 0.79 to 2.92), but these were minor
events. The benefit of reduction in infection-related mortality (RR 0.49, 95% CI 0.31 to 0.77) far outweighed
any mortality from adverse effects because all-cause mortality was still markedly reduced (RR 0.52, 95% CI
0.37 to 0.74). These studies translate into a number needed to treat of 50 (95% CI 34 to 268) in order to
prevent one death from all causes in neutropenic patients.
To date, only two studies22,23 have reported differences in costs, and both showed a cost benefit for prophylaxis.
These studies focused on individual resource use elements, such as the total cost of antibiotics or hospital
inpatient days. None of the trials included a comprehensive cost analysis or a full economic evaluation.
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Levofloxacin prophylaxis may, in addition to preventing infection, improve response to antimyeloma
treatment. Delivery of antimyeloma treatment is often delayed by infection and so reducing infectious
episodes may increase the amount of antimyeloma treatment given. There is epidemiological and laboratory
evidence that the cytokines and inflammatory mediators associated with bacterial infection may promote
the growth of myeloma cells.17 By reducing infections, antibiotic prophylaxis may reduce myeloma growth
and potentiate response to antimyeloma treatment. This will be the first trial to assess these factors.
However, quinolones, along with other antibiotics, are implicated in increased risk of colonisation with
antibiotic-resistant bacteria and invasive infection by those bacteria. These HCAIs have been an ever-increasing
problem to the NHS over the past 10 years, accounting for significant morbidity and mortality. Up to one in
four people carry S. aureus, and C. difficilemay be carried by 1–3% of healthy people.24 Up to 30% of long-term
hospitalised patients may carry C. difficile. There were 36,095 cases of C. difficile-associated diarrhoea in the UK
in 2008–9.24
There is an increasing perception that antibiotic prophylaxis will increase numbers of HCAIs. A Midlands
survey (carried out by the TEAMM trial management group) found that 24 haematologists did not use
antibiotic prophylaxis alongside conventional myeloma chemotherapy, whereas eight haematologists did so
in selected patients (unpublished audit). Half of the haematologists routinely used antibiotic prophylaxis in
patients receiving intensive myeloma chemotherapy. Guidelines for the diagnosis and management of
multiple myeloma published in 2009 by the UK Myeloma Forum3 on behalf of the British Committee for
Standards in Haematology state that:
. . . there is insufficient evidence to recommend the routine use of prophylactic antibiotics (Grade C
recommendation; level IV evidence).
Bird et al.3
There are insufficient data on the relationship between changes in carriage rate of potentially pathogenic
organisms during antibiotic treatment and the risk of subsequent infection with the same organism.
From meta-analysis25 on antibiotic prophylaxis trials in neutropenia, there was no significant increase in
C. difficile infection (7/1250 patients receiving a fluoroquinolone prophylaxis vs. 5/1279 receiving placebo
or no treatment). Furthermore, recruitment to these trials predates Tackling Early Morbidity and Mortality
in Myeloma (TEAMM) and the current problems with HCAIs by > 7 years. Although recent European
guidelines26 recommend fluoroquinolone prophylaxis in severe neutropenia, adherence to this
recommendation is not universal. In trials in which resistance data have been reported, patients on
fluoroquinolones did not develop more infections with pathogens resistant to the drug than patients on
placebo (RR 1.04, 95% CI 0.73 to 1.5). By reducing the number of clinical infections, levofloxacin may
reduce the total amount of antibiotics used in these patients and lessen the emergence of resistance.22
Although the emergence of bacteria resistant to fluoroquinolones can occur in units using fluoroquinolone
antibiotic prophylaxis, there are no clear data on whether or not patients are harmed as a result.27,28
In summary, the above data show that fluoroquinolone prophylaxis in neutropenia is very effective,
but there are concerns about inducing fluoroquinolone-resistant organisms and HCAIs. This supports
the equipoise position for this trial. No substantial trial of antibiotic prophylaxis in myeloma has been
undertaken. The proven efficacy of levofloxacin in neutropenic patients and the sensitivity to levofloxacin
of bacteria that cause infection in myeloma indicate that levofloxacin prophylaxis will also be effective in
myeloma. The higher absolute risk of early death in myeloma (≈10% in the first 12 weeks from diagnosis
in some risk groups) suggests that antibiotic prophylaxis may be even more effective in myeloma than in
neutropenia. As there is a need for such an antibiotic trial in myeloma, it provides an excellent opportunity
to collect data on HCAIs and quantify absolute risk of colonisation and infection during antibiotic
prophylaxis. Data from the proposed trial will help to inform rational decisions about risks and benefits of
antibiotic prophylaxis in many areas of medicine.
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Research objectives
To assess the risks, benefits and cost-effectiveness of levofloxacin in newly diagnosed symptomatic
myeloma by a prospective, multicentre, randomised, double-blind, placebo-controlled trial.
Research hypotheses
Levofloxacin used once daily as antibacterial prophylaxis in newly diagnosed symptomatic myeloma will:
1. reduce the rate of febrile episodes, hospitalisation and death
2. increase response to antimyeloma treatment
3. improve quality of life (QoL) and overall survival.
The trial will also test if levofloxacin affects the carriage of, and invasive infection by, three important
groups of bacteria: (1) C. difficile, (2) S. aureus [including meticillin-resistant Staphylococcus aureus (MRSA)]
and (3) extended-spectrum beta-lactamase (ESBL) coliforms, and will answer the following research
questions:
1. Is the carriage of these organisms increased in patients receiving levofloxacin compared with those
receiving placebo?
2. Is the carriage of these organisms associated with later invasive infections?
3. Does levofloxacin increase the rate of invasive infections by these three groups of organisms?
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Chapter 2 Methods
Trial design
Tackling Early Morbidity and Mortality in Myeloma was a randomised, double-blind, placebo-controlled,
multicentre phase III trial assessing the benefit of antibiotic prophylaxis and its effect on HCAIs in patients
with symptomatic multiple myeloma. Target recruitment was originally 800 patients; however, this was
extended to up to 1000 patients because of a high rate of recruitment and availability of investigational
medicinal product (IMP). Patients were randomised in a 1 : 1 ratio to 500 mg of levofloxacin for 12 weeks
or placebo to match. The primary outcome was time to first febrile episode or death. Secondary outcomes
included, but were not limited to, response to antimyeloma treatment, carriage and invasive infections with
C. difficile, MRSA and ESBL coliforms, QoL and overall survival.
Amendments to the protocol
Listed below are the amendments to the TEAMM protocol that were significant in increasing recruitment potential:
l The original protocol stated that patients had to begin trial treatment within 7 days of commencing
antimyeloma treatment unless they were already on a broad-spectrum antibiotic for treatment of an
infection. Before commencing recruitment, the number of days was increased from 7 to 14 days,
irrespective of antibiotic treatment status. This allowed patients more time to consider the trial and
research staff more time to obtain baseline samples without affecting the scientific integrity of the trial.
l Earlier versions of the protocol requested that a diagnostic skeletal survey be performed before patients
could enter the trial. The protocol was amended prior to recruitment to relax the wording around
diagnostic skeletal surveys. As skeletal surveys are part of the national diagnostic standard for multiple
myeloma, it was felt that this did not need to be mandated and this was removed as a potential barrier
to inclusion if patients had experienced a slightly different diagnostic journey.
l The protocol was changed to make it clear that patients were able to enter the trial even if they were
taking another antibiotic treatment at the time of recruitment. Our lead microbiologist felt that it was
probable that a number of patients would present for randomisation suffering from infections for
which they were receiving antibiotic treatment. As long as there was no contraindication, patients
could begin their trial treatment at the same time as their antibiotic treatment as this is in line with
what is suggested when patients experience infections during the trial. It was felt that this would
maximise the pool of eligible patients as long as details of this treatment were collected at baseline.
l In October 2015, the protocol was amended to allow the trial to recruit up to a further 200 patients as
recruitment had been so successful and there was a surplus of IMP.
l Minor clarifications to eligibility criteria and clarifications on central laboratory testing were submitted
alongside the above amendments.
l The primary end point was ‘number of febrile episodes’ analysed by a Kaplan–Meier curve and log-rank
test (i.e. time-to-event analysis censoring deaths as an event). The primary end point, ‘number of febrile
episodes’, was changed to ‘time to febrile episode’ to make this clear.
These amendments were all approved by the ethics committee.
Ethics and research and development approvals
Favourable opinion was given by National Research Ethics Service Committee West Midlands – Coventry and
Warwickshire on 29 July 2011 (Research Ethics Committee reference number 11/WM/0220). Research and
development (R&D) approval was obtained from University Hospitals Birmingham NHS Foundation Trust on
4 October 2011. Permissions to conduct the trial at each site were obtained from individual NHS trusts.
Participating hospitals are listed in the Acknowledgements. All sites were activated between April 2012 and
August 2015.
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Sponsorship
TEAMM was co-ordinated by the Warwick Clinical Trials Unit (WCTU) at the University of Warwick. The
University of Warwick had a co-sponsorship agreement with the University of Birmingham (acting as lead
sponsor). The University of Birmingham was responsible for the provision of the chief investigator, serious
adverse event (SAE) review, drafting and issuing clinical study site agreements, acting as custodian for trial
samples collected, contracting with third parties and the haematology laboratory analysis. The University
of Warwick was responsible for the administration of the trial, ensuring compliance with Good Clinical
Practice, the design and approval of trial documents, and pharmacovigilance.
Participants
The trial sought to recruit patients with symptomatic myeloma who had not previously received active
antimyeloma treatment for their disease. These patients were recruited from haematology departments in
NHS hospital trusts covering England, Northern Ireland and Wales.
Inclusion criteria
Patients were eligible for this trial if:
l they were aged ≥ 21 years and able to give informed consent
l they had newly diagnosed symptomatic myeloma based on internationally agreed criteria
l there was an intention to treat (ITT) their myeloma actively
l they were within 14 days of starting, and no more than 14 days into, a programme of
antimyeloma treatment
l they were able to provide written informed consent.
Exclusion criteria
Patients were ineligible for this trial if:
l they had a contraindication to levofloxacin
l they were known to have sensitivity/allergy to levofloxacin or other quinolones
l they had a history of tendon disorders related to fluoroquinolone administration
l they were receiving amiodarone or arsenic trioxide
l they were on active antiepileptic treatment
l they were women of childbearing age who were not willing to use appropriate methods of
contraception to prevent pregnancy or women who were breastfeeding
l they were thought to have mandatory requirement for antibacterial prophylaxis (with the exception of
Pneumocystis prophylaxis, if regarded as essential)
l they had received previous treatment for myeloma, except for the following:
¢ local radiotherapy to relieve bone pain or spinal cord compression
¢ prior bisphosphonate treatment
¢ previous (< 5 years since diagnosis) or concurrent active malignancies, except surgically removed
basal or squamous cell carcinoma of the skin, treated carcinoma in situ of the breast or cervix or
incidental histological finding of prostate cancer [tumour, node, metastasis (TNM) stage of T1a or
T1b]. Patients with remote histories (> 5 years) of other cured malignancies could be entered.
Settings and locations
A total of 93 NHS hospitals throughout England, Northern Ireland and Wales took part in the trial. All
centres were required to provide confirmation of trust R&D approval to conduct the trial at each site. Each
site’s principal investigator (PI) and their delegated team underwent training on the trial protocol by the
trial co-ordinator prior to the start of recruitment. This occurred via either a face-to-face meeting or a
teleconference. Only when this training had been undertaken and all approvals and documentation were
in place was the site opened to recruitment. Activation of recruitment was confirmed in writing by the trial
co-ordinator.
METHODS
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Recruitment procedure
Participants were identified in new patient haematology clinics and multidisciplinary team meetings. The
trial was then discussed with potential patients and the trial research nurse. Patients had to have had a
new diagnosis of symptomatic myeloma and be within 14 days of their antimyeloma treatment start date.
Once the trial had been discussed in detail and written patient information was provided, informed
consent was taken following the process below.
Informed consent
There was no pre-agreed specified time to consent; however, it was recommended that patients were
given at least 24 hours to go away, consider and talk to family about taking part in the trial. Consent was
required to be informed and voluntary, with time for questions and reflection. However, the patient had
the right also to make an immediate decision to consent.
Consent to participate was sought by the clinician involved in the patient’s care, with the involvement of
the research nurse in the consent discussion. Consent to participate was confirmed by the patient initialling
each of the appropriate boxes on the consent form and signing the form in the presence of the person
taking consent. A copy was given to the patient; one copy was also kept in the patient notes, and the
original was kept in the local site file.
The TEAMM intervention
Patient randomisation and blinding
Written informed consent was obtained for all patients recruited to the trial. Randomisation of participants
occurred through the WCTU Randomisation Service. Treatment allocation was performed using a
minimisation algorithm and was stratified by hospital, estimated glomerular filtration rate (eGFR) and
intention to give high-dose chemotherapy with autologous stem cell transplant (Figure 1).
At the point of randomisation, eligibility of the patient was confirmed and a check was performed on the
consenting doctor to make sure they had been appropriately trained and delegated by the centre’s PI.
Confirmation of the patient’s participation in the trial was sent to their general practitioner (GP) by the
research team at the site using an approved template letter provided by the trial team. Trial treatment
allocation was blinded to the clinicians, patients and the co-ordinating centre. The trial statistician allocated
the term ‘active’ or ‘placebo’ in a 50 : 50 split to a list of 1500 randomly generated drug pack numbers.
This list was sent (with password protection) to the drug packaging company that put the active drugs or
placebo in the correctly labelled packs. This list was then used to build the bespoke randomisation and
drug inventory system after the terms ‘active’ and ‘placebo’ were changed to ‘A’ or ‘B’ for concealment
purposes. The trial statistician retained the master list, which revealed the identity of ‘A’ and ‘B’. Ordering
of the drug for each site was done via the database that picked at random an even number of ‘A’ pack
numbers and ‘B’ pack numbers from those at the storage facility. Once these pack numbers were received
by the sites, they were activated and available to be allocated to patients when randomised.
Emergency unblinding could be requested on grounds of safety by any clinician who was involved in
the medical care of the patient. Emergency unblinding was performed by telephone contact with the
Emergency Scientific and Medical Services team at Guy’s and St Thomas’ Hospital, which held a master
unblinding list with the allocated pack numbers. Emergency unblinding was available 24 hours a day,
365 days a year, and was considered an option only when the patient’s future treatment required
knowledge of the trial treatment assignment.
Treatment
All patients entering TEAMM received antimyeloma treatment and supportive care including
bisphosphonates as per standard practice at their hospital trust. If it was intended that the patient would
proceed to high-dose chemotherapy with autologous stem cell transplant, this information was collected at
randomisation and taken into account during stratification.
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When patients were within 14 days either side of starting a programme of antimyeloma treatment, they
received 500 mg of levofloxacin or placebo-to-match tablets daily for 12 weeks (84 days). The start of the
antimyeloma treatment was determined as the start of steroids or chemotherapy, whichever came first.
In a situation in which patients’ renal function was compromised, it was recommended that patients
took a reduced dose of the trial drug, as levofloxacin is eliminated from the body mainly via excretion of
unmetabolised drug in the urine by the kidneys. eGFR, provided locally, when possible, was assessed at
baseline and reassessed at each scheduled trial visit to identify changes in renal function that would
necessitate a change in dose of levofloxacin. It was recommended that eGFR was assessed within the 7- to
14-day period prior to randomisation. Those patients with an eGFR of > 50 ml/minute/1.73 m2 took two
tablets once per day (a dose of 500 mg), those patients with an eGFR of 20–50 ml/minute/1.73 m2 took
one tablet daily (a dose of 250 mg) and those patients with an eGFR of < 20 ml/minute/1.73 m2 took
a half-tablet daily (a dose of 125 mg). The active and placebo tablets were in identical breakable form.
Dose reductions were recorded on the front of the patient diary, which was provided at each trial visit in
conjunction with a review of eGFR.
Patients were asked to complete diaries during and after the 12-week treatment period, which were used to
capture information related to drug compliance, health resource use and febrile episodes. Patients were asked
Randomise eligible and consenting patients
with newly diagnosed symptomatic myeloma
who are within 14 days of starting active 
antimyeloma therapy
Post-treatment assessment at 16 weeks
500 mg of levofloxacin once daily for 
12 weeks (dose can be altered to 
accommodate for reduced renal function)
Up to 500 patients 
Placebo-to-match tablets for 12 weeks
Up to 500 patients
On-treatment assessments at 0, 4, 8 and 12 weeks
• QoL
• Stool/blood/urine samples
• Health economics
• Compliance and infection assessment
• QoL
• Stool/blood/urine samples
• Health economics
Up to 1000 patients
Annual follow-up assessment
FIGURE 1 Trial schema.
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to take their temperature daily (at a similar time each day) using a digital oral thermometer provided by the
co-ordinating centre. They were also asked to take and record their temperature at any time they felt unwell.
If a temperature of ≥ 38 °C was recorded, they were encouraged to contact the hospital for assessment,
whether or not antibiotic treatment was required. In the event of a febrile episode, it was suggested that
patients remain on the trial drug and that management of infections should be as for an individual who was
taking active levofloxacin. Patients were treated as per standard practice depending on the nature of the
infection. On resolution of the infection, it was recommended that patients continue taking the trial drug.
Any patient who had stopped taking the trial drug while being treated for an infection was asked to restart
promptly on resolution of the infection. Any treatment breaks were recorded on the case report forms (CRFs)
and excess tablets remaining as a result were returned to pharmacies for accountability purposes.
Supportive treatment
Supportive treatment practices common to each centre were allowed; this included the use of
bisphosphonates, prophylactic antivirals and prophylactic Pneumocystis treatment. The use of prophylactic
Pneumocystis treatment was discouraged and the use of nebulised pentamidine over oral co-trimoxazole
(Septrin®, Actavis, Barnstaple, UK) was preferred. Other antibacterial prophylaxis was not allowed.
Central laboratory assessments
Microbiology assessments
Microbiological analysis was conducted at the Department for Medical Microbiology at St George’s
Hospital, London, and the Birmingham Public Health Microbiology (PMH) laboratory. Nasal swabs and stool
samples were requested from patients at baseline (before the first dose of trial medication) and at 4, 8 and
12 weeks when receiving TEAMM treatment and again at 16 weeks. These were used to assess carriage of
S. aureus, C. difficile and ESBL coliforms. Any toxigenic strains of C. difficile were identified by culture and
ribotyping. Extended multilocus VNTR analysis typing will be performed on all isolates in the Birmingham
PMH laboratory. ESBL-positive Gram-negative bacteria from faecal screens and clinical specimens (when
available) were identified and sent to the Birmingham PMH laboratory for genotyping of CTX-M beta-
lactamase genes using denaturing high-performance liquid chromatography. Nasal swabs were cultured
for MRSA, and isolates were typed and stored. Cultures from invasive infections isolated locally were
transferred to the central laboratory at St George’s Hospital for typing when possible.
Immunology assessments
Immunology analysis was conducted by the Clinical Immunology Service at the University of Birmingham.
Ethylenediaminetetraacetic acid (EDTA) blood, clotted blood and urine were requested from patients at
baseline (before the first dose of trial medication) and at 4, 8 and 12 weeks when receiving TEAMM
treatment and again at 16 weeks and 1 year. These samples were used to assess paraprotein levels,
prognostic factors and markers of immunocompetence.
Measurements at entry and at 8 and 12 weeks included levels of:
l whole and free light chain (flc) paraprotein in serum and urine
l β2-microglobulin, albumin, creatinine, calcium and C-reactive protein (CRP)
l complement components C3 and C4
l acute-phase response proteins and cytokines
l serum levels of polyclonal immunoglobulin (specific antibody against panels of both bacterial and viral
antigenic targets and type I natural antibody levels)
l single-platform flow cytometric enumeration of lymphocyte subsets including type I and type 2 B cells,
memory B cells; gamma/delta, cluster of differentiation 4 (CD4) and CD8 T cells; naive and memory
subsets; Treg cells; and C cells
l monocyte subsets defined by CD14 and CD16 dendritic cells
l buffy coat cells, plasma and serum aliquoted and stored at –80 °C (not measured at 8 weeks).
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Measurements at 4 and 16 weeks included levels of:
l whole and flc paraprotein in serum and urine
l β2-microglobulin, albumin, creatinine, calcium, CRP response, markers of inflammation, and humoral
and cellular immunocompetence.
The schedule of assessments is shown in Table 1.
Patient follow-up
Patients were followed up at approximately 4-week intervals during their 12 weeks of TEAMM treatment.
They were seen again at 16 weeks and had a further follow-up at 1 year post TEAMM treatment start date.
Serious adverse events
Investigators were required to inform the WCTU about the occurrence of a SAE within 24 hours of
becoming aware of the event. SAEs had to be reported if they occurred between the first dose of trial
medication and up to 30 days after the last dose was taken. An AE was considered to be a SAE if one of
the following conditions applied:
l results in death
l is immediately life-threatening
l requires hospitalisation or prolongation of existing hospitalisation
l leads to the development of any grade 4 non-haematological toxicity (excluding alopecia)
l results in persistent or significant disability or incapacity
l is otherwise medically significant (e.g. important medical events that may not be immediately life-threatening
nor result in death or hospitalisation, but may jeopardise the patient or may require intervention to
prevent one of the other outcomes listed above, excluding new cancers or result of overdose).
A serious adverse reaction (SAR) was defined as a SAE that has a definite, probable or possible causal
relationship to levofloxacin. Causality was assessed by both a clinician at site and the chief investigator. SARs
that were unexpected according to the summary of product characteristics for levofloxacin were considered to
be suspected unexpected serious adverse reactions. For every AE symptom, an AE term and grade was applied
by the site using the Common Terminology Criteria for Adverse Events (CTCAE) version 4.03.
The following SAEs were not required to be reported as they relate to myeloma and its treatment:
l disease progression
l disease-related deaths
l routine treatment or monitoring if the studied indication is not associated with any deterioration
in condition
l treatment, which was elective or preplanned, for a pre-existing condition, not associated with any
deterioration in condition
l general care not associated with any deterioration in condition
l treatment on an emergency outpatient basis for an event not fulfilling any of the definitions of ‘serious’
(as provided above) and not resulting in hospital admission
l hospitalisation for palliative care
l grade 4 haematological toxicity is an expected consequence of effective treatment and is required to
be reported only if it fulfils the criteria of a SAE (as defined above)
l treatment (including hospitalisation or extension of hospitalisation) for transfusions or pain relief
l surgical interventions for skeletal-related events (e.g. fixation of fractures or vertebroplasty)
l skeletal-related events, including bone fractures, spinal cord compression and increased bone pain
l hypercalcaemia
l extravasation
l toxicities that meet serious criteria that developed prior to entry to the trial.
METHODS
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TABLE 1 Schedule of investigation
Event
Start
of trial
treatment
Trial visits (post start of trial treatment)
4 weeks
(± 2 weeksa)
8 weeks
(± 2 weeksa)
12 weeks
(end of
treatment) 16 weeks 12 months
Informed consent taken ✗
Medical history to include ECOG
performance status and weight
and comorbidities
✗ ✗ ✗ ✗ ✗ ✗
Inclusion criteria satisfied ✗
Levofloxacin/placebo supplied to
patient
✗
QoL (EQ-5D, EORTC QLQ-C30
and HADS)
✗ ✗ ✗
QoL (EQ-5D, EORTC QLQ-C30,
EORTC QLQ-MY24 and HADS)
✗ ✗
Patient diary supplied to patient
(includes questions on health
resource use)
✗ ✗ ✗
Post-treatment patient diary
supplied to patient
✗
Compliance with trial medication
assessed (counting of empty
blister packs)
✗ ✗ ✗
Details of infections and hospital
admissions collected
✗ ✗ ✗ ✗
AEs ✗ ✗ ✗ ✗
Details of supportive care
collected
✗ ✗ ✗ ✗ ✗
12–20ml of clotted peripheral
blood, 8 ml of EDTA blood (at
start of treatment), 4 ml of EDTA
blood thereafter and 20ml of
urine to the University of
Birmingham
✗ ✗ ✗ ✗ ✗ ✗
Stool sample and nasal swab to
St George’s Hospital
✗ ✗ ✗ ✗ ✗
Bone marrow aspirate ± trephine ✗
Full blood count ✗ ✗ ✗ ✗ ✗ ✗
Biochemistry screen ✗ ✗ ✗ ✗ ✗ ✗
eGFR using modification of diet
in renal disease formula
✗ ✗ ✗ ✗ ✗ ✗
ECOG, Eastern Cooperative Oncology Group; EORTC QLQ-C30, European Organization for Research and Treatment of
Cancer Quality of Life Questionnaire-C30; EORTC QLQ-MY24, European Organization for Research and Treatment of
Cancer Quality of Life Questionnaire-24-item myeloma-specific module; EQ-5D, EuroQoL-5 Dimensions; HADS, Hospital
Anxiety and Depression Scale.
a The timing of viisits was flexible to allow them to coincide with chemotherapy visits as far as possible.
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Patients who died on treatment or within 30 days of the last dose of treatment were reviewed separately
by the chief investigator and by a consultant haematologist who was independent of the trial.
Patient withdrawal
It was made clear in the patient information sheet (PIS) that patients were free to withdraw at any point
after consenting to take part without having to give a reason, and that withdrawal would not affect the
standard of care they would receive. When the withdrawal reason was known, it was supplied to the trial
office via the withdrawal form. Three different withdrawal options were given to maximise data collection
and options were discussed with the patient when possible:
1. Patient withdrew from treatment only – this option meant that the patient continued on the trial with
all active assessments other than administration of the trial drug.
2. Patient withdrew from treatment and assessments – this option meant that the patient did not
complete any assessments or take an active role in the trial, but was happy for us to collect data
about their disease status and standard treatment they were receiving. This will enable long-term
follow-up to be conducted on these patients.
3. Patient withdrew consent – for these patients, no further data were collected or used in the analysis
after the date of withdrawal. Data collected between the date of consent and the date of consent
withdrawal have still been used unless specified by the patient.
Patients could also have been withdrawn from the trial at the discretion of the chief investigator and/or
Trial Steering Committee if safety was a concern.
Patients moving out of area
When patients moved area and were no longer attending visits at the same centre, every effort was made
to transfer the follow-up of patients to the new centre where their treatment was continuing. This was
possible only if the new centre had the relevant approvals to participate in TEAMM.
Outcomes
Primary outcome measure: time to first febrile episode or death from all causes within
12 weeks of starting trial treatment
A febrile episode was identified and counted by a single oral temperature of ≥ 38 °C (recorded either by
a health-care professional or by the patient/carer, provided that the patient/carer had been trained and
assessed as competent in temperature taking) and the patient was given anti-infectives.
A single febrile episode was defined as the initial febrile event and any subsequent fevers until that course
of anti-infectives was stopped.
Capture of febrile episodes was via (1) documentation in hospital and (2) patient diary cards on which
patients were asked to self-report temperature on a daily basis and at any time they felt unwell.
Information gathered from documentation in hospital or in patient diaries was assessed every 4 weeks
and translated onto on-treatment and infection CRFs.
Secondary outcomes
From start of trial treatment to 12 weeks
l Number of deaths and infection-related deaths: information on deaths was captured via notification of
death and SAE forms.
l Number of days in hospital: information on hospital admissions was collected via SAE forms,
on-treatment CRFs and follow-up CRFs.
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l Number of days in hospital on anti-infectives: for each infection, a separate infection CRF was
submitted, which collected all anti-infective treatment and any hospital admissions associated with
the infection episode.
l Carriage and invasive infections with S. aureus, C. difficile and ESBL coliforms: nasal swabs and stool
samples from patients were sent at 4-weekly intervals when on TEAMM treatment to the central
microbiology laboratory. Samples were cultured to detect the presence of the organisms of interest.
l Patient characteristics, steroid usage and indices of immunocompetence and their relationship to
colonisation by, and development of, infection from S. aureus, C. difficile and ESBL coliforms and
non-HCAI and Eastern Cooperative Oncology Group (ECOG) performance status: CRFs at all time
points collected information on performance status. Steroid information was captured on a treatment
summary CRF that requested information about each antimyeloma treatment cycle. This was looked at
in conjunction with the indices of immunocompentence, which resulted from the central immunology
laboratory analysis of the blood and urine samples collected at all time points.
l Number of clinically documented total infections, episodes of severe sepsis (CTCAE grade 3 or 4) and
suspected infections: febrile episodes (as defined above) and infections in which there was no
associated fever (but which were treated with anti-infectives) were recorded on infection CRFs.
Episodes of severe sepsis were captured via SAE forms.
l Incidence of microbiologically proven infections, the pathogens and their susceptibility to antibacterials:
the infection CRF captured information about microbiological diagnosis and SAE forms prompted for
microbiology reports to be sent to the trials office when there were positive microbiological cultures.
Organisms’ sensitivity profiles were usually present on local microbiological reports.
l Days on anti-infective treatment for treatment of infection: name and duration of treatment with each
anti-infective were captured via infection CRFs.
l Response to antimyeloma treatment and its relationship to infection: response to antimyeloma
treatment was looked at centrally using the blood and urine samples collected from patients.
This information was looked at in relation to infections reported via infection CRFs.29,30
From start of trial treatment to beyond 12 weeks
l Carriage and invasive infections with S. aureus, C. difficile and ESBL coliforms between
12 and 16 weeks to assess for delayed effects from the intervention that was stopped at 12 weeks:
organisms of interest were cultured from stool samples and nasal swabs that were taken at the
16-week time point (4 weeks post end-of-trial treatment).
l Response to antimyeloma treatment at 16 weeks. Because of the half-life of paraproteins,
measurement of myeloma response cannot be undertaken until a minimum of 4 weeks after an
intervention – blood and urine samples were sent to the central immunology laboratory for analysis at
the 16-week time point, approximately 4 weeks after the treatment end date.
l QoL: the following validated questionnaires were used to assess QoL –
¢ EuroQoL-5 Dimensions (EQ-5D)31 – five-point scales and one 100-point summary scale (completed
at all time points up to week 16)
¢ European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30
(EORTC QLQ-C30)32 – five functional scales, three symptom scales and one global scale and six
single items for assessment of general QoL (completed at all time points up to week 16)
¢ European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-24-item
myeloma-specific module (EORTC-QLQ-MY24) – 24 questions covering disease symptoms,
treatment side effects, body image and future perspectives of patients with multiple myeloma
(completed only at baseline and week 12)
¢ Hospital Anxiety and Depression Scale (HADS)33 – a screening tool for anxiety and depression
(completed at all time points up to week 16).
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l Health economics: daily diary cards completed by patients captured elements of health resource use in
combination with information captured on the CRF.
l Overall survival: captured via notification of death CRFs and flagging with the Office for
National Statistics.
Sample size
The primary and first set of secondary outcomes were reached within 12 weeks of trial treatment. The
primary outcome measure was time to first febrile episode or death from all causes, using a Kaplan–Meier
survival curve. Assuming that the proportion of patients having a febrile episode or death was 30% in the
first 3 months and that prophylactic antibacterials would reduce that rate to 20%, recruiting 800 patients
into the trial (400 in each arm) would allow differences in excess of 10% to be detected with 90% power
using a two-sided test at the 5% level of significance. Recruiting 1000 patients into the trial (500 in each
arm) would allow differences in excess of 8% to be detected with 90% power using a two-sided test at
the 5% level of significance. Recruiting 1000 patients would also allow detection of a levofloxacin-induced
threefold increase in the rate of C. difficile-positive stools (from 5% to 15%) from entry to the trial to
12 weeks, with 95% power and 5% level of significance (two-sided test).
Other analyses include incidence of probable infections with site, severity and treatment; response
to antimyeloma treatment and its relationship to infection; patient characteristics and indices of
immunocompetence (blood leucocyte subset enumeration and antibacterial antibody titres) as prognostic
markers for colonisation and invasive infection by antibiotic-resistant organisms; health economics; and
QoL (by daily diary card and 4-weekly EQ-5D up to 16 weeks). With 1000 patients, it would be possible
to report reliable estimates for these secondary outcomes.
Statistical methods
The main analysis, comparing time to first febrile episode or death from all causes within the first 12 weeks,
was carried out using a log-rank comparison, with the start time being the date on which the patient
started trial treatment to the time of a reported event, or to a censor date for those with no events reported
after 12 weeks.34 All randomised patients were included in the analysis of the primary end point as ITT
using the date of randomisation as the start date for any patients not starting trial treatment.35
The secondary end points such as C. difficile-containing stools, MRSA and ESBL coliform carriage rates and
number of invasive infections associated with the identical organism previously carried were assessed using
chi-squared tests with continuity adjustments. Mantel–Haenszel tests for combining 2 × 2 tables were then
used to adjust for stratification variables and various prognostic factors. Patients who were randomised and
had started treatment were included in the analyses of the secondary end points.
Overall survival was calculated from the date on which the patient started trial treatment to the date of
death or date of censorship, as appropriate. Overall survival analysis was based on all-cause mortality
and assessed using Kaplan–Meier curves.34 The main treatment effect was assessed using the log-rank
test. Kaplan–Meier curves for the primary outcome were constructed for each treatment arm and Cox
proportional hazards models were used to compare arms after adjustment for stratification variables and
imbalances in important baseline factors.34,36 Covariates were assessed graphically for non-proportionality
of hazards. When there was an indication of non-proportionality, a time-dependent variable (its product
with time) was introduced to test non-proportionality. If the Wald chi-squared p-value was < 0.05 for this
term, then non-proportionality was assumed and a restricted mean survival time approach used with the
test of the difference in restricted means presented instead of the hazard ratio (HR).37,38 These analyses
were carried out on an ITT basis.
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The analyses of all other secondary end points, incidence of probable infections with site, severity
and treatment, response to antimyeloma therapy and its relationship to infection and indices of
immunocompetence (blood leucocyte subset enumeration and antibacterial antibody titres) were
undertaken using the appropriate statistical analyses tools.
Statistical analyses were performed using SAS® version 9.4 (SAS Institute Inc., Cary, NC, USA). SAS and all
other SAS Institute Inc. product or service names are registered trademarks or trademarks of SAS Institute
Inc. in the USA and other countries. ® indicates USA registration.
Independent Data and Safety Monitoring Committee
An independent Data and Safety Monitoring Committee (DSMC) was established, consisting of an
independent statistician, haematologist and microbiologist. Their main objective was to advise the Trial
Steering Committee if there is evidence or reason why the study should be amended or terminated based
on recruitment rates, compliance, safety or efficacy. The DSMC met after the first 50 patients were
recruited, and annually thereafter. Confidential reports containing recruitment, protocol compliance, safety
data and interim analyses of outcomes (not formally tested outside the trial statistical analyses plan, which
was agreed with the DSMC) were reviewed by the DSMC. Interim analyses of the primary outcome were
presented to the DSMC using conservative tests with significance determine by a p-value of 0.001 (to
preserve the overall alpha level of 0.05). All analyses were blinded to the trial statistician and the DSMC
until agreement to unblind at the end of the trial.
The original power calculations aimed to detect a difference of 10% (i.e. from 30% in the control arm to 20%
in the treatment arm) with 90% power at the two-sided 5% level of significance. The first planned look at
the primary end point when 150 patients had completed the 12-week assessment indicated that the original
assumptions held true (i.e. a 31% rate in the control arm vs. a 21% rate in the treatment arm; documented
in the DSMC December 2013 report). The prespecified look at the data before the trial recruitment closed
(i.e. 760 patients recruited and 642 recruited patients having completed the 12-week assessment) indicated
that the rate in the placebo arm may be reduced to 23% (note that this analysis remained blind to the
treatment arm). After much discussion, the DSMC made recommendations to increase the sample size from
800 patients to up to 1000 patients (the maximum that could be accommodated by the available drug supply)
within the current funding window. Increasing the sample size from the original 800 patients to up to
1000 patients allowed the power to be retained at 80% with the ability to detect differences in excess of
7% depending on the final rate in the control arm.
Database and data processing
The database was held on WCTU’s Microsoft SQL Server (Microsoft Corporation, Redmond, WA, USA)
system and imposed rules for data entry, which included having a valid range for responses, linked dates
and patient identification (ID) numbers.
Data were single entered into the database by trial personnel. Checks were carried out on 100% of data
entered by new starters and, following full training, 10% of data entered by trial personnel were checked
each month. Unacceptable error levels in 10% checks were followed up with further checking and
retraining. The trial statistician carried out checks of plausibility of values and missing data to enable
further queries to be resolved prior to freezing data for scheduled analyses.
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Chapter 3 Results
Screening and recruitment
Recruitment
A total of 977 patients were recruited between 3 August 2012 and 29 April 2016 from 93 NHS Hospitals
(levofloxacin, n = 489; placebo, n = 488). Figure 2 shows actual compared with target recruitment.
Two patients who were randomised withdrew consent on the day of randomisation and were withdrawn
from further analyses as no data were collected. Twenty-five patients did not start trial treatment; baseline
information was collected for 23 of these patients, and these patients are included in the analysis of the
primary end point under ITT.
Screening
Sites were encouraged to screen all patients with newly diagnosed symptomatic myeloma to see if they
were eligible. It was requested that all patients with whom the TEAMM trial had been discussed were
recorded on the screening log provided. Sites were asked to record patient initials, date of birth, the date
screening was initiated, if the patient consented and if they were subsequently randomised; in the case of
patients who were not randomised, the sites were asked to provide a reason if possible. Screening logs
were requested, on average, once every 6 months. More frequent requests were not necessary because of
successful recruitment throughout. A final request was made for screening data after recruitment ended
in April 2016. In total, 76 out of the 93 sites returned some screening data. Appendix 1 shows the sites
not wishing to participate (see Table 40), the number of patients screened at each site (see Table 41) and
the most common reasons for screening failures (see Table 42). A total of 2183 potential patients were
screened on the basis of the data available on the returned screening logs; of these, 977 (45%) went on
to be randomised.
0
100
200
300
400
500
600
700
800
900
1000
M
ar
ch
 2
01
2
M
ay
 2
01
2
Ju
ly
 2
01
2
Se
p
te
m
b
er
 2
01
2
N
o
ve
m
b
er
 2
01
2
Ju
ly
 2
01
3
Se
p
te
m
b
er
 2
01
3
N
o
ve
m
b
er
 2
01
3
Ja
n
u
ar
y 
20
13
M
ar
ch
 2
01
3
M
ay
 2
01
3
Ju
ly
 2
01
4
Se
p
te
m
b
er
 2
01
4
N
o
ve
m
b
er
 2
01
4
Ja
n
u
ar
y 
20
14
M
ar
ch
 2
01
4
M
ay
 2
01
4
Ju
ly
 2
01
5
Se
p
te
m
b
er
 2
01
5
N
o
ve
m
b
er
 2
01
5
Ja
n
u
ar
y 
20
15
M
ar
ch
 2
01
5
Ja
n
u
ar
y 
20
16
M
ar
ch
 2
01
6
M
ay
 2
01
5
Actual
Target
Recruitment
Date
N
u
m
b
er
 o
f 
p
at
ie
n
ts
FIGURE 2 Cumulative recruitment.
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Of the 1206 patients who were unable to be consented and randomised into the trial, the majority were
found to be ineligible as a result of being outside the 14-day window for starting the TEAMM medication
after the start of their antimyeloma treatment. This was a problem when patients had started a steroid
treatment for their myeloma prior to commencing full cycles of chemotherapy. Of the remaining patients,
278 declined to take part without providing a detailed reason as to why. When explanations were provided,
the most common reason for declining to participate was that patients had too much going on in their lives.
With a new diagnosis of myeloma, many patients being elderly and having other comorbidities, patients felt
that taking tablets and temperatures and completing a diary were too much to cope with. Other common
reasons were not wanting to take part in a clinical trial or not wanting to take part in more than one trial
as many were also eligible for other complementary myeloma trials.
Recruitment by centre across treatment arms
Table 2 shows the final number of patients recruited from each of the 93 centres, by treatment arm.
Withdrawals
Table 3 lists the three levels of withdrawal from the trial and the reasons for withdrawal within those
groupings. Of the patients who withdrew, 32% withdrew from treatment but agreed to continue with all
trial-related activities with full data collection, 36% were happy for us to collect long-term health and
survival data from them but did not want to continue with any trial-related activities and 31% withdrew
their consent for us to collect any further information regarding them or their condition. As a minimum,
even for withdrawn patients, baseline data were collected for all patients when possible.
TABLE 2 Recruitment, by centre and treatment arm
Centre
Treatment arm, n (%)
Total (N= 977),
n (%)Levofloxacin (N= 489) Placebo (N= 488)
Altnagelvin Hospital 6 (1.2) 5 (1.0) 11 (1.1)
Antrim Hospital 3 (0.6) 1 (0.2) 4 (0.4)
Basildon University Hospital 2 (0.4) 3 (0.6) 5 (0.5)
Basingstoke and North Hampshire Hospital 1 (0.2) 2 (0.4) 3 (0.3)
Bradford Royal Infirmary 4 (0.8) 4 (0.8) 8 (0.8)
Broomfield Hospital (Chelmsford) 4 (0.8) 4 (0.8) 8 (0.8)
Calderdale Royal Hospital (Halifax) 0 (0.0) 1 (0.2) 1 (0.1)
Castle Hill Hospital (Cottingham) 8 (1.6) 9 (1.8) 17 (1.7)
Chesterfield Royal Hospital 7 (1.4) 6 (1.2) 13 (1.3)
City General Hospital (Stoke-on-Trent) 19 (3.9) 20 (4.1) 39 (4.0)
Colchester General Hospital 15 (3.1) 16 (3.3) 31 (3.2)
Craigavon Area Hospital 3 (0.6) 3 (0.6) 6 (0.6)
Darent Valley Hospital (Dartford) 12 (2.5) 11 (2.3) 23 (2.4)
Dewsbury & District Hospital 2 (0.4) 0 (0.0) 2 (0.2)
Diana, Princess of Wales Hospital (Grimsby) 1 (0.2) 1 (0.2) 2 (0.2)
Dorset County Hospital (Dorchester) 1 (0.2) 1 (0.2) 2 (0.2)
Ealing Hospital (Southall) 5 (1.0) 7 (1.4) 12 (1.2)
Frenchay Hospital (Bristol) 1 (0.2) 2 (0.4) 3 (0.3)
George Eliot Hospital (Nuneaton) 3 (0.6) 3 (0.6) 6 (0.6)
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TABLE 2 Recruitment, by centre and treatment arm (continued )
Centre
Treatment arm, n (%)
Total (N= 977),
n (%)Levofloxacin (N= 489) Placebo (N= 488)
Glan Clwd Hospital (Rhyl) 1 (0.2) 0 (0.0) 1 (0.1)
Gloucestershire Royal Hospital 3 (0.6) 2 (0.4) 5 (0.5)
Good Hope Hospital (Sutton Coldfield) 3 (0.6) 3 (0.6) 6 (0.6)
Grantham and District Hospital 1 (0.2) 1 (0.2) 2 (0.2)
Guy’s Hospital (London) 9 (1.8) 8 (1.6) 17 (1.7)
Heartlands Hospital (Birmingham) 10 (2.0) 11 (2.3) 21 (2.1)
Hereford County Hospital 3 (0.6) 4 (0.8) 7 (0.7)
Hillingdon Hospital (Uxbridge) 1 (0.2) 1 (0.2) 2 (0.2)
Huddersfield Royal Infirmary 4 (0.8) 4 (0.8) 8 (0.8)
Kettering General Hospital 1 (0.2) 1 (0.2) 2 (0.2)
King’s College Hospital (Denmark Hill, London) 2 (0.4) 2 (0.4) 4 (0.4)
Kings Mill Hospital (Sutton-in-Ashfield) 13 (2.7) 12 (2.5) 25 (2.6)
Kingston Hospital (Kingston upon Thames) 2 (0.4) 2 (0.4) 4 (0.4)
Leicester Royal Infirmary 4 (0.8) 3 (0.6) 7 (0.7)
Leighton Hospital (Crewe) 1 (0.2) 2 (0.4) 3 (0.3)
Lincoln County Hospital 6 (1.2) 5 (1.0) 11 (1.1)
Macclesfield District General Hospital 0 (0.0) 1 (0.2) 1 (0.1)
Manchester Royal Infirmary 6 (1.2) 6 (1.2) 12 (1.2)
Medway Maritime Hospital (Gillingham) 13 (2.7) 13 (2.7) 26 (2.7)
Milton Keynes General Hospital 4 (0.8) 3 (0.6) 7 (0.7)
New Cross Hospital (Wolverhampton) 5 (1.0) 4 (0.8) 9 (0.9)
North Middlesex University Hospital Trust (London) 5 (1.0) 5 (1.0) 10 (1.0)
Northampton General Hospital 9 (1.8) 10 (2.0) 19 (1.9)
Northwick Park Hospital (Harrow) 5 (1.0) 6 (1.2) 11 (1.1)
Pilgrim Hospital (Boston) 5 (1.0) 2 (0.4) 7 (0.7)
Pinderfields General Hospital (Wakefield) 1 (0.2) 1 (0.2) 2 (0.2)
Pontefract General Infirmary 2 (0.4) 0 (0.0) 2 (0.2)
Poole Hospital 0 (0.0) 2 (0.4) 2 (0.2)
Princess Royal University Hospital (Orpington) 16 (3.3) 15 (3.1) 31 (3.2)
Queen Alexandra Hospital (Portsmouth) 26 (5.3) 25 (5.1) 51 (5.2)
Queen Elizabeth Hospital (King’s Lynn) 8 (1.6) 8 (1.6) 16 (1.6)
Queen Elizabeth Hospital (London) 2 (0.4) 1 (0.2) 3 (0.3)
Queen Elizabeth Hospital (Birmingham) 6 (1.2) 7 (1.4) 13 (1.3)
Queen’s Hospital (Romford) 6 (1.2) 7 (1.4) 13 (1.3)
Queen’s Hospital (Burton upon Trent) 3 (0.6) 3 (0.6) 6 (0.6)
Royal Berkshire Hospital (Reading) 7 (1.4) 6 (1.2) 13 (1.3)
continued
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TABLE 2 Recruitment, by centre and treatment arm (continued )
Centre
Treatment arm, n (%)
Total (N= 977),
n (%)Levofloxacin (N= 489) Placebo (N= 488)
Royal Bournemouth Hospital 1 (0.2) 2 (0.4) 3 (0.3)
Royal Devon and Exeter Hospital (Wonford, Exeter) 5 (1.0) 5 (1.0) 10 (1.0)
Royal Gwent Hospital (Newport) 0 (0.0) 1 (0.2) 1 (0.1)
Royal Hallamshire Hospital (Sheffield) 3 (0.6) 3 (0.6) 6 (0.6)
Royal Hampshire County Hospital (Winchester) 3 (0.6) 4 (0.8) 7 (0.7)
Royal Liverpool University Hospital 2 (0.4) 2 (0.4) 4 (0.4)
Royal Shrewsbury Hospital 1 (0.2) 1 (0.2) 2 (0.2)
Royal Surrey County Hospital (Guildford) 3 (0.6) 4 (0.8) 7 (0.7)
Royal United Hospital (Bath) 5 (1.0) 7 (1.4) 12 (1.2)
Russells Hall Hospital (Dudley) 19 (3.9) 19 (3.9) 38 (3.9)
Salisbury District Hospital 9 (1.8) 8 (1.6) 17 (1.7)
Sandwell General Hospital (West Bromwich) 13 (2.7) 12 (2.5) 25 (2.6)
South Warwickshire Hospital 3 (0.6) 2 (0.4) 5 (0.5)
Southampton General Hospital 7 (1.4) 7 (1.4) 14 (1.4)
Southend Hospital (Westcliff-on-Sea) 5 (1.0) 6 (1.2) 11 (1.1)
Southmead Hospital (Bristol) 8 (1.6) 6 (1.2) 14 (1.4)
St James’s University Hospital (Leeds) 5 (1.0) 6 (1.2) 11 (1.1)
St. Helier Hospital (Carshalton) 14 (2.9) 14 (2.9) 28 (2.9)
Stafford Hospital 6 (1.2) 4 (0.8) 10 (1.0)
Stoke Mandeville Hospital (Aylesbury) 7 (1.4) 6 (1.2) 13 (1.3)
Sunderland Royal Hospital 2 (0.4) 4 (0.8) 6 (0.6)
The Great Western Hospital (Swindon) 6 (1.2) 7 (1.4) 13 (1.3)
Torbay Hospital (Torquay) 1 (0.2) 3 (0.6) 4 (0.4)
University Hospital Coventry 15 (3.1) 17 (3.5) 32 (3.3)
University Hospital Lewisham (London) 2 (0.4) 3 (0.6) 5 (0.5)
Ulster Hospital (Belfast) 9 (1.8) 9 (1.8) 18 (1.8)
Warrington Hospital 4 (0.8) 4 (0.8) 8 (0.8)
West Middlesex University Hospital (Isleworth) 9 (1.8) 8 (1.6) 17 (1.7)
West Wales General Hospital (Carmarthen) 5 (1.0) 5 (1.0) 10 (1.0)
Wexham Park Hospital (Slough) 2 (0.4) 3 (0.6) 5 (0.5)
Whipps Cross University Hospital (London) 2 (0.4) 2 (0.4) 4 (0.4)
Withybush General Hospital (Haverfordwest) 2 (0.4) 1 (0.2) 3 (0.3)
Wrexham Maelor Hospital 10 (2.0) 8 (1.6) 18 (1.8)
Wycombe Hospital (High Wycombe) 5 (1.0) 5 (1.0) 10 (1.0)
Wythenshawe Hospital (Manchester) 6 (1.2) 5 (1.0) 11 (1.1)
Total 489 (100) 488 (100) 977 (100)
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Unblinding by treatment arm
The unblinding service was contacted regarding TEAMM patients on 29 occasions: 14 of the calls, after
further discussion, did not result in the treatment allocation being unblinded, and 15 of the calls resulted
in the treatment allocation being unblinded to the caller (two of the calls were redirected to a more
appropriate service). Examples of situations in which patients’ treatment allocation was unblinded included
tendonitis/tendon rupture, unexpected deterioration in kidney or liver function, confusion, suspected
Stevens–Johnson syndrome and unexplained neurological symptoms.
Data return
Data were locked on 24 April 2017. Table 4 reports the number of CRFs returned and expected at the
time of analysis.
Consolidated Standards of Reporting Trials flow diagram
The Consolidated Standards of Reporting Trials (CONSORT) flow diagram is shown in Figure 3.
TABLE 3 Withdrawals, by treatment arm
Withdrawal status Reason for withdrawal
Treatment arm, n (%)
Total, n (%)Levofloxacin Placebo
Ceased treatment but remained
on follow-up as per protocol
(N = 73, 32%)
Suspected trial drug toxicity 21 (54) 11 (32) 32 (44)
Participant decision 8 (20.5) 10 (29) 18 (25)
Other reason 10 (26) 13 (38) 23 (31.5)
Withdrawn from treatment and
assessments (N= 82, 36%)
Suspected trial drug toxicity 6 (13) 9 (24) 15 (18)
Participant decision 24 (53) 18 (49) 42 (51)
Other reason 15 (33) 10 (27) 25 (30)
Withdrawn consent for further
data to be collected (N= 71,
31%)
Suspected trial drug toxicity 5 (14) 5 (14) 10 (14)
Participant decision 19 (53) 23 (66) 42 (59)
Other reason 12 (33) 7 (20) 19 (27)
TABLE 4 Expected and actual CRF return
Time point
CRF return
Outstanding CRFs being chased (n)Received (n) Expected (n)
Eligibility 977 977 –
Randomisation 977 977 –
Baseline 975 975 –
Week 4 925 961 36
Week 8 856 883 27
Week 12 818 832 14
Week 16 799 811 12
Treatment summary 947 975 28
Annual follow-up 716 758 42
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Assessed for eligibility
(n = 2183)
Allocation
Analysis
Follow-up
Randomised
(n = 977)
Enrolment
 • Not meeting inclusion criteria, n = 435
 • Declined to participate, n = 494
 • Other reasons, n = 66
 • Not known, n = 211
• Participant reason, n = 10
• Suspected drug toxicity, n = 11
• Other reason, n = 13
• Excluded from analysis, n = 0 • Excluded from analysis, n = 0
Allocated to levofloxacin
(n = 489)
Lost to follow-up
(n = 36)
Allocated to placebo
(n = 488)
Excluded
(n = 1206)
• Between 0 and  4 weeks, n = 40
• Between 4 and 8 weeks, n = 33
• Between 8 and 12 weeks, n = 23
• Received allocated intervention, n = 477
• Did not receive allocated intervention, n = 12
Withdrawals
(96 patients within 12 weeks)
• Received allocated intervention, n = 475
• Did not receive allocated intervention, n = 13
Withdrawals
(87 patients within 12 weeks)
• Between 0 and   4 weeks, n = 43
• Between 4 and 8 weeks, n = 30
• Between 8 and 12 weeks, n = 14
• Withdrew from further data collection, n = 36
Withdrawals
• Post 12 weeks, n = 9
Discontinued intervention
(n = 39)
• Participant reason, n = 8
• Suspected drug toxicity, n = 21
• Other reason, n = 10
Analysed for primary end point
(n = 489)
Analysed for secondary end points
(n = 489)
Lost to follow-up
(n = 36)
• Transferred hospital, no details, n = 1
• Withdrew from further data collection, n = 35
Discontinued intervention
(n = 34)
Withdrawals
• Post 12 weeks, n = 3
Analysed for primary end point
(n = 488)
Analysed for secondary end points
(n = 488)
FIGURE 3 The CONSORT flow diagram.
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Baseline characteristics
Stratification factors of participants by treatment arm
Treatment allocation by minimisation was balanced by site, eGFR on entry into the trial and intention to
give high-dose chemotherapy with autologous stem cell transplant, as shown in Table 5.
Baseline characteristics of participants by treatment arm
Baseline characteristics were well balanced across treatment arms, as shown in Table 6.
Disease characteristics at presentation were also well balanced, as shown in Table 7.
TABLE 5 Randomisation, by treatment arm
Factor Grouping
Treatment arm, n (%)
Total (N= 977),
n (%)Levofloxacin (N= 489) Placebo (N= 488)
eGFR (ml/
minute/1.73 m2)
> 50 369 (75) 369 (76) 738 (76)
20–50 95 (19) 93 (19) 188 (19)
< 20 25 (5) 26 (5) 51 (5)
High-dose
chemotherapy
with autologous
stem cell
transplant
No 223 (46) 222 (46) 445 (46)
Yes 266 (54) 266 (54) 532 (54)
Sex Male 316 (65) 295 (60) 611 (63)
Female 173 (35) 193 (40) 366 (37)
Age (years) N 489 488 977
Median 67 67 67
IQR 59–75 61–75 60–75
IQR, interquartile range.
TABLE 6 Baseline characteristics and baseline treatment information, by treatment arm
Factor Grouping
Treatment arm, n (%)
Total (N= 975),
n (%)Levofloxacin (N= 489) Placebo (N= 486)
Performance
status at
randomisation
0 164 (34) 173 (36) 337 (35)
1 209 (43) 188 (39) 397 (41)
2 80 (16) 76 (16) 156 (16)
3 24 (5) 36 (7) 60 (6)
4 2 (< 1) 5 (1) 7 (1)
Missing 10 (2) 8 (2) 18 (2)
Performance
status 6 months
prior to
randomisation
0 327 (67) 311 (64) 638 (65)
1 119 (24) 132 (27) 251 (26)
2 16 (3) 22 (5) 38 (4)
3 5 (1) 6 (1) 11 (1)
4 0 (0) 1 (< 1) 1 (0)
Missing 22 (5) 14 (3) 36 (4)
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TABLE 6 Baseline characteristics and baseline treatment information, by treatment arm (continued )
Factor Grouping
Treatment arm, n (%)
Total (N= 975),
n (%)Levofloxacin (N= 489) Placebo (N= 486)
Ethnicity White 452 (92) 437 (90) 889 (91)
Mixed 1 (< 1) 2 (0.4) 3 (< 1)
Asian or British Asian 10 (2) 17 (4) 27 (3)
Black or black British 26 (5) 28 (6) 54 (6)
Chinese or other 0 (0) 1 (< 1) 1 (< 1)
Missing 0 (0) 1 (< 1) 1 (< 1)
Prior infection C. difficile 2 (< 1) 1 (< 1) 3 (< 1)
MRSA 6 (1) 7 (1) 13 (1)
ESBL coliforms 3 (1) 5 (1) 8 (1)
Anti-infectives
in month prior
No 332 (68) 331 (68) 663 (68)
Yes 75 (15) 76 (16) 151 (15)
Missing 82 (17) 79 (16) 161 (17)
Steroids 14 days
prior to
randomisation
Yes 248 (51) 246 (51) 494 (51)
Corticosteroids Prednisolone 24 (5) 18 (4) 42 (4)
Dexamethasone 226 (46) 229 (47) 455 (47)
Other 0 (0) 2 (< 1) 2 (< 1)
Planned
antimyeloma
treatment
Any bortezomib (Velcade®;
Janssen-Cilag Ltd., Beerse, Belgium)
regimen
150 (31) 144 (30) 294 (30)
Cyclophosphamide, thalidomide,
dexamethasone
116 (24) 119 (24) 235 (24)
Cyclophosphamide, thalidomide,
dexamethasone (attenuated)
74 (15) 83 (17) 157 (16)
Other 56 (11) 56 (12) 112 (11)
Revlimid, cyclophosphamide,
dexamethasone
33 (7) 37 (8) 70 (7)
Revlimid, cyclophosphamide,
dexamethasone (attenuated)
38 (8) 32 (7) 70 (7)
Melphalan, prednisolone, thalidomide 17 (3) 12 (2) 29 (3)
Melphalan, prednisolone 3 (1) 1 (< 1) 4 (< 1)
Missing 2 (< 1) 2 (< 1) 4 (< 1)
Bisphosphonate
status at
randomisation
Not given 68 (14) 60 (12) 128 (13)
Given/will be given 419 (86) 419 (87) 838 (86)
Missing 2 (< 1) 7 (1) 9 (1)
Bisphosphonate Zolendronate 284 (68) 280 (67) 564 (67)
Pamidronate 111 (26) 105 (25) 216 (26)
Clodronate 14 (3) 23 (5) 37 (4)
Other 3 (1) 7 (2) 10 (1)
Prophylactic
anti-infective
status
No 170 (35) 166 (34) 336 (34)
Yes 240 (48) 237 (50) 477 (49)
Missing 82 (17) 80 (16) 162 (17)
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TABLE 7 Disease characteristics
Factor Grouping
Treatment arm, n (%)
Total (N= 975),
n (%)Levofloxacin (N= 489) Placebo (N= 486)
Skeletal disease
Corrected calcium (µmol/l) < 2.5 339 (72) 354 (75) 693 (74)
2.5–2.75 101 (22) 94 (20) 94 (21)
> 2.75 29 (6) 20 (5) 25 (5)
Evidence of bone disease Yes 338 (69) 350 (72) 688 (71)
Site of bone disease Vertebral fracture/
collapse
118 (24) 144 (30) 262 (27)
Lytic lesions 234 (48) 245 (50) 479 (49)
Fractured rib 33 (7) 24 (5) 57 (6)
Osteoporosis 38 (8) 37 (8) 75 (8)
Other fracture 42 (9) 41 (8) 83 (9)
Tumour burden
Serum β2-microglobulin
(mg/l)
< 4 189 (46) 192 (47) 381 (46)
4–8 148 (36) 152 (37) 300 (37)
> 8 73 (18) 67 (16) 140 (17)
Haematopoietic function
Anaemia
(haemoglobin g/dl)
< 7.5 9 (2) 13 (3) 22 (2)
7.5–10 163 (34) 166 (34) 329 (34)
> 10 314 (65) 305 (63) 619 (64)
Thrombocytopenia
(platelets × 109/l)
< 150 69 (14) 79 (16) 148 (15)
> 150 417 (86) 404 (84) 821 (85)
Neutrophils (× 109/l) < 1.8 35 (7) 55 (11) 90 (9)
1.8–3 138 (29) 132 (27) 270 (28)
> 3 311 (64) 296 (61) 607 (63)
Lymphocytes > 0–1 118 (24) 125 (26) 243 (25)
> 1–3.5 345 (71) 339 (70) 684 (71)
> 3.5 21 (4) 19 (4) 40 (4)
Renal disease
Serum creatinine (µmol/l) < 130 384 (79) 383 (80) 767 (80)
130–199 57 (12) 54 (11) 111 (11)
> 199 42 (9) 43 (9) 85 (9)
Blood urea (µmol/l) < 6.5 229 (49) 225 (49) 454 (48)
6.5–10 146 (31) 148 (32) 294 (32)
> 10 91 (20) 89 (19) 180 (19)
Stage
International Staging
System
Stage I 100 (24) 116 (28) 216 (26)
Stage II 188 (46) 165 (40) 353 (43)
Stage III 121 (30) 130 (32) 251 (31)
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Protocol deviations/non-compliance
One patient was retrospectively found not to be eligible because they were found to have multiple
plasmacytoma and not myeloma when further results came to light. A total of 24 patients were, at some
point during their treatment, taking the incorrect dose on the basis of their eGFR result. Among this group,
clinician decisions not to increase the dose based on patients’ conditions are classed as deviations. The
remainder of instances of non-compliance were down to site errors or patient confusion. Details of the
type of non-compliances are shown in Table 8.
Protocol deviations are shown in Table 9. A number of patients did not take the TEAMM medication for
the correct number of days as stated in the protocol (84 days), some took it for fewer days than expected
and some took it for more days than was stated. Those who took TEAMM treatment for fewer days than
expected were required to note this either in a withdrawal form or on the on-treatment form as missed
treatment. Patients who took the trial medication for more than the 84 days of treatment misunderstood
the trial procedure and continued to take remaining tablets as a result of treatment breaks or dose
reductions. Patients taking trial treatment for up to 98 days were not classed as non-compliers as it was
felt that the data would not be significantly affected by this. The remaining patients who took trial
treatment for > 98 days were classed as protocol violations. There were 13 patients who failed to begin
their randomised treatment within the 14-day eligibility window stated in the protocol. All of these
patients were eligible at the time of randomisation and all violations resulted from a change in the
patient’s circumstances that resulted in the anticipated start date changing to one outside the 14-day
window. These non-compliances are balanced by treatment arm, as shown in Table 9.
TABLE 8 Reported non-compliance
Type of protocol non-compliance
Non-compliance
Violations (n) Deviations (n)
Failure to report SAE 13 0
Incorrect dose on basis of eGFR: lower dose than protocol stated 13 6
Incorrect dose on basis of eGFR: higher dose than protocol stated 5 0
Failure to start TEAMM medication within 14 days of antimyeloma treatment 5 8
Continued treatment past the 84-day period stated in the protocol 11 0
Stool sample taken after first dose of TEAMM medication 0 1
Retrospectively found not to be eligible 1 0
Incorrect pack number dispensed 2 0
Prescription and administration of a contraindicated drug 5 1
Patient incorrectly told to stop taking trial drug before 12-week time point 1 0
Total 56 16
TABLE 9 Protocol deviations, by treatment arm
Non-compliance
Treatment arm, n (%)
Total (N= 925),
n (%)Levofloxacin (N= 468) Placebo (N= 457)
Taken for > 98 days 7 (1) 4 (1) 11 (1)
Started > 14 days of starting antimyeloma
treatment
7 (1) 6 (1) 13 (1)
Lower dose 10 (2) 9 (2) 19 (2)
Higher dose 3 (< 1) 2 (< 1) 5 (< 1)
RESULTS
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Treatment data across 12 weeks
Data were captured on participants while on treatment at 4, 8 and 12 weeks. At the time of data lock,
a total of 2599 treatment forms had been returned by 925 patients. Table 10 presents on-treatment
information by treatment arm.
The treatment information for the entire treatment period (from 0 to 12 weeks) is summarised in Table 11.
TABLE 10 Treatment data at 4, 8 and 12 weeks
Time point Grouping
Treatment arm, n (%)
Total (N= 925),
n (%)
Levofloxacin
(N= 468)
Placebo
(N= 457)
Treatment data at 4 weeks
Trial drug dose revised No 411 (88) 420 (92) 831 (90)
Yes 43 (9) 26 (6) 69 (7)
Missing 14 (3) 11 (2) 25 (3)
Revised dose (mg) 500 32 (74) 18 (69) 50 (72)
250 7 (16) 6 (23) 13 (19)
125 4 (9) 2 (8) 6 (9)
Randomised treatment missed No 298 (64) 293 (64) 591 (64)
Yes 74 (16) 73 (16) 147 (16)
Missing 96 (20) 91 (20) 187 (20)
Number of days treatment missed, n, median (IQR) 64, 5 (2–13) 62, 5 (2–9) 126, 5 (2–11)
Diarrhoea episodes No 409 (87) 377 (82) 786 (85)
Yesa 54 (12) 73a (16) 127 (14)
Missing 5 (1) 7 (1.5) 12 (1)
Dialysis since last visit No 456 (97) 447 (98) 903 (98)
Yes 7 (1.5) 5 (1) 12 (1)
Missing 5 (1) 5 (1) 10 (1)
Steroids for treatment of myeloma No 15 (3) 9 (2) 24 (3)
Yes 367 (78) 365 (80) 732 (79)
Missing 86 (18) 83 (18) 169 (18)
Participant’s general condition Improving 143 (31) 131 (29) 274 (30)
Stable 253 (54) 269 (59) 522 (56)
Worsening 61 (13) 45 (10) 106 (11)
Missing 11 (2) 12 (3) 23 (2)
Participant’s current bone pain None 130 (28) 116 (25) 246 (27)
Mild 123 (26) 120 (26) 243 (26)
Moderate 98 (21) 105 (23) 203 (22)
Severe 21 (4) 15 (3) 36 (4)
Missing 96 (20.5) 101 (22) 197 (21)
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TABLE 10 Treatment data at 4, 8 and 12 weeks (continued )
Time point Grouping
Treatment arm, n (%)
Total (N= 925),
n (%)
Levofloxacin
(N= 468)
Placebo
(N= 457)
Bone pain compared with last visit Improving 138 (29) 121 (26) 259 (28)
Stable 204 (44) 213 (47) 417 (45)
Worsening 45 (10) 37 (8) 82 (9)
Missing 81 (17) 86 (19) 167 (18)
Time point Grouping
Treatment arm, n (%)
Total (N= 856),
n (%)
Levofloxacin
(N= 430)
Placebo
(N= 426)
Treatment data at 8 weeks
Trial drug dose revised No 389 (90) 387 (91) 776 (91)
Yes 27 (6) 20 (5) 47 (5)
Missing 14 (3) 19 (4) 33 (4)
Revised dose (mg) 500 15 (56) 12 (60) 27 (58)
250 11 (41) 7 (35) 18 (38)
125 1 (4) 1 (5) 2 (4)
Randomised treatment missed No 304 (71) 308 (72) 612 (72)
Yes 50 (12) 39 (9) 89 (10)
Missing 76 (18) 79 (18) 155 (18)
Number of days treatment missed, n, median (IQR) 47, 3 (2–12) 29, 10 (3–17) 76, 6 (2–14.5)
Diarrhoea episodes No 378 (88) 377 (88.5) 755 (88)
Yes 48 (11) 41 (10) 89 (10)
Missing 4 (1) 8 (2) 12 (1)
Dialysis since last visit No 423 (98) 417 (98) 840 (98)
Yes 5 (1) 3 (1) 8 (1)
Missing 2 (0.47) 6 (1) 8 (1)
Steroids for treatment of myeloma No 19 (4) 22 (5) 41 (5)
Yes 342 (80) 335 (79) 677 (79)
Missing 69 (16) 69 (16) 138 (16)
Participant’s general condition Improving 154 (36) 177 (42) 331 (39)
Stable 219 (51) 189 (44) 408 (48)
Worsening 46 (11) 47 (11) 93 (11)
Missing 11 (3) 13 (3) 24 (3)
Participant’s current bone pain None 140 (33) 134 (31) 274 (32)
Mild 124 (29) 113 (27) 237 (28)
Moderate 80 (19) 83 (19) 163 (19)
Severe 8 (2) 8 (2) 16 (2)
Missing 78 (18) 88 (21) 166 (19)
Bone pain compared with last visit Improving 127 (30) 112 (26) 239 (28)
Stable 192 (45) 201 (47) 393 (46)
Worsening 40 (9) 31 (7) 71 (8)
NA/missing 71 (16.5) 82 (19) 153 (18)
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TABLE 10 Treatment data at 4, 8 and 12 weeks (continued )
Time point Grouping
Treatment arm, n (%)
Total (N= 856),
n (%)
Levofloxacin
(N= 430)
Placebo
(N= 426)
Treatment data at 12 weeks
Trial drug dose revised No 336 (81) 321 (80) 657 (80)
Yes 4 (1) 4 (1) 8 (1)
Missing 76 (18) 77 (19) 153 (19)
Revised dose (mg) 500 2 (50) 1 (25) 3 (38)
250 2 (50) 2 (50) 4 (50)
Missing – (–) 1 (25) 1 (12)
Randomised treatment missed No 293 (70) 289 (72) 582 (71)
Yes 46 (11) 41 (10) 87 (11)
Missing 77 (18.5) 72 (18) 149 (18)
Number of days treatment missed, n, median (IQR) 46, 6.5 (2–16) 35, 6 (2–10) 81, 6 (2–13)
Diarrhoea episodes No 368 (88) 359 (89) 272 (89)
Yes 45 (11) 38 (9) 83 (10)
Missing 3 (1) 5 (1) 8 (1)
Dialysis since last visit No 408 (98) 393 (98) 801 (98)
Yes 6 (1) 5 (1) 11 (1)
Missing 2 (0.5) 4 (1) 6 (1)
Steroids for treatment of myeloma No 23 (5.5) 25 (6) 48 (6)
Yes 337 (81) 321 (80) 658 (80)
Missing 56 (13) 56 (14) 112 (14)
Participant’s general condition Improving 156 (37.5) 158 (39) 314 (38)
Stable 203 (49) 204 (51) 407 (50)
Worsening 47 (11) 35 (9) 82 (10)
Missing 10 (2) 5 (1) 15 (2)
Participant’s current bone pain None 148 (36) 160 (40) 308 (38)
Mild 131 (31.5) 111 (28) 242 (30)
Moderate 58 (14) 58 (14) 116 (14)
Severe 8 (2) 8 (2) 16 (2)
Missing 71 (17) 65 (16) 136 (17)
Bone pain compared with last visit Improving 110 (26) 114 (28) 224 (27)
Stable 198 (48) 194 (48) 392 (48)
Worsening 27 (6.5) 26 (6.5) 53 (6.5)
NA/missing 81 (19.5) 68 (17) 149 (18)
IQR, interquartile range; NA, not applicable.
a One episode of diarrhoea on the placebo arm was microbiologically proven to be C. difficile.
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TABLE 11 Treatment data summarised from 0 to 12 weeks
Factor Grouping
Treatment arm, n (%)
Total (N= 2599),
n (%)
Levofloxacin
(N= 1314)
Placebo
(N= 1285)
Trial drug dose revised No 1136 (86) 1128 (88) 2264 (87)
Yes 74 (6) 50 (4) 124 (5)
Missing 104 (8) 107 (8) 211 (8)
Revised dose (mg) 500 49 (66) 31 (62) 80 (64.5)
250 20 (27) 15 (30) 35 (28)
125 5 (7) 3 (6) 8 (6)
Missing 0 (0) 1 (2) 1 (1)
Randomised treatment missed No 895 (68) 890 (69) 1785 (69)
Yes 170 (13) 153 (12) 323 (12)
Missing 249 (19) 242 (19) 491 (19)
Number of days’ treatment missed, n, median (IQR) 157, 5 (2–13) 126, 6 (2–11) 283, 5 (2–13)
Diarrhoea episodes No 1155 (88) 1113 (87) 2268 (87)
Yesa 147 (11) 152 (12) 299 (11.5)
Missing 12 (1) 20 (2) 32 (1)
Dialysis since last visit No 1287 (98) 1257 (98) 2544 (98)
Yes 18 (1) 13 (1) 31 (1)
Missing 9 (1) 15 (1) 24 (1)
Steroids for treatment of myeloma No 57 (4) 56 (4) 113 (4)
Yes 1046 (80) 1021 (80) 2067 (80)
Missing 211 (16) 208 (16) 419 (16)
Participant’s general condition Improving 453 (34) 466 (36) 919 (35)
Stable 675 (51) 662 (51.5) 1337 (51)
Worsening 154 (12) 127 (10) 281 (10)
Missing 32 (2) 30 (2) 62 (2)
Participant’s current bone pain None 418 (32) 410 (32) 828 (32)
Mild 378 (29) 344 (27) 722 (28)
Moderate 236 (18) 246 (19) 482 (18.5)
Severe 37 (3) 31 (2) 68 (3)
Missing 245 (19) 254 (20) 499 (19)
Bone pain compared with last visit Improving 375 (29) 347 (27) 722 (28)
Stable 594 (45) 608 (47) 1202 (46)
Worsening 112 (9) 94 (7) 206 (8)
NA/missing 233 (18) 236 (18) 469 (18)
IQR, interquartile range; NA, not applicable.
a One episode of diarrhoea on the placebo arm was microbiologically proven to be C. difficile.
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Infections
Febrile episodes
Table 12 presents the number of febrile episodes experienced by treatment arm. A total number of
264 febrile episodes were reported, with 113 episodes of these being reported by patients in the levofloxacin
arm, compared with 151 in the placebo arm. The number of patients reporting febrile episodes was
consistently higher in the placebo arm.
TABLE 12 Total number of reported febrile episodes, by treatment arm
Visit
Treatment arm, n (%)
Total (N= 930), n (%)Levofloxacin (N= 470) Placebo (N= 460)
0–4 weeks
Febrile episodes since last visit
0 408 (87) 380 (83) 788 (85)
1 55 (12) 75 (16) 130 (14)
2 7 (1) 5 (1) 12 (1)
p-trend = 0.15
Number of patients reporting infections 62 80 142
Total number of episodes 69 85 154
Visit
Treatment arm, n (%)
Total (N= 860), n (%)Levofloxacin (N= 432) Placebo (N= 428)
4–8 weeks
Febrile episodes since last visit
0 410 (95) 390 (91) 800 (93)
1 21 (5) 36 (8) 57 (7)
2 1 (< 1) 2 (< 1) 3 (< 1)
p-trend = 0.03
Number of patients reporting infections 22 38 60
Total number of episodes 23 40 63
Visit
Treatment arm, n (%)
Total (N= 821), n (%)Levofloxacin (N= 417) Placebo (N= 404)
8-12 weeks
Febrile episodes since last visit
0 397 (95) 379 (94) 776 (95)
1 19 (5) 24 (6) 43 (5)
2 1 (< 1) 1 (< 1) 2 (< 1)
p-trend = 0.41
Number of patients reporting infections 20 25 45
Total number of episodes 21 26 47
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There was a significant trend in the number of febrile episodes reported across treatment arm within the
0- to 12-week summary (Mantel–Haenszel χ= 5.52; p= 0.02), with more febrile episodes reported in the
placebo arm. This difference can be explained by the number of febrile episodes reported within the 4- to
8-week period from starting the trial treatment (p= 0.03).
There were 264 febrile episodes reported, for which infection forms were returned. Details on the site,
type and confirmation of infections are detailed in Table 13.
TABLE 12 Total number of reported febrile episodes, by treatment arm (continued )
Visit
Treatment arm, n (%)
Total (N= 934), n (%)Levofloxacin (N= 471) Placebo (N= 463)
0–12 weeks
Febrile episodes since last visit
0 379 (80) 338 (73) 717 (77)
1 74 (16) 104 (22) 178 (19)
2+ 18 (4) 21 (5) 39 (4)
p-trend= 0.02
Number of patients reporting infections 92 125 217
Total number of episodes 113 151 264
TABLE 13 Febrile episode details, by treatment arm (N= 264)
Factor Grouping
Treatment arm, n (%)
Total (N= 264),
n (%)
Levofloxacin
(N= 113)
Placebo
(N= 151)
Randomised treatment stopped during
episode
No 55 (49) 86 (57) 141 (53)
Yes 57 (50) 63 (42) 120 (46)
Missing 1 (1) 2 (1) 3 (1)
Clinically diagnosed No 37 (33) 58 (38) 95 (36)
Yes 76 (67) 93 (62) 169 (64)
Site of clinically diagnosed infection Lower respiratory tract 39 (47) 49 (51) 88 (49)
Upper respiratory tract 11 (13) 11 (11) 22 (12)
Intravenous catheter associated 1 (1) 1 (1) 2 (1)
Bloodstream 5 (6) 8 (8) 13 (7)
Urinary tract infection 6 (7) 7 (7) 13 (7)
Gastrointestinal tract 2 (2) 3 (3) 5 (3)
Skin soft tissue 6 (7) 8 (8) 14 (8)
Other sitea 7 (8) 7 (7) 14 (8)
Unknown 6 (7) 1 (1) 7 (4)
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Other (non-febrile) infections
There were 249 patients who reported to have suffered a non-febrile infectious episode; there were 116 in
the levofloxacin arm, compared with 133 patients in placebo arm (Table 14). A total of 323 episodes were
reported (144 in the levofloxacin arm vs. 179 in the placebo arm).
There was a borderline trend in the number of non-febrile infections reported across treatment arms
within the 0- to 12-week summary (Mantel–Haenszel χ= 3.67; p= 0.06), with more episodes reported in
the placebo arm.
At the time of data lock, 323 infection forms reporting details of non-febrile episodes had been received:
144 from the levofloxacin arm and 179 from the placebo arm. Details of these non-febrile episodes
reported on the infection forms are summarised in Table 15.
TABLE 13 Febrile episode details, by treatment arm (N= 264) (continued )
Factor Grouping
Treatment arm, n (%)
Total (N= 264),
n (%)
Levofloxacin
(N= 113)
Placebo
(N= 151)
Type of infection (confirmed or
suspected)
Bacterial 28 (25) 39 (26) 67 (25)
Fungal 3 (3) 1 (1) 4 (2)
Viral 12 (11) 12 (8) 24 (9)
Bacterial and viral 0 (0) 1 (1) 1 (< 1)
Bacterial and fungal 1 (1) 1 (1) 2 (1)
Not known 51 (45) 79 (52) 130 (49)
Missing 18 (16) 18 (12) 36 (14)
Laboratory specimens taken No 13 (11) 20 (13) 33 (13)
Yes 88 (78) 124 (82) 212 (80)
Missing 12 (11) 7 (5) 19 (7)
Positive cultures (multiple per infection) Yes 22 (10) 38 (16) 60 (13)
Organism suspected or confirmed No 76 (67) 102 (67) 178 (68)
Yes 18 (16) 33 (22) 51 (19)
Missing 19 (17) 16 (11) 35 (13)
Admitted to hospital No 24 (21) 36 (24) 60 (23)
Yes 88 (78) 114 (75) 202 (76)
Missing 1 (1) 1 (1) 2 (1)
Admitted to intensive therapy unit Yes 3 (3) 5 (3) 8 (3)
Infection developed in hospital No 101 (89) 137 (91) 238 (90)
Yes 10 (9) 14 (9) 24 (9)
Missing 2 (2) 0 (0) 2 (1)
a There were 14 ‘other’ reported sites of febrile infections: seven in the levofloxacin arm and seven in the placebo arm.
The seven febrile infections reported in the levofloxacin arm were suspected meningitis; acute kidney infection;
diverticular abscess; generalised myalgia, possibly viral; hospital-acquired pneumonia and hospital-acquired kidney injury,
both on diagnosis; reaction to either allopurinol or thalidomide; and an intraoperative tear during spinal surgery, in
which the patient’s temperature spiked after surgery, an infection was suspected. The seven febrile infections reported in
the placebo were neutropenic sepsis (two patients), neutropenic sepsis and anaphylaxis-type reaction, neutropenic sepsis
allergic reaction to medication, acute cholecystitis, fever and atrial fibrillation, and testicles.
DOI: 10.3310/hta23620 HEALTH TECHNOLOGY ASSESSMENT 2019 VOL. 23 NO. 62
© Queen’s Printer and Controller of HMSO 2019. This work was produced by Drayson et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
33
TABLE 14 Number of non-febrile infections, by treatment arm
Visit
Treatment arm, n (%)
Total (N= 930), n (%)Levofloxacin (N= 469) Placebo (N= 461)
0–4 weeks
Non-febrile episodes since last visit
0 400 (85) 398 (86) 798 (86)
1 66 (14) 56 (12) 122 (13)
2 3 (1) 7 (2) 10 (1)
p-trend= 0.95
Number of patients reporting infections 69 63 132
Total number of episodes 72 70 142
Visit
Treatment arm, n (%)
Total (N= 860), n (%)Levofloxacin (N= 432) Placebo (N= 428)
4–8 weeks
Non-febrile episodes since last visit
0 397 (92) 376 (88) 773 (90)
1 33 (8) 48 (11) 81 (9)
2 2 (< 1) 4 (1) 6 (1)
p-trend= 0.05
Number of patients reporting infections 35 52 87
Total number of episodes 37 56 93
Visit
Treatment arm, n (%)
Total (N= 821), n (%)Levofloxacin (N= 417) Placebo (N= 404)
8–12 weeks
Non-febrile episodes since last visit
0 382 (92) 356 (88) 738 (90)
1 35 (8) 43 (11) 78 (9)
2 0 5 (1) 5 (1)
p-trend= 0.04
Number of patients reporting infections 35 48 83
Total number of episodes 35 53 88
Visit
Treatment arm, n (%)
Total (N= 935), n (%)Levofloxacin (N= 470) Placebo (N= 465)
0–12 weeks
Non-febrile episodes since last visit
0 354 (75) 332 (71) 686 (73)
1 94 (20) 95 (20) 189 (20)
2+ 22 (5) 38 (8) 60 (6)
p-trend= 0.06
Number of patients reporting infections 116 133 249
Total number of episodes 144 179 323
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TABLE 15 Non-febrile infection details, by treatment arm
Factor Grouping
Treatment arm, n (%)
Total (N= 323),
n (%)
Levofloxacin
(N= 144)
Placebo
(N= 179)
Randomised treatment stopped during
episode
No 104 (72) 153 (85) 257 (80)
Yes 37 (26) 22 (12) 59 (18)
Missing 3 (2) 4 (2) 7 (2)
Clinically diagnosed No 20 (14) 17 (10) 37 (11)
Yes 124 (86) 161 (90) 285 (88)
Missing 0 (0) 1 (1) 1 (< 1)
Site of clinically diagnosed infection Lower respiratory tract 46 (37) 48 (30) 94 (33)
Upper respiratory tract 21 (17) 22 (14) 43 (15)
Skin soft tissue 18 (14) 24 (15) 42 (15)
Othera 17 (14) 25 (15) 42 (15)
Urinary tract infection 12 (10) 26 (16) 38 (13)
Dental/abscess 4 (3) 6 (4) 10 (3)
Gastrointestinal tract 4 (3) 3 (2) 7 (2)
Intravenous catheter associated 1 (1) 4 (2) 5 (2)
Bloodstream 1 (1) 1 (1) 2 (1)
Unknown 1 (1) 2 (1) 3 (1)
Bone/joint 0 (0) 1 (1) 1 (< 1)
Type of infection confirmed or
suspected
Bacterial 37 (26) 60 (34) 97 (30)
Fungal 12 (8) 8 (4) 20 (6)
Viral 10 (7) 16 (9) 26 (8)
Bacterial and viral 0 (0) 1 (1) 1 (< 1)
Bacterial and fungal 1 (1) 0 (0) 1 (< 1)
Fungal and viral 1 (1) 0 (0) 1 (< 1)
Not known 64 (44) 77 (43) 141 (44)
Missing 19 (13) 17 (10) 36 (11)
Laboratory specimens taken No 68 (47) 87 (49) 155 (48)
Yes 64 (44) 76 (42) 140 (43)
Missing 12 (8) 16 (9) 28 (9)
Positive cultures (multiple per infection) Yes 27 (27) 44 (40) 71 (34)
Suspected or confirmed presence of an
organism
No 100 (69) 113 (63) 213 (66)
Yes 26 (18) 48 (27) 74 (23)
Missing 18 (13) 18 (10) 36 (11)
Admitted to hospital No 100 (69) 142 (79) 242 (75)
Yes 42 (29) 37 (21) 79 (24)
Missing 2 (1) 0 (0) 2 (1)
Admitted to intensive therapy unit Yes 1 (1) 1 (1) 2 (1)
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Total infections
A total of 411 patients reported an infection (febrile or non-febrile) on their on-treatment form (190 in the
levofloxacin arm and 221 in the placebo arm). A total of 587 infectious episodes were reported (257 in the
levofloxacin arm and 330 in the placebo arm), as shown in Table 16.
TABLE 15 Non-febrile infection details, by treatment arm (continued )
Factor Grouping
Treatment arm, n (%)
Total (N= 323),
n (%)
Levofloxacin
(N= 144)
Placebo
(N= 179)
Infection developed in hospital No 127 (88) 155 (87) 282 (87)
Yes 14 (10) 16 (9) 30 (9)
Missing 3 (2) 8 (4) 11 (4)
a There were 42 ‘other sites of clinically diagnosed infections’: 17 in the levofloxacin arm and 25 in the placebo arm. The
17 infections reported in patients in the levofloxacin arm were eye infection (two patients), oral thrush (two patients),
intra-abdominal abscess (two patients), pelvic abscess (two patients), cellulitis/orbital cellulitis (two patients), sinusitis,
tickly cough – possible chest infection, vaginal candidiasis, bilateral pedal oedema overlying skin blisters and ulcers,
no-infection-treated hyponatraemia, pain in right ear and jaw and poorly controlled AF and opiate excess. The 25 infections
reported in the placebo group were eye infection/conjunctivitis (eight patients), mouth/oral thrush (five patients), sinusitis/
ear infection (four patients), shingles (three patients), blepharitis, cardiac (endocarditis), Haemophilus influenzae,
peripheral nerve infection and suspected cellulitis (recorded by an out-of-hours GP) on the right lower leg – later
confirmed as deep-vein thrombosis.
TABLE 16 Total number of infections (febrile and non-febrile), by treatment arm
Visit
Treatment arm, n (%)
Total (N= 932), n (%)Levofloxacin (N= 470) Placebo (N= 462)
0–4 weeks
Total number of infections since last visit
0 342 (73) 329 (71) 671 (72)
1 115 (24) 111 (24) 226 (24)
2 13 (3) 22 (5) 35 (4)
p-trend= 0.32
Number of patients reporting infections 128 133 261
Total number of infections 141 155 296
Visit
Treatment arm, n (%)
Total (N= 860), n (%)Levofloxacin (N= 432) Placebo (N= 428)
4–8 weeks
Total number of infections since last visit
0 375 (87) 341 (80) 716 (8)
1 54 (12) 78 (18) 132 (15)
2 3 (1) 9 (2) 12 (1)
p-trend= 0.003
Number of patients reporting infections 57 87 144
Total number of infections 60 96 156
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There was a significant trend in the total number of infections reported across treatment arms within the
0- to 12-week summary (Mantel-Haenszel χ= 7.89; p= 0.005), with more patients reporting total infections in
the placebo arm. This difference can be explained by the number of infections reported per patient between
the 4- to 12-week period from starting trial treatment.
At the time of data lock, 587 infection forms reporting details of these episodes had been received: 257
from patients of the levofloxacin arm and 330 from patients of the placebo arm. Infection details are
shown in Table 17.
Incidence of microbiologically proven infections, the pathogens and their susceptibility
to antibacterials
The identity of species cultured from invasive isolates were extracted from laboratory reports of the
112 specimens. The laboratory reports were obtained for patients in which positive cultures were detected;
of the 131 patients reported with positive cultures, 49 were reported in the levofloxacin arm and 82 were
reported in the placebo arm (Table 17). A total of 112 organisms were detected: 44 from the levofloxacin
arm and 69 from the placebo arm. There were fewer Gram-negative infections reported in the levofloxacin
arm than in the placebo arm (Table 18).
TABLE 16 Total number of infections (febrile and non-febrile), by treatment arm (continued )
Visit
Treatment arm, n (%)
Total (N= 821), n (%)Levofloxacin (N= 417) Placebo (N= 404)
8–12 weeks
Total number of infections since last visit
0 363 (87) 331 (82) 694 (85)
1 52 (12) 67 (17) 119 (14)
2 2 (< 1) 6 (1) 8 (1)
p-trend = 0.03
Number of patients reporting infections 54 73 127
Total number of infections 56 79 135
Visit
Treatment arm, n (%)
Total (N= 936), n (%)Levofloxacin (N= 471) Placebo (N= 465)
0–12 weeks
Total number of infections since last visit
0 281 (60) 244 (52) 525 (56)
1 138 (29) 143 (31) 281 (30)
2 38 (8) 54 (12) 92 (10)
3+ 14 (3) 24 (5) 38 (4)
p-trend = 0.005
Number of patients reporting infections 190 221 411
Total number of infections 257 330 587
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TABLE 17 Details of total infection episodes
Factor Grouping
Treatment arm, n (%)
Total
(N= 587),
n (%)
Levofloxacin
(N= 257)
Placebo
(N= 330)
Randomised treatment stopped during
episode
No 159 (62) 239 (72) 398 (68)
Yes 94 (37) 85 (26) 179 (30)
Missing 4 (2) 6 (2) 10 (2)
Clinically diagnosed No 57 (22) 75 (23) 132 (22)
Yes 200 (78) 254 (77) 454 (77)
Missing 0 (0) 1 (< 1) 1 (< 1)
Site of clinically diagnosed infection Lower respiratory tract 85 (41) 97 (38) 182 (39)
Upper respiratory tract 32 (15) 33 (13) 65 (14)
Skin soft tissue 24 (12) 32 (12) 56 (12)
Other 24 (12) 32 (12) 56 (12)
Urinary tract infection 18 (9) 33 (13) 51 (11)
Dental/abscess 4 (2) 7 (3) 11 (2)
Gastrointestinal tract 6 (3) 6 (2) 12 (3)
Intravenous catheter associated 2 (1) 5 (2) 7 (2)
Bloodstream 6 (3) 9 (3) 15 (3)
Unknown 7 (3) 3 (1) 10 (2)
Bone/joint 0 (0) 1 (< 1) 1 (< 1)
Type of infection (confirmed or suspected) Bacterial 65 (25) 99 (30) 164 (28)
Fungal 15 (6) 9 (3) 24 (4)
Viral 22 (9) 28 (8) 50 (9)
Bacterial and viral 0 (0) 2 (1) 2 (< 1)
Bacterial and fungal 2 (1) 1 (< 1) 3 (1)
Fungal and viral 1 (< 1) 0 (0) 1 (< 1)
Not known 115 (45) 156 (47) 271 (46)
Missing 37 (14) 35 (11) 72 (12)
Laboratory specimens taken No 81 (32) 107 (32) 188 (32)
Yes 152 (59) 200 (61) 352 (60)
Missing 24 (9) 23 (7) 47 (8)
Positive cultures (multiple per infection) Yes 49 (16) 82 (24) 131 (20)
Suspected or confirmed presence of an
organism
No 176 (68) 215 (65) 391 (67)
Yes 44 (17) 81 (25) 125 (21)
Missing 37 (14) 34 (10) 71 (12)
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TABLE 18 Reported potentially pathogenic or invasive isolates from local laboratories, by treatment arm
Species
Treatment arm, n (%)
Total (n)Levofloxacin Placebo
Total number of Gram-negative
organisms 6 (18) 27 (82) 33
Enterobacteriaceae 4 14 18
Pseudomonas species 0 5 5
Other Gram-negative organisms 2 8 10
Total number of Gram-positive infections 16 (44) 20 (56) 36
S. aureus 4 6 10
Streptococcus pneumoniae 0 3 3
Coagulase-negative Staphylococcus 5 5 10
Other Gram-positive organisms 7 6 13
Total number of other bacterial infections 4 (50) 4 (50) 8
Anaerobic 1 2 3
Mixed growth 3 2 5
Total number of viral infections 10 (50) 10 (50) 20
Adenovirus 1 0 1
Cytomegalovirus 1 0 1
Herpes simplex/varicella 3 0 3
Influenza 2 5 7
Metapneumovirus 0 2 2
Parainfluenza 2 3 5
Respiratory syncytial virus (RSV) 1 0 1
Candida speciesa 8 (53) 7 (47) 15
Total number of isolates 44 (39) 69 (61) 112
a The majority (i.e. 14/15) were oral/upper respiratory samples.
TABLE 17 Details of total infection episodes (continued )
Factor Grouping
Treatment arm, n (%)
Total
(N= 587),
n (%)
Levofloxacin
(N= 257)
Placebo
(N= 330)
Admitted to hospital No 124 (48) 178 (54) 302 (51)
Yes 130 (51) 151 (46) 281 (48)
Missing 3 (1) 1 (< 1) 4 (1)
Admitted to intensive therapy unit Yes 4 (2) 6 (2) 10 (2)
Infection developed in hospital No 228 (89) 292 (88) 520 (89)
Yes 24 (9) 30 (9) 54 (9)
Missing 5 (2) 8 (2) 13 (2)
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Reported sensitivities of invasive organisms from local laboratories
Note that, although the numbers are small, all isolates in the levofloxacin arm of the trial are resistant to
quinolones, as shown in Table 19.
Deaths and infection-related deaths
Overall, a total of 116 deaths were reported among the 977 randomised patients (levofloxacin, n = 61;
placebo, n = 55). A total of 30 patients (total of 52 causes) died within 12 weeks of starting trial treatment
(levofloxacin, n = 8; placebo, n = 22). One patient randomised to placebo died prior to starting trial
treatment. A total of 86 patients died post 12 weeks (levofloxacin, n = 53; placebo, n = 33). Table 20
presents causes of death by treatment arm. A total of 220 causes of death were reported for the
116 deaths, as selection of multiple causes is permitted on the death form. Cause of death was not
available for one patient on placebo who died in a nursing home.
TABLE 19 Reported sensitivities of invasive organisms reported by local laboratories
Antibiotic category
Treatment arm
Levofloxacin Placebo
Number sensitive/number tested % Number sensitive/number tested %
Quinolone 0/3 0 7/8 88
Penicillin 10/19 53 16/30 53
Aminoglycoside 5/7 71 11/13 85
Co-amoxiclav 4/5 80 9/14 64
Piperacillin/tazobactam 2/2 100 7/8 88
Carbapenem 2/2 100 6/6 100
Cephalosporin 2/2 100 6/8 75
Other 34/44 76 62/83 75
TABLE 20 Causes of death, by treatment
Causes of death within 12 weeks Treatment arm, n (%)
Total (N= 52),
n (%)Disease related Cause of death
Levofloxacin
(N= 13)
Placebo
(N= 39)
Myeloma related Myeloma/disease progression 4 (31) 13 (33) 17 (33)
Overwhelming tumour load 0 (0) 0 (0) 0 (0)
Infection 2 (15) 6 (15) 8 (15)
Renal failure 2 (15) 4 (10) 6 (12)
Skeletal 0 (0) 1 (3) 1 (2)
Subtotal 8 24 32
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TABLE 20 Causes of death, by treatment (continued )
Causes of death within 12 weeks Treatment arm, n (%)
Total (N= 52),
n (%)Disease related Cause of death
Levofloxacin
(N= 13)
Placebo
(N= 39)
Non-myeloma related Cardiac 2 (15) 8 (20) 10 (19)
Respiratory 1 (8) 2 (5) 3 (6)
Neurological 0 (0) 1 (3) 1 (2)
Other malignancy 0 (0) 0 (0) 0 (0)
Infection 1 (8) 2 (5) 3 (6)
Other 1 (8) 2 (5) 3 (6)
Subtotal 5 15 20
Total infection related 3 8 11
Causes of death post 12 weeks Treatment arm, n (%)
Total (N= 168),
n (%)Disease related Cause of death
Levofloxacin
(N= 106)
Placebo
(N= 62)
Myeloma related Myeloma/disease progression 44 (42) 22 (35) 66 (39)
Overwhelming tumour load 4 (4) 2 (3) 6 (4)
Infection 13 (12) 10 (16) 23 (14)
Renal failure 7 (7) 6 (10) 13 (8)
Skeletal 2 (2) 1 (2) 3 (2)
Subtotal 70 41 111
Non-myeloma related Cardiac 10 (9) 6 (10) 16 (10)
Respiratory 8 (8) 7 (11) 15 (9)
Neurological 2 (2) 1 (2) 3 (2)
Other malignancy 0 (0) 1 (2) 1 (1)
Infection 6 (6) 2 (3) 8 (5)
Other 10 (9) 4 (6) 14 (8)
Subtotal 36 21 57
Total infection related 19 12 31
Total causes of death Treatment arm, n (%)
Total (N= 220),
n (%)Disease related Cause of death
Levofloxacin
(N= 119)
Placebo
(N= 101)
Myeloma related Myeloma/disease progression 48 (40) 35 (35) 83 (38)
Overwhelming tumour load 4 (3) 2 (2) 6 (3)
Infection 15 (13) 16 (16) 31 (14)
Renal failure 9 (7) 10 (10) 19 (8)
Skeletal 2 (2) 2 (2) 4 (2)
Subtotal 78 (65) 65 (65) 143 (65)
continued
DOI: 10.3310/hta23620 HEALTH TECHNOLOGY ASSESSMENT 2019 VOL. 23 NO. 62
© Queen’s Printer and Controller of HMSO 2019. This work was produced by Drayson et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
41
The majority of deaths were attributed to myeloma-related causes (n = 143, 65%) as opposed to
non-myeloma-related causes (n = 77, 35%). Infection-related cause of death was less common in the
levofloxacin arm (three causes) than in the the placebo arm (eight causes) within 12 weeks. However,
more infection-related causes of death were reported in the levofloxacin arm (19 causes) than in the
placebo arm (12 causes) post 12 weeks.
All deaths within 12 weeks were reviewed by an independent clinician to ascertain causes of death.
Deaths post 12 weeks were reviewed by the two clinical chief investigators.
Time to first event by treatment arm across 12 weeks
Table 21 shows the number of febrile episodes, deaths and febrile episodes and deaths combined by
treatment arm within the first 12 weeks. A total of 210 patients reported febrile infections (levofloxacin,
n = 91; placebo, n = 119) out of the total 977 patients randomised.
Time to first event was calculated from the date of starting trial treatment to the date of febrile episode or
date of death for the 229 patients reporting a febrile episode or death within 12 weeks. The remaining
patients were censored at date of withdrawal or the last date considered appropriate. Figure 4 shows the
19% of patients randomised to levofloxacin reporting a febrile episode, or death, within 12 weeks from
the start of trial treatment compared with the 27% in the placebo arm; log-rank χ2 test = 9.78; HR 0.66,
95% CI 0.51 to 0.86; p = 0.002 in favour of levofloxacin.
TABLE 20 Causes of death, by treatment (continued )
Total causes of death Treatment arm, n (%)
Total (N= 220),
n (%)Disease related Cause of death
Levofloxacin
(N= 119)
Placebo
(N= 101)
Non-myeloma related Cardiac 12 (10) 14 (14) 26 (12)
Respiratory 9 (8) 9 (9) 18 (8)
Neurological 2 (2) 2 (2) 4 (2)
Other malignancy 0 (0) 1 (< 1) 1 (< 1)
Infection 7 (6) 4 (4) 11 (5)
Other 11 (9) 6 (6) 17 (8)
Subtotal 41 (35) 36 (35) 77 (35)
TABLE 21 Combined events (febrile episodes and deaths), by treatment arm
Event category
Treatment arm, n (%)
Total (N= 977), n (%)Levofloxacin (N= 489) Placebo (N= 488)
None 394 354 748
Febrile episode only 87g 91 112 g 119 199 g 210
Death only 4 15 19
Febrile episode and death 4 7 11
Total events 95 (19) 134 (27) 229 (23)
RESULTS
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The Cox regression analysis showed that treatment is the most important factor and still retains
significance in a multivariate model adjusting for baseline factors. A Cox regression model excluding
treatment indicates that no other factors predict time to febrile episode or death. Assessing the individual
factors indicates that ECOG performance status is the only factor with a borderline significance. Table 22
shows the treatment effect unadjusted and adjusted by baseline factors. It can be seen that adjustment
makes little difference to the overall treatment effect.
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FIGURE 4 Time to first event (febrile or death) within 12 weeks. Log-rank χ2 test = 9.78; HR 0.66, 95% CI 0.51 to
0.86; p= 0.002.
TABLE 22 Cox regression to predict febrile episode or death within 12 weeks of starting trial treatment
Factor Grouping Coefficient p-value HR (95% CI)
Treatment only (n = 977; 229 events)
Treatment Placebo, levofloxacin –0.42 0.002 0.66 (0.51 to 0.86)
Treatment adjusted for baseline factors (n= 668; 166 events)
Treatment Placebo, levofloxacin –0.32 0.04 0.73 (0.53 to 0.99)
ECOG performance status at randomisation 0–2, 3–4 0.46 0.11 1.58 (0.90 to 2.78)
Vertebral fractures Absent, present –0.21 0.27 0.81 (0.56 to 1.17)
Neutrophils (× 109/l) < 1.8, ≥ 1.8 –0.30 0.22 0.74 (0.46 to 1.19)
ESBL isolated at baseline No, yes 0.18 0.46 1.20 (0.74 to 1.94)
International Staging System Stage I, II, III –0.05 0.61 0.95 (0.77 to 1.16)
Individual factors – univariate
ECOG (n = 957, events = 226) 0, 1, 2, 3, 4 0.13 0.07 1.14 (0.99 to 1.31)
ECOG 0–2, 3–4 0.45 0.04 1.57 (1.01 to 2.44)
Vertebral (n = 977, events = 229) Absent, present 0.02 0.90 1.02 (0.76 to 1.36)
ESBL isolated at baseline (n= 785, events= 187) No, yes 0.39 0.06 1.49 (0.98 to 2.27)
Neutrophils (n= 967, events = 229) Continuous –0.02 0.37 0.98 (0.94 to 1.02)
Prophylactic Septrin (n = 946, events = 224) No, yes –0.52 0.0008 0.59 (0.44 to 0.80)
continued
DOI: 10.3310/hta23620 HEALTH TECHNOLOGY ASSESSMENT 2019 VOL. 23 NO. 62
© Queen’s Printer and Controller of HMSO 2019. This work was produced by Drayson et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
43
The most significant individual baseline factor was the use of prophylactic Septrin (HR 0.59, 95% CI
0.44 to 0.80; p = 0.0008), followed by treatment (HR 0.66, 95% CI 0.51 to 0.86; p = 0.002). Adjusting
treatment for prophylactic Septrin use made little difference to the treatment effect, indicating that these
two variables have independent prognostic value (Figure 5).
TABLE 22 Cox regression to predict febrile episode or death within 12 weeks of starting trial treatment (continued )
Factor Grouping Coefficient p-value HR (95% CI)
Anti-infective history (treatment of infection
month prior to trial treatment) (n= 814,
events = 182)
No, yes 0.36 0.04 1.43 (1.01 to 2.01)
Steroids in 14 days prior to randomisation
(n= 970, events = 229)
No, yes –0.09 0.52 0.92 (0.71 to 1.19)
Treatment and prophylactic Septrin (n = 946, events = 224)
Treatment Placebo, levofloxacin –0.41 0.002 0.66 (0.51 to 0.86)
Prophylactic Septrin No, yes –0.52 0.0009 0.59 (0.44 to 0.81)
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FIGURE 5 Treatment adjusted for Septrin (p= 0.002). (a) Septrin; and (b) no Septrin.
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Overall survival
Overall survival was calculated from the date of starting trial treatment to the date of death or being
censored at date last alive. Figure 6 shows that 98% of patients on levofloxacin survived for 12 weeks,
compared with 95% of patients on placebo (p = 0.94). Twelve-month survival was similar across arms
(levofloxacin, 90%; placebo, 91%). Follow-up of surviving patients was the same [median 12 months;
interquartile range (IQR) 11–13 months] in both arms.
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FIGURE 6 Overall survival, by treatment. Log-rank χ2 test= 0.004; p= 0.94.
Micro-organism sample return and acquisition
Table 23 shows the numbers of C. difficile, MRSA and ESBL Gram-negative organisms that were present at
baseline. It also shows the number of new acquisitions between baseline and 16 weeks. The total number
of nasal and stool samples returned between baseline and 16 weeks is indicated in the left-hand column.
There were no differences in new ESBL acquisitions between the placebo and levofloxacin arms (30 vs. 25,
respectively). There were no differences in acquisitions for C. difficile (8 vs. 11) and MRSA (7 vs. 4) between
the placebo and levofloxacin arms.
Days on additional anti-infective treatment and total doses taken for
treatment of infection, by treatment arm
A summation of all anti-infective drugs prescribed for the treatment of infections during the trial treatment
period by treatment arm, excluding TEAMM trial medication, is shown in Table 24.
Response to antimyeloma treatment
Response to myeloma treatment within the first 12 weeks is an early indication of whether or not patients will
reach stable disease. The main reason why patients do not respond is disease progression. Changes between
blood samples collected at baseline and the last sample collected within 12 weeks will indicate if patients have
had an early response to antimyeloma treatment. This will be presented as part of the TEAMM National Institute
for Health Research (NIHR) Efficacy and Mechanism Evaluation (EME) grant (reference number 14/24/04).
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TABLE 23 Organisms isolated, by treatment arm
Organism
Treatment arm, (n)
Total, (n)Levofloxacin Placebo
C. difficile ESBL MRSA C. difficile ESBL MRSA C. difficile ESBL MRSA
Present at baseline
(785 stool and
928 nasal samples)
1 19 5 5 37 9 6 56 14
New acquisitions
Week 4 (706 stool and
805 nasal samples)
4 8 0 3 11 4 7 19 4
Week 8 (662 stool and
759 nasal samples)
0 5 1 2 7 1 2 12 2
Week 12 (634 stool
and 719 nasal samples)
3 3 1 2 7 2 5 10 3
Week 16 (593 stool
and 650 nasal samples)
4 9 2 1 5 0 5 14 2
Total new acquisitions
(2595 stool and
2933 nasal samples)
11 25 4 8 30 7 19 55 11
TABLE 24 Days on additional anti-infective treatment and total doses taken for treatment of infection,
by treatment arm
Factor
Treatment arm
Wilcoxon two-sample p-valueLevofloxacin Placebo
Total number of days on anti-infectives
n 186 207 0.19
Median 16 20
IQR 12–30 12–32
Range 2–129 2–235
Total dose taken (g or l)
n 160 180 0.99
Median 8 9
IQR 3–25 2–27
Range 0.02–65 0.02–60
Total 99 192
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Serious adverse events
Since the start of the trial, a total of 597 SAEs have been reported to the TEAMM trial office (of these,
308 were from patients on levofloxacin and 289 were from patients on placebo). Tables 25–28 present
information relating to the type of event by treatment for all SAEs and summarises the severity and
causality assessments, and outcomes of each event by treatment.
TABLE 25 Event type, by treatment arm
Event type
Treatment arm, n (%)
Total, n (%)Levofloxacin Placebo
Death 2 (0.6) 5 (2) 7 (1)
Life-threatening event 1 (0.3) 7 (2) 8 (1)
Hospitalisation or prolongation of hospitalisation 235 (76) 227 (78) 462 (77)
Persistent or significant disability/incapacity 5 (2) 4 (1) 9 (1)
Congenital anomaly/birth defect – (–) – (–) – (–)
Other reason 16 (5) 19 (7) 35 (6)
Hospitalisation and other reason 6 (2) 2 (1) 8 (1)
Life-threatening event, hospitalisation, disability/incapacity 3 (1) 3 (1) 6 (1)
Death, life-threatening event, hospitalisation 0 (0) 2 (1) 2 (0.3)
Hospitalisation and disability/incapacity 11 (4) 2 (1) 13 (2)
Life-threatening event and hospitalisation 28 (9) 16 (6) 44 (7)
Disability/congenital anomaly/other reason 0 (0) 1 (0.3) 1 (0.2)
Death and hospitalisation 1 (0.3) 0 (0) 1 (0.2)
Death and hospitalisation/other reason 0 (0) 1 (0.3) 1 (0.2)
Total 308 (100) 289 (100) 597 (100)
TABLE 26 Severity assessment, by treatment arm
Severity
Treatment arm, n (%)
Total (N= 597), n (%)Levofloxacin (N= 308) Placebo (N= 289)
Mild 38 (12) 29 (10) 67 (11)
Moderate 136 (44) 141 (49) 277 (46)
Severe 101 (33) 86 (30) 187 (31)
Fatal/life-threatening 32 (10) 33 (11) 65 (11)
Missing 1 (0.3) 0 (0) 1 (0.2)
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In summary, 597 SAEs were reported for patients (levofloxacin, n = 308; placebo, n = 289), with the
majority reported as being unlikely to be related to or unrelated to the study drug (537/597, 90%) but, instead,
related to hospitalisation or prolongation of existing hospitalisation (462/597, 77%). Toxicity reported to be
related to levofloxacin (38 episodes) compared with placebo (22 episodes) had a trend towards more
gastrointestinal disorders (fours events of nausea/vomiting on levofloxacin vs. one event on placebo) but
fewer episodes of diarrhoea (five episodes on levofloxacin vs. nine episodes on placebo), rash (six episodes
on levofloxacin vs. one episode on placebo), psychiatric disorders (two episodes on levofloxacin vs. no
episodes on placebo) and musculoskeletal and connective tissue disorders (seven episodes on levofloxacin
and one episode on placebo) (see Table 44). Appendix 2 provides further information as regards the
summary of the CTCAE categories of all SAEs reported (see Table 43) together with their terms of SAEs
by treatment (see Table 43). In addition, reported SARs are detailed (see Tables 44 and 45).
Quality of life
Within the scope of the TEAMM grant, QoL was measured at baseline and at 4, 8, 12 and 16 weeks for
patients who consented to fill in the QoL booklets. These data include the responses to the EQ-5D, which
are reported in Chapter 4, as well as to the EORTC QLQ-C30, EORTC QLQ-MY24 and HADS.
TABLE 27 Causality assessment, by treatment arm
Causality
Treatment arm, n (%)
Total (N= 597), n (%)Levofloxacin (N= 308) Placebo (N= 289)
Definitely 1 (0.3) 0 (0) 1 (0.2)
Probably 8 (3) 5 (2) 13 (2)
Possibly 29 (9) 17 (6) 46 (8)
Unlikely 126 (41) 120 (42) 246 (41)
Unrelated 144 (47) 147 (51) 291 (49)
TABLE 28 Outcome of event, by treatment arm
Outcome
Treatment arm, n (%)
Total (N= 597), n (%)Levofloxacin (N= 308) Placebo (N= 289)
Resolved – no sequelae 229 (74) 220 (76) 449 (75)
Resolved – with sequelae 67 (22) 44 (15) 111 (19)
Unresolved 2 (1) 1 (0.3) 3 (0.5)
Death 9 (3) 24 (8) 33 (6)
Consent withdrawn prior
to resolution
1 (0.3) 0 (0) 1 (0.2)
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Chapter 4 Health economic analysis
Introduction
An economic evaluation was conducted to estimate the cost-effectiveness of prophylactic levofloxacin
compared with placebo in newly diagnosed symptomatic myeloma. The economic evaluation was
conducted alongside the TEAMM clinical trial so that only the data collected during the trial were analysed.
Cost and outcome data were collected from trial participants for 16 weeks. However, if the intervention is
successful in reducing mortality, the benefits may extend beyond this period. Consequently, the economic
evaluation includes a within-trial cost-effectiveness analysis over 16 weeks but also explores longer-term
outcomes using an analysis extrapolated to 12 months from randomisation.
Methods
Aim and end points
The primary aim of this analysis was to assess the cost-effectiveness of antibiotic prophylaxis using levofloxacin
alongside antimyeloma therapy compared with using placebo alongside antimyeloma treatment in patients with
newly diagnosed symptomatic myeloma. The primary end point was the cost per quality-adjusted life-year (QALY)
gained at 16 weeks. The methods used for this within-trial analysis were guided by the recommendations of the
National Institute for Health and Care Excellence (NICE) methods guide.39
Perspective and time frame
The trial adopted a health-care and Personal Social Service provider perspective. Direct costs and outcomes
of patients randomised to levofloxacin versus placebo were compared over the 16-week time horizon of the
trial. As the time frame of the trial was < 1 year, discounting of the costs and benefits was not required.
Measurement of outcomes
Primary outcome
This analysis used the QALY as the main outcome measure. QALYs are a generic measure of health that
take account of both the quality and length of life, such that 1 QALY is equal to 1 year of life lived in a
state of full health.40
Health state utility values were obtained from patient responses to the EQ-5D three-level version questionnaire,31
which was administered at baseline and at weeks 4, 8, 12 and 16 post randomisation. The EQ-5D is a
commonly used generic measure of health-related quality of life (HRQoL) and NICE’s39 preferred outcome
measure for cost-effectiveness analysis. Patient responses were converted to utility values using the standard
UK general population time trade-off tariff values.41 The utility values represent patients’ QoL and were
multiplied by duration (t) in each health state to generate QALYs. An area under the curve approach was
adopted for estimating QALYs with a linear transition assumed between adjacent time points:
QALY=

(EQ-5Dbaseline+EQ-5D4)/2½  × t

+

(EQ-5D4+EQ-5D8)/2½  × t

+

(EQ-5D8+EQ-5D12)/2½  × t

+

(EQ-5D12 + EQ-5D16)/2½  × t

,
(1)
where EQ-5Dbaseline, EQ-5D4, EQ-5D8, EQ-5D12 and EQ-5D16 are the EQ-5D scores at baseline, week 4, week 8,
week 12 and week 16, respectively. If an individual died during the trial, it was assumed that their utility value
was 0 from the date of death to trial end and assumed a linear transition to this value from their last completed
EQ-5D.
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The EORTC QLQ-C30 was also administered alongside the EQ-5D questionnaire at each trial follow-up.
QALYs were calculated using the EORTC-8D as a sensitivity analysis in order to examine the effect of
using a disease-specific measure of HRQoL compared with a generic measure (EQ-5D).32
Total QALYs were calculated for each patient over the 16 weeks and summary statistics were generated
by intervention group. Differences between groups were compared using independent-sample t-tests.
Secondary outcome
A secondary outcome measure considered in the analysis was number of febrile episodes. This is the
primary outcome measure for the clinical analysis and allowed a useful complementary economic analysis
of the cost per febrile episode avoided. Details of febrile episodes were collected in clinic visits at the start
of trial treatment and then every 4 weeks until the end of treatment in week 12.
Measurement of resource use
All health-care resource use was estimated from the perspective of the health-care and Personal Social
Service provider and was collected for the trial period of 16 weeks from randomisation. This included
primary care such as GP visits and nurse home visits as well as secondary care such as outpatient visits and
other hospital admissions. At 12 months, data were limited to the number of hospital admissions and
associated length of stay between 16 weeks and 12 months.
Resource use was captured using three complementary approaches of data collection within the trial:
(1) patient diaries, (2) trial CRFs and (3) hospital data. Patients completed diaries of resource use, which
they brought with them to follow-up visits. Nurses used the patient diaries to summarise resource use on
the CRFs following discussions with patients, at which time corrections to the resource use were made.
Hospital data reporting admissions were also collected, which were used alongside patient-reported
resource use.
As multiple sources of data were used to capture resource use, there was potential for discrepancies
between the sources in the resource use recorded for any given patient. For example, the number of
hospital visits recorded on hospital systems may differ from the number recalled by patients. When there
were discrepancies between data sources, it was assumed that hospital records were more reliable and
these data were given precedence. In order to test the effect of this assumption, sensitivity analyses were
conducted using the data from patient recall.
Cost analysis
All resource use data were converted to costs using appropriate UK unit costs estimated at the time of
analysis. Unit costs were assigned to health-care resource use from the British National Formulary (BNF),42
Personal Social Services Research Unit’s (PSSRU) Unit Costs of Health and Social Care 201543 and the
Department of Health and Social Care’s NHS Reference Costs 2014 to 2015.44 Costs were assigned on a
per-unit basis with unit values taken from the resource use data collected within the trial (i.e. from patient
diaries, CRFs and hospital data). All inpatient and outpatient hospital stays or use of community health and
social services that occurred within the trial period were costed irrespective of whether or not their use was
directly associated with the treatment of myeloma. Unit costs for the main resource use items (those specified
on the resource use CRF) are presented in Table 29, together with the costing of the treatment medications.
In addition to those resource use items specified in the form, patients were also given a free-text box to enter
other items of resource use. These items were costed individually, and full unit costs, including those used to
cost additional resource use items recorded, are outlined in Appendix 3 (see Tables 45–47).
Patients’ use of health-care resources and total costs were calculated for the ITT population. Total costs
for each patient were calculated as the sum of costs assigned for hospital, community health and social
services and medication use.
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Adjusting for baseline imbalance
Using a randomised controlled study design means that the baseline and socioeconomic characteristics of
groups being compared should be well balanced. However, despite randomisation, there will inevitably
be some differences in mean baseline values between groups. This is of particular importance because a
patient’s utility at baseline is likely to be correlated with their utility over the follow-up period. Therefore,
the imbalance in baseline utilities needs to be accounted for when calculating the differential effects
between treatment arms.47,48 Multiple regression analysis was used to estimate differential mean QALYs
and to predict adjusted QALYs controlling for utility at baseline.
Missing data
In economic analyses conducted alongside clinical trials, incomplete or missing data are inevitable. Based
on descriptive analysis of the missing data, the analysis was conducted under the assumption that the
missing data were missing at random (MAR). Analysis of the number of missing data by trial group at each
follow-up and visual analysis of missing data patterns indicated that the data were unlikely to be missing
completely at random as the proportion of missing data differed by time point (although the proportion of
data missing did not differ by treatment allocation).49 This was explored further using logistic regression to
investigate which factors were associated with the probability of missing data. This indicated that MAR
may be a plausible assumption under which to conduct the analysis. However, it was noted that it is
difficult to rule out missing not at random because the unobserved data are unknown. Consequently,
TABLE 29 Unit costs for main resource use items
Resource item Unit cost (£) Source Details
Trial medication
Levofloxacin, 250 mg 11.57 per
10-tablet pack
BNF 2017 Normal dose: two tablets per day
Moderate renal failure: one tablet per day
Severe renal failure: half-tablet per day
Levofloxacin, 500 mg 11.40 per
10-tablet pack
BNF 2017
Community health and social services
GP visit, surgery 36.00 per visit PSSRU 2016, p. 14545 GP, per patient contact lasting 9.22 minutes,
including direct care staff costs
District nurse visit 38.00 per visit NHS Reference Costs
2015 to 201646
District nurse, adult, face to face
CC: N02AF; SC: NURS
Home help or care worker
visit
24.00 per visit PSSRU 2016, p. 16045 Face-to-face 1-hour weekday session
Hospital-based or residential care services
Hospital inpatient 298.41 per day NHS Reference Costs
2015 to 201646
Total Healthcare Resource Groups, average of
all non-elective inpatient excess bed-days
Hospital critical/intensive
care unit
521.00 per day NHS Reference Costs
2015 to 201646
Medical adult patients (unspecified specialty),
adult critical care, zero organs supported,
CC: XC07; SC: CCU03
Hospital outpatient 135.00 per visit PSSRU 2016, p. 9545 Weighted average of all outpatient attendances
A&E 137.74 per visit NHS Reference Costs
2015 to 201646
Emergency medicine, average unit costs of all
emergency medicine attendances
Residential home 90.00 per day PSSRU 2016, p. 2645 Private sector residential home cost per
permanent resident day
A&E, accident and emergency; CC, currency code; SC, service code.
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when there were missing data, multiple imputation methods were used to generate estimates of missing
values based on the distribution of observed data. The multiple imputation approach is the recommended
method of imputation for economic evaluation alongside clinical trials as it includes randomness to reflect
the uncertainty inherent in missing data by using iterative multivariable regression techniques.50
When choosing the level at which to impute missing data (more or less aggregated), a balance needs
to be struck between maintaining the data structure and achieving a stable imputation model.49
Consequently, for QoL data, missing EQ-5D index values were imputed at each follow-up. For costs,
missing data were imputed at the level of total health and social services costs, total hospital costs and
total treatment costs, not at the unit of resource level. EQ-5D index values were recorded as missing if
any EQ-5D items were missing. Missing baseline EQ-5D values were imputed using mean imputation to
ensure that imputed values were independent of the treatment allocation.51 Missing EQ-5D scores at the
remaining follow-ups were imputed using multiple imputation methods. Costs were counted as missing if
all resource use items on the CRF were missing and missing cost data were imputed at each follow-up
using multiple imputation methods.
The imputation was performed in Stata® version 14 (StataCorp LP, College Station, TX, USA) using
predictive mean matching to perform multiple imputation by chained equations. Predictive mean matching
ensures that only plausible values of the missing variable are imputed as the imputed value is drawn from
another individual whose predicted value is close to the predicted value of the individual with the missing
observation.49
Cost-effectiveness analysis
Primary analysis
The cost-effectiveness analysis adopted an ITT perspective for analysing and summarising the health
economic trial data. The primary analysis consisted of a cost–utility analysis over the 16-week trial period
and included adjustment for baseline variables and imputation of missing data. The incremental cost
per QALY gain as a result of the use of levofloxacin compared with placebo was calculated. This was
calculated by dividing the mean difference in cost of the two treatment arms by the mean difference in
QALYs to produce an incremental cost-effectiveness ratio (ICER), as follows:
ICER = (CostA−CostB)/(QALYA−QALYB). (2)
The ICER represents the additional cost per QALY gained for each intervention compared with the next
best alternative.52 NICE39 considers a cost per QALY within the range £20,000–30,000 to be acceptable.
The lower limit of this threshold (λ = £20,000) was used to determine cost-effectiveness. Interventions with
an ICER < £20,000 per QALY gained are generally considered cost-effective.
Secondary analyses
The secondary analyses included a cost-effectiveness analysis, in which the cost per febrile episode avoided
attributable to antibiotic prophylaxis compared with placebo was calculated. This analysis was conducted
in a similar way to the primary analysis; however, as data on febrile episodes were collected only over
the treatment period (baseline to 12 weeks), the time horizon for this analysis was 12 weeks, rather than
16 weeks (as was used in the primary analysis). In addition, a cost–utility analysis was conducted over a
12-month time horizon.
Sensitivity analysis
Alternative scenarios were explored in the sensitivity analysis to test the robustness of the main trial
analysis results. The effect of not imputing missing data was considered with an analysis including only
complete cases. In addition, the effect of adjusting for baseline imbalance on cost-effectiveness was
explored using an analysis with no adjustment for baseline differences between groups. Further sensitivity
analyses were conducted to explore the effect of using a disease-specific measure of HRQoL to calculate
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QALYs rather than EQ-5D. The effect of the decision to prioritise hospital data over patient-recorded data
was also explored with an analysis using only resource use data recorded by patients. The effect of costing
hospital stays as either long or short stays based on Hospital Episode Statistics (HES) classifications, rather
than using a cost per day, was also explored. Finally, the effect of using the same dose (250-mg) tablets
to calculate treatment costs for all patients in the levofloxacin arm of the trial was explored in a sensitivity
analysis that instead calculated treatment costs using 500-mg levofloxacin tablets for patients who took
250 mg or 500 mg (the same costing method as in the base case was used for patients who took 125 mg
of levofloxacin). ICERs from each of the scenarios were compared with the main trial results to identify
areas of uncertainty.
For the 12-month analysis, the sensitivity of results to the choice of prediction model employed was also
evaluated.
Uncertainty analysis
The level of sampling uncertainty around the ICER was determined using a non-parametric bootstrap to
generate 10,000 estimates of incremental costs and benefits. The bootstrapped estimates were plotted
on the cost-effectiveness plane to illustrate the uncertainty surrounding the cost-effectiveness estimates.53
Net monetary benefit (NMB) was also calculated for each of the bootstrapped estimates. NMB combines
cost-effectiveness and willingness to pay (WTP) to give an explicit monetary valuation of the health
outcome. It is calculated by rearranging the ICER and incorporating the WTP per QALY threshold value,
such that NMB is derived for each patient as:
NMB = (λ × QALYs)− costs, (3)
where λ is the value a decision-maker would be willing to pay per incremental QALY gained. For any given
threshold value (λ), treatments with an average incremental NMB of > 0 should be adopted. The expected
NMB was used to estimate the probability that antibiotic prophylaxis is cost-effective given a range of
threshold values (λ = £1000 to λ = £100,000) that were plotted on the cost-effectiveness acceptability
curve (CEAC).54 The CEAC illustrates the probability that antibiotic prophylaxis is cost-effective compared
with placebo when used alongside antimyeloma treatment as a function of the WTP threshold (λ). It is
constructed using 10,000 bootstrapped samples from the original data and plotting the proportion of
times each treatment represents the maximum average net benefit for a range of WTP thresholds (λ). The
cost-effectiveness frontier was also plotted to show the intervention that provides the highest net benefit
for a given threshold.
Value-of-information analysis
Value-of-information analysis was conducted to estimate the potential gains from the elimination of
uncertainty that could result from conducting additional research.50 As decisions must be made based on
the information that is currently available, and as such information may be imperfect, there remains an
element of uncertainty and a chance that the wrong decision will be made. In the event of a ‘wrong’
decision, costs will be incurred in the form of health benefit and cost of resources forgone. The expected
value of perfect information (EVPI) is derived from the expected costs associated with the uncertainty. The
EVPI was calculated using the bootstrapped sample to calculate the average net benefit loss as a result of
the ‘wrong’ decision. EVPI was calculated as follows:
EVPI = Eθmax jNB( j, θ)−max jEθNB( j, θ), (4)
where EθmaxjNB(j,θ) is the expected net benefit with perfect information and maxjEθNB(j,θ) is the expected
net benefit with current information. The expected net benefit with perfect information is calculated
as the mean value of NMB when the intervention with the higher NMB is chosen for each simulation.
The expected net benefit with current information is calculated as the mean value of NMB when the
intervention with the higher expected net benefit is chosen across all simulations.55
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There were 5540 new cases of myeloma in 2015 in the UK given an age-standardised incidence rate of
9.6 per 100,000 population.1 It was assumed that the decision is relevant for a period of 10 years, after
which time it is reasonable to assume that the treatment pathway may have changed (i.e. alternative
therapies becoming available). The EVPI is presented for this population with myeloma in the UK over
a range of cost-effectiveness thresholds. A discount rate of 3.5% was used to discount the future
value of additional research to the present value.39 If additional research that removes uncertainty can be
conducted at an expected cost lower than the EVPI, then such research may be warranted.
Results
Sample
Of the 977 patients recruited to the trial, complete resource use and EQ-5D results for all follow-ups were
available for 511 patients.
Resource use and costs
Table 30 shows the average resource use of all patients in each treatment arm who returned at least one
resource use questionnaire over the 16-week duration of the trial (levofloxacin, n = 469; placebo, n = 461).
Table 31 also gives a more detailed breakdown of hospital admissions from the available hospital data.
Average health-care costs over the trial period are presented in Table 32. The mean total costs of community
health and social services were £224.87 [standard deviation (SD) £605.66] for the levofloxacin group and
£190.13 (SD £486.41) for the placebo group. The mean total costs for hospital and residential care services
were £3620.60 (SD £4579.35) for the levofloxacin group and £3255.17 (SD £4167.70) for the placebo
group. For relevant unit costs, see Table 46. For further breakdown of resource use and costs, see Tables 47
and 48.
Independent-sample t-tests were undertaken to explore differences in mean total NHS costs associated
with the treatment arms. Although the difference in total NHS costs appears considerable, the difference
was not significant at the 5% level (p = 0.053).
TABLE 30 Average resource use per patient over the 16 weeks in each treatment arm
Resource use
Treatment arm
Levofloxacin Placebo
Mean (SD) Min. Max. Mean (SD) Min. Max.
Community health and social services
GP 1.02 (1.59) 0 16 1.08 (1.78) 0 13
Nurse 3.0 (10.65) 0 113 2.61 (9.77) 0 104
Care worker 2.01 (11.7) 0 131 1.58 (10.00) 0 116
Hospital or residential care services
Hospital inpatient days 6.23 (12.38) 0 105 5.69 (11.24) 0 102
Hospital ICU days 0.05 (0.65) 0 10 0.22 (3.21) 0 66
Hospital outpatient 10.25 (8.79) 0 44 9.76 (9.13) 0 53
Hospital A&E 0.6 (1.15) 0 14 0.51 (0.90) 0 5
Residential care 0.32 (2.93) 0 42 0.3 (4.5) 0 94
A&E, accident and emergency; ICU, intensive care unit; max., maximum; min., minimum; SD, standard deviation.
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Quality-of-life data
Mean (SD) EQ-5D scores for each treatment arm at each time point are presented in Table 33. When
patients died during the trial, the EQ-5D score was recorded as 0 from the date of death. EQ-5D scores
increase throughout the trial period in both treatment arms. This increase is slightly larger in the levofloxacin
group. Baseline EQ-5D scores were very similar and independent-sample t-tests indicated that there was
no statistically significant difference in EQ-5D scores at baseline (p = 0.88). The primary analysis uses an
TABLE 31 Hospital admissions, by treatment arm
Factor Grouping
Treatment arm
Levofloxacin Placebo
Number of admissions 1 149 140
2 66 51
3 14 13
4 3 7
Total number admissions 330 307
Length of hospital admission (days) 1–7 180 183
8–14 81 58
15–21 28 22
22–28 13 19
> 28 27 26
Missing 6 1
Number of ICU admissions 3 5
Length of ICU admission (days) 3 2 3
9 1 –
10 1 1
17 – 1
66 – 1
Total number of patients admitted 232 211
ICU, intensive care unit.
Note
The whole duration of hospital admissions is reported in this table. In some cases, the hospital admission started before the
start of the trial or ended after the end of the trial.
TABLE 32 Mean health-care costs, by treatment arm
Total costs (£)
Treatment arm
Levofloxacin Placebo
Mean (SD) Min. Max. Mean (SD) Min. Max.
Community health and
social services
224.87 (605.66) 0.00 5472.00 190.13 (486.41) 0.00 4003.76
Hospital and residential
care services
3620.60 (4579.35) 0.00 39,655.81 3255.17 (4167.70) 0.00 36,107.61
Trial medication 164.10 (63.16) 0.00 300.82 0.00 (0.00) 0.00 0.00
Total NHS cost 4009.62 (4669.23) 34.71 40,503.64 3445.30 (4228.41) 0.00 36,107.61
Max., maximum; min., minimum; SD, standard deviation.
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adjustment for baseline characteristics; however, the effect of conducting the analysis without this
adjustment was explored in a sensitivity analysis.
Table 34 shows the mean EQ-5D change scores between baseline and each of the follow-up time points.
Independent sample t-tests indicated that the variation among groups in the changes in EQ-5D scores was
not statistically significant (p = 0.69).
TABLE 33 Mean (SD) EQ-5D scores, by treatment arm and time point (complete outcome data)
Time point
Treatment arm
Levofloxacin Placebo
Baseline
Mean (SD) 0.59 (0.33) 0.59 (0.35)
n valid (missing) 426 (63) 439 (49)
Week 4
Mean (SD) 0.60 (0.3) 0.58 (0.32)
n valid (missing) 384 (105) 383 (105)
Week 8
Mean (SD) 0.62 (0.28) 0.60 (0.3)
n valid (missing) 377 (112) 375 (113)
Week 12
Mean (SD) 0.62 (0.28) 0.62 (0.32)
n valid (missing) 357 (132) 371 (117)
Week 16
Mean (SD) 0.63 (0.29) 0.62 (0.29)
n valid (missing) 354 (135) 373 (115)
TABLE 34 Mean EQ-5D change from baseline to each follow-up for each treatment arm
Time point
Treatment arm
Levofloxacin Placebo
Baseline to week 4
Mean (SD) 0.01 (0.28) –0.01 (0.28)
n valid (missing) 349 (140) 360 (128)
Baseline to week 8
Mean (SD) 0.01 (0.3) 0.01 (0.3)
n valid (missing) 340 (149) 354 (134)
Baseline to week 12
Mean (SD) 0.03 (0.31) 0.03 (0.32)
n valid (missing) 324 (165) 351 (137)
Baseline to week 16
Mean (SD) 0.04 (0.31) 0.03 (0.33)
n valid (missing) 319 (170) 347 (141)
HEALTH ECONOMIC ANALYSIS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
56
Missing data
A total of 521 patients had complete EQ-5D scores across all time points. The remaining 456 patients had
EQ-5D scores missing for at least one of the time periods. There were 112 (11%) missing EQ-5D scores at
baseline, which were imputed independently of treatment allocation. A total of 934 (24%) EQ-5D scores
were missing across the remaining follow-ups (weeks 4–16) and were imputed for the cost-effectiveness
analysis. Of those scores that were missing, 71 (2%) were missing as a result of partially completed EQ-5D
forms and the remaining were missing in all elements of the EQ-5D. A total of 704 patients completed
resource use questionnaires for all follow-ups. The remaining 273 had missing resource use for at least
one of the time periods. At the first follow-up in week 4, 887 (91%) patients completed resource use
questionnaires. The completion rate dropped over the duration of the trial to 84% completed at week 8,
80% completed at week 12 and 76% completed at week 16.
Cost-effectiveness results
Cost-effectiveness results are presented in Table 35, which shows the costs and QALYs gained for each
treatment arm, the incremental costs and QALYs, and the resulting ICER. The levofloxacin group had the
highest QALYs gained over the trial period. The mean total cost was also highest for the levofloxacin group.
The results suggest that the use of prophylactic levofloxacin would not be cost-effective compared with placebo.
This is as a result of smaller QALY gains and higher costs in the levofloxacin arm than in the placebo arm.
An ICER value of £231,377.42 per QALY gain is yielded, which is well above the NICE cost per QALY threshold.
Bootstrapped estimates of the incremental costs and incremental effects are plotted on the cost-
effectiveness plane in Figure 7. This shows the joint distribution of incremental costs and incremental
effects in the cost-effectiveness plane for levofloxacin compared with placebo. Most of the points in the
Levofloxacin vs. placebo
WTP threshold = £20,000
– 1000
– 500
0
500
1000
1500
2000
– 0.006 – 0.004 – 0.002 0.000 0.002 0.004 0.006
Incremental cost (£)
Incremental QALYs
FIGURE 7 The cost-effectiveness plane: levofloxacin vs. placebo.
TABLE 35 Cost-effectiveness results
Treatment arm
Cost (£) QALY
ICER (£/QALY)Mean (SD) Incremental Mean (SD) Incremental
Placebo 3272.19 (4173.23) 0.1818 (0.006)
Levofloxacin 3871.45 (4622.02) 599.26 0.1845 (0.006) 0.0026 231,377.42
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cloud lie above the cost-effectiveness threshold line, indicating that the use of levofloxacin is unlikely to
be a cost-effective use of resources. Although 98.2% of the iterations fall in the north-east quadrant
(more costly, more beneficial), only 1.8% fall in the south-east quadrant (less costly, more beneficial).
Net monetary benefit
The NMB for each treatment arm, calculated from the bootstrapped estimates of costs and QALYs, is
presented in Table 36. Given the decision rule, the NMB results indicate that the use of prophylactic
levofloxacin is not a cost-effective use of resources because the expected value of NMB is negative.
The probability that the treatments are cost-effective is presented on the CEAC shown in Figure 8. This shows
that the use of prophylactic levofloxacin is very unlikely to be a cost-effective use of resources even at high
cost-effectiveness threshold values.
Sensitivity analysis
The cost-effectiveness results for each scenario explored in the sensitivity analysis are presented in Table 37.
Given that the base-case analysis was conducted using imputed data, a sensitivity analysis that used only
complete cases was conducted. In addition, sensitivity analyses were conducted to explore the effect of
adjusting for baseline differences by repeating the analysis without the baseline adjustment, and to explore
the effect of the decision to give precedence to hospital data by using patient-reported hospital admission
data instead of the hospital-provided data. The effect of using a condition-specific measure of HRQoL
compared with a generic measure was also explored with a sensitivity analysis using the EORTC QLQ-C30
instead of the EQ-5D. A sensitivity analysis was also conducted to explore the effect of costing hospital stays
as either long or short stays based on HES classifications, rather than using a cost per day (see Table 46
for relevant unit costs). A final sensitivity analysis was conducted in which treatment costs were calculated
using 500-mg levofloxacin tablets for patients who took 250 mg or 500 mg, rather than calculating the
cost of treatment using 250-mg tablets for all patients. In each case, the results of the sensitivity analyses
support the results of the base-case analysis and indicate that the use of prophylactic levofloxacin is not a
cost-effective use of resources.
Secondary analysis
A secondary analysis to explore the cost per febrile episode avoided was also conducted. In line with the
primary outcome of the trial, this analysis was conducted over a 12-week time horizon. There were no
missing febrile episode data and cost data were imputed using multiple imputation as in the primary
health economic analysis. Cost-effectiveness results from the secondary analysis are presented in Table 38.
This shows that the additional cost per febrile episode avoided was £4021.26. This amounts to a mean
additional cost of £8.15 per patient treated (calculated as the difference in mean cost per patient between
the treatment arms/incremental febrile episodes avoided).
Explicit predefined reference threshold values to allow interpretation of the cost per febrile episode avoided are
not available. However, the cost of treating a febrile episode may be used as a yardstick for interpretive purposes.
A generalised linear model (family: gamma; link: identity) was fitted to the trial cost data to estimate the cost of an
infection. This produced an estimate of the cost of an infection of £1805.87 (standard error 180.22). As the cost
of treating an infection is lower than the cost of preventing a febrile episode, it may be concluded that the use of
levofloxacin for prevention is not a cost-effective use of resources.
TABLE 36 Net monetary benefit (λ = £20,000)
Treatment arm Expected value NMB (£) Standard error 95% CI
Levofloxacin –184.74 2.10 –188.87 to –180.62
Placebo 361.43 1.89 357.72 to 365.14
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FIGURE 8 Cost-effectiveness acceptability curve: levofloxacin vs. placebo.
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Secondary analysis: sensitivity analysis
The cost-effectiveness results for each scenario explored as sensitivity analyses are presented in Table 39.
Sensitivity analyses were conducted to explore the effect of uncertainty in the estimates of costs. As in the
primary analysis, the effect of the decision to give precedence to hospital data was explored in a sensitivity
analysis using patient-reported hospital admission data instead. Scenarios considering a reduction in overall
costs (–20%) and an increase in overall costs (+20%) were also explored. In each case, the results of the
sensitivity analyses support the results of the base-case analysis and indicate that, when compared with an
estimated cost per infection of £1806, the use of levofloxacin does not appear to be a cost-effective use of
resources.
Value-of-information analysis
The population EVPI at the NICE cost-effectiveness threshold value of £20,000 per QALY gained is
£99,131. The population EVPI for other values of the cost-effectiveness threshold is plotted in Figure 9.
TABLE 37 Sensitivity analysis: cost-effectiveness results
Treatment arm
Cost (£) QALY
ICER (£/QALY)Mean (SD) Incremental Mean (SD) Incremental
Complete-case analysis
Placebo 3111.76 (3333.24) 0.195 (0.005)
Levofloxacin 4114.17 (4393.45) 1002.41 0.193 (0.005) –0.002 Dominated
Without baseline adjustment
Placebo 3272.19 (4173.23) 0.182 (0.080)
Levofloxacin 3871.45 (4622.02) 599.26 0.185 (0.071) 0.003 189,648.23
Hospital admissions from patient recall
Placebo 3256.96 (4312.75) 0.182 (0.006)
Levofloxacin 3645.90 (3988.37) 388.93 0.184 (0.006) 0.003 142,490.94
Hospital admissions costed as long/short stays
Placebo 6036.30 (7783.69) 0.182 (0.006)
Levofloxacin 6658.43 (7821.83) 622.13 0.185 (0.006) 0.003 210,385.20
Alternative costing of levofloxacin
Placebo 3272.19 (4173.23) 0.182 (0.006)
Levofloxacin 3796.26 (4624.56) 524.07 0.185 (0.006) 0.003 179,031.58
Condition-specific HRQoL
Placebo 3274.28 (4171.64) 0.206 (0.007)
Levofloxacin 3868.36 (4624.28) 594.08 0.211 (0.006) 0.006 105,386.04
TABLE 38 Secondary analysis: cost-effectiveness results
Treatment arm
Total cost (£) Febrile episodes
ICER (£/febrile
episode avoided)Incurred (12 weeks) Incremental Total number
Incremental
avoided
Placebo 581,503.40 149
Levofloxacin 722,247.50 140,744.06 114 35 4021.26
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Discussion
Principal findings
The trial-based cost-effectiveness analysis indicated that the use of prophylactic levofloxacin alongside
antimyeloma treatment was not a cost-effective use of NHS resources compared with placebo.
Both treatment arms showed an increase in EQ-5D score over the trial period but, although levofloxacin
was associated with slightly higher total QALY gains, the difference in QALYs was very small. This may, in
part, be explained by the fact that benefits were measured only over the trial period of 16 weeks and that
any longer-term benefits were not considered. In terms of costs, the levofloxacin arm was found to be the
most costly treatment. This was driven by greater resource use in the levofloxacin arm, both in terms of
hospitalisations and the use of community health and social services. Consequently, the principal finding
that the use of prophylactic levofloxacin would not be a cost-effective use of resources is driven by the
(statistically significant) difference in costs.
Base-case cost-effectiveness results were not sensitive to alternative assumptions explored in the sensitivity
analyses. The secondary analysis found that the cost per febrile episode avoided in the levofloxacin arm
was £8849.31. In the absence of a predefined decision rule for outcomes measures in natural units, the
value judgement on whether or not this presents a good use of resources is left to the decision-maker.
TABLE 39 Sensitivity analysis: cost per febrile episode avoided
Treatment arm
Total cost (£) Febrile episodes
ICER (£/febrile
episode avoided)Incurred (12 weeks) Incremental Total number
Incremental
avoided
Hospital admissions from patient recall
Placebo 581,260.40 149
Levofloxacin 722,025.90 140,765.50 114 35 4021.87
Increase costs by 20%
Placebo 697,804.10 149
Levofloxacin 866,697.00 168,892.90 114 35 4825.51
Reduce costs by 20%
Placebo 465,202.80 149
Levofloxacin 577,798.00 112,595.20 114 35 3217.01
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FIGURE 9 Expected value of perfect information.
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An estimate of the value of perfect information suggested that further research to remove uncertainty and
enable more robust economic decisions to be made would be worth £99,131. If additional research can be
conducted at an expected cost lower than this value, then such research would be warranted to reduce
uncertainty.
Strengths and weaknesses of the economic analysis
The main strength of this analysis lies in the randomised controlled design of the trial. This enabled the
collection of high-quality data that were subsequently used in this analysis to conduct the 16-week
within-trial analysis.
However, the relatively short duration of follow-up has made consideration of longer-term outcomes
difficult. This has partly been addressed by conducting an extrapolated analysis over a 12-month time
horizon; however, the use of more robust methods to consider a longer follow-up would be beneficial as
part of any future research.
Meaning of the trial
Although fewer febrile episodes and deaths were experienced in the levofloxacin arm of the trial, this
does not translate into the use of prophylactic levofloxacin being a cost-effective use of resources. This is
driven by higher costs in the levofloxacin arm as a result of high levels of resource use in terms of both
hospitalisations and the use of community health and social services that are maintained despite the
reduction in infections. Consequently, the higher costs in the levofloxacin arm combined with only very
small gains in QALYs indicate that the use of prophylactic levofloxacin would not be a cost-effective
treatment option alongside antimyeloma treatment.
Unanswered questions and further research
Although the analysis conducted here provides useful insights into the costs and effects over the trial
period of 16 weeks, further research is required to provide more robust evidence on the cost-effectiveness
over a longer time horizon. This will be particularly relevant if the benefits of prophylactic levofloxacin are
maintained or develop in the long term. More research is needed to investigate whether or not the cost
for avoided febrile episode is cost-effective.56
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Chapter 5 Discussion
Interpretation
The trial indicated that prophylactic levofloxacin caused a significant reduction in febrile episodes and
deaths during the 12-week treatment period (log-rank = 9.78; p = 0.002). The largest benefit was
observed within 4–8 weeks. Levofloxacin also reduced the number of other (non-febrile) infectious
episodes (p-trend = 0.06). The data gathered on these ‘other infections’ are of particular interest because
these data have not, to our knowledge, been previously collected on such a large scale. Our data show
that these ‘other infections’ are a substantial burden for both patients and the health-care system. They
were more frequent than febrile episodes (323 other infections vs. 264 febrile episodes). Again, the benefit
of prophylaxis in these ‘other infections’ became apparent during the 4- to 8-week period and continued
up to 12 weeks. The body site experiencing the greatest reduction in infections was the urinary tract,
probably because levofloxacin is broadly effective against Gram-negative organisms. Upper respiratory
tract infections are frequently caused by viruses and, therefore, would be unaffected by levofloxacin.
Information on infections was collected only up to 12 weeks but longer-term survival data were collected
up to 12 months. During months 3–6, patients were not on prophylaxis and yet the survival benefit
continued for those who had taken levofloxacin. If levofloxacin had prevented death in those patients
destined to respond to antimyeloma treatment and subsequently survive beyond 12 months, the survival
benefit might have been expected to continue. A possible interpretation of our finding that the survival
curves came together by 6 months is that levofloxacin may reduce or delay the risk of death in patients
with poorly responsive or refractory disease. Therefore, the cause of death was analysed in the 116 deaths
reported during the 12-month trial period. There were fewer deaths attributed to infection in the
levofloxacin arm (three patients) than in the placebo arm (eight patients) during the 12-week treatment
period, but more in the levofloxacin arm (19 patients) than in the placebo arm (12 patients) post 12 weeks.
These data support our possible interpretation outlined above. Although levofloxacin may have reduced the
number of deaths in the first 12 weeks from 22 to 8, there were a further 86 deaths in the next 40 weeks
from many causes and the reversal of levofloxacin survival advantage may have been influenced by the
volume of the later deaths.
There was little benefit from levofloxacin until after the first 4 weeks, and this time delay in benefit from
prophylaxis in reducing febrile episodes and other infections is intriguing. The response to treatment of
an established infection with antibiotics is expected within 48 hours. This observed delay in benefit from
prophylaxis may suggest that some form of biological process needs to take place before the benefit is
realised. One suggestion may be that a change in the patient’s immune response or microbiome may be
necessary before the benefit of prophylaxis is established. The theory that a biological process may take
place in the patient before the benefit of prophylaxis becomes apparent may also be supported by the
observation that the survival curves remained separated for months 3–6. It is possible that the benefit of
levofloxacin prophylaxis may continue to reduce infections for a period after withdrawing levofloxacin,
but this was not measured in the trial.
There was no significant increase in HCAIs in patients on levofloxacin during the 16 weeks of the trial,
disproving the theory that the use of prophylactic levofloxacin may trigger an excess of HCAIs. In addition,
despite prospectively looking for colonisation with resistant organisms, there were fewer episodes of
colonisation noted in the levofloxacin arm. However, it is possible that a longer period of levofloxacin
prophylaxis may induce colonisation or infection with HACIs. There is a need to better understand the reasons
for the risks of colonisation with resistant organisms and infections in the first 4 weeks of levofloxacin
prophylaxis. There is also a need to explore the effects of a longer duration of levofloxacin prophylaxis.
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A total of 597 SAEs were reported (308 in the levofloxacin group and 289 in the placebo group), with most
reported as unlikely to be related to or unrelated to the study drug (537/597 events, 90%) and a majority
reported to be attributable to hospitalisation or prolongation of existing hospitalisation (462/597 events,
77%). Toxicity reported to be related to levofloxacin (38 episodes) compared with placebo (22 episodes)
had a tendency to manifest as gastrointestinal disorders, rash, psychiatric disorders and musculoskeletal/
connective tissue disorders, but these were very rare events.
The health economic analysis showed a slight increase in QALYs over 16 weeks for levofloxacin prophylaxis,
but this was associated with higher health-care costs. Despite the reduction in febrile episodes and deaths
in the patients taking prophylactic levofloxacin, the 16-week cost-effectiveness analysis indicated that
prophylactic levofloxacin would not be a cost-effective use of NHS resources. This result was driven by higher
use of health-care resources in the levofloxacin arm and only very small gains in QALYs. Consequently, the
aforementioned reduction in febrile episodes and deaths did not translate into gains in QALYs that were
sufficient to outweigh the additional costs. This result was robust to sensitivity analyses. As the benefit of
levofloxacin prophylaxis in reducing infections and death became most apparent after 4 weeks, it would
be useful to perform the analysis over the period of 4–16 weeks. This analysis is planned for the future.
In addition, the analysis of 12-month data is ongoing. More research is needed to investigate whether or
not the cost for avoided febrile episode is cost-effective.56
Generalisability
Strengths of the study
This was a large randomised, double-blind, placebo-controlled trial for the intervention, with broad entry
criteria, and patients with poor performance status were not excluded. Patients could be on any antimyeloma
treatment regimen; hence, data were collected prospectively in a real-life situation. All suspected infectious
episodes were captured, with the only definition being that patients were given an anti-infective treatment
by a health-care professional. These data were the most comprehensive yet recorded for newly diagnosed
multiple myeloma patients. A large number of patient and treatment data have been recorded, which
allowed the analysis of secondary outcomes as prespecified in the protocol. The longer-term secondary
analyses, such as detailed survival analysis and analysis of cost-effectiveness up 12 months and QoL, are
ongoing.
Limitations of the study
Despite the study having broad entry criteria, the patient population recruited into the study was healthier than
expected, with a median age of 67 years and only 7% of patients of performance status 3 or 4. The 3-month
overall survival of patients in our study was in excess of 95%. However, population data show that the median
age of myeloma patients at diagnosis is 71 years and the 3-month overall survival is 83%.57 Therefore, the
study was not fully representative of the patient population presenting with multiple myeloma. There was a
concern raised by some investigators at the start of the trial that the prophylactic use of antibiotics may trigger
HCAIs and, as a consequence, that there may have been a degree of selection bias to randomise fitter patients
into the trial. Despite refining the protocol to include patients with impaired renal function, more patients than
expected had eGFR values within the > 50ml/minute/1.73 m2 range, which may be a reflection of over
selection of fewer patients with renal impairment.
Patients had to be willing to provide stool samples and nasal swabs throughout the study as well as to
complete the daily diary with data on temperature, patient-reported outcomes and QoL. Screening logs
were collected and the main reason for not entering the trial was the unwillingness to provide samples
and complete daily diaries. There was a protocol amendment early in the study to allow patients to enter
the study within 14 days of starting antimyeloma treatments rather than 7 days, as initially stipulated.
It may be that recruitment to a supportive care trial needs to accommodate patient emotions around
receiving a diagnosis of myeloma and starting antimyeloma treatment before supportive care interventions
can be considered.
DISCUSSION
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The recruitment of a relatively healthy patient population to this study has several implications. The benefit
of levofloxacin prophylaxis may be even more pronounced in the general myeloma population than the
study demonstrated. In addition, if levofloxacin prophylaxis reduces infection and death in some poor
performance status patients who have biologically responsive disease but are at risk of early death because
of frailty, there could be a prolonged survival benefit for these patients. Our study may not have been able
to demonstrate this because it was a selected patient population.
Levofloxacin prophylaxis was given for only 12 weeks. As the benefit in favour of levofloxacin was still
evident at this time point, it is possible that there may be a benefit to continuing prophylaxis for longer.
It is important to note that a relatively low C. difficile carriage at baseline was found for patients on
the TEAMM trial (0.7% compared with an expected 10% in hospital patients and 1% in the general
population), which may be a reflection of the new NHS policies to minimise infections in hospital or the
fact that many of these patients are mainly outpatients.
Overall evidence
This study supports the use of levofloxacin as prophylaxis for myeloma patients undergoing antimyeloma
treatment. A small study of prophylactic co-trimoxazole in early myeloma showed a reduction in bacterial
infections but was too small to detect reduced mortality and 25% of patients were unable to tolerate the
drug.18 Two large studies22–24,58 confirmed the efficacy of prophylactic levofloxacin in preventing bacterial
infection in neutropenia, and subsequent meta-analyses showed superiority of fluoroquinolone antibiotics
over other classes of antibiotic.
Overall conclusions
In the authors’ opinion, this study supports the use of prophylactic levofloxacin for patients undergoing
antimyeloma treatment. This is the largest study in the literature assessing the use of levofloxacin to reduce
febrile episodes and other infections for myeloma patients. Most patients in the trial were fitter then
expected with a lower carriage rate of C. difficile.
There was no difference for new acquisitions of or invasive infections by C. difficile, MRSA and ESBL
Gram-negative organisms when assessed up to 16 weeks.
Despite being clinically effective, levofloxacin in prophylaxis is not a cost-effective health-care programme
from the NHS standpoint. However, this result is focused only on incremental QALYs gained, which are
usually negligible when measured for such a short period of time (16 weeks). More research is needed to
investigate whether or not the cost for avoided febrile episode is cost-effective.
Further research
Laboratory investigation of immunity, inflammation and disease activity on stored samples (funded by the
TEAMM NIHR EME programme grant reference number 14/24/04) will provide insights into the triad of
(1) myeloma disease activity, (2) immune competence and (3) infections and HCAIs to stratify patients for
risk of infection, to guide use of prophylactic antibiotics and to improve response to antimyeloma therapies.
Further research to establish the optimal duration of prophylactic antibiotics for these patients is needed.
There may be a benefit to treat for the whole duration of antimyeloma treatment in order to give
maximum protection for these patients. In addition, the use of Septrin gave additional benefit to
levofloxicin. This needs to be investigated within a future clinical trial.
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Appendix 1 Additional recruitment details
T able 40 lists the sites that did not want to participate in the trial and their reasons for not participating.
Table 41 lists the numbers of patients screened and randomised at each site.
TABLE 40 Sites not wishing to participate
Site Reasons for not participating
University College London Hospital C. difficile risk
Ysbyty Gwynedd Withdrew because of a MHRA safety alert for levofloxacin and acute liver injury
Peterborough City Hospital Decided against participating after reading protocol: no reason given
Harrogate District Hospital C. difficile risk
Maidstone Hospital C. difficile risk
Scunthorpe General Hospital No response
Luton and Dunstable Hospital Capacity: may review again
East Surrey & Crawley Hospitals C. difficile risk
Frimley Park Hospital C. difficile risk
Ashford and St Peter’s Hospitals C. difficile risk
Chelsea and Westminster Hospital Postage cost
MHRA, Medicines and Healthcare products Regulatory Agency.
TABLE 41 Numbers of patients screened and randomised at each site
Site
Patients (n)
Screened Randomised
Altnagelvin Hospital 24 11
Antrim Hospital 20 4
Basildon University Hospital 28 5
Basingstoke and North Hampshire Hospital 6 3
Bradford Royal Infirmary 44 8
Broomfield Hospital (Chelmsford) 17 8
Calderdale Royal and Huddersfield Royal Infirmary 32 9
Castle Hill Hospital (Cottingham) 34 17
Chesterfield Royal Hospital 33 13
Colchester General Hospital 71 31
County Hospital – 10
Craigavon Area Hospital 17 6
Darent Valley Hospital (Dartford) 111 23
Diana, Princess Of Wales Hospital (Grimsby) 5 2
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TABLE 41 Numbers of patients screened and randomised at each site (continued )
Site
Patients (n)
Screened Randomised
Dorset County Hospital (Dorchester) 10 2
Ealing Hospital (Southall) 25 12
Frenchay Hospital (Bristol) – 3
George Eliot Hospital (Nuneaton) 16 6
Glan Clwd Hospital (Rhyl) – 1
Glangwili General Hospital 15 10
Gloucestershire Royal Hospital 22 5
Good Hope Hospital – 6
Grantham and District Hospital – 2
Great Western Hospital 28 13
Guy’s and St Thomas’ Hospital 20 17
Heartlands Hospital 36 21
Hereford County Hospital 16 7
Hillingdon Hospital 4 2
Kettering General Hospital 5 2
King’s College Hospital (Denmark Hill, London) – 4
King’s Mill Hospital (Sutton-in-Ashfield) – 25
Kingston Hospital (Kingston upon Thames) 17 4
Leicester Royal Infirmary – 7
Leighton Hospital (Crewe) 9 3
Lincoln County Hospital 28 11
Macclesfield District General Hospital 10 1
Manchester Royal Infirmary – 12
Medway Maritime Hospital (Gillingham) 35 26
Mid Yorkshire Hospitals 21 6
Milton Keynes Hospital 18 7
New Cross Hospital (Wolverhampton) – 9
North Bristol Hospital 4 0
North Devon District Hospital 5 0
North Middlesex University Hospital Trust (London) 15 10
Northampton General Hospital 53 19
Northwick Park Hospital (Harrow) 43 11
Pilgrim Hospital (Boston) – 7
Poole Hospital – 2
Princess Royal University Hospital (Orpington) 42 31
Queen Alexandra Hospital (Portsmouth) 123 51
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TABLE 41 Numbers of patients screened and randomised at each site (continued )
Site
Patients (n)
Screened Randomised
Queen Elizabeth Hospital (Birmingham) 14 13
Queen Elizabeth Hospital (King’s Lynn) 57 16
Queen Elizabeth Hospital (Woolwich) 10 3
Queen’s Hospital (Burton upon Trent) 18 6
Queen’s Hospital (Romford) 38 13
Royal Berkshire Hospital (Reading) 20 13
Royal Bournemouth Hospital – 3
Royal Devon and Exeter Hospital (Wonford, Exeter) 25 10
Royal Gwent Hospital (Newport) – 1
Royal Hallamshire Hospital (Sheffield) 29 6
Royal Hampshire County Hospital (Winchester) 17 7
Royal Liverpool University Hospital 6 4
Royal Shrewsbury Hospital 19 2
Royal Stoke University Hospital – 39
Royal Surrey County Hospital (Guildford) 11 7
Royal United Hospital (Bath) 33 12
Russells Hall Hospital – 38
Salisbury District Hospital 46 17
Sandwell General Hospital (West Bromwich) 58 25
Southampton General Hospital 26 14
Southend University Hospital 16 11
Southmead Hospital (Bristol) 18 14
St. Helier Hospital (Carshalton) 120 28
St James’s University Hospital (Leeds) 16 11
Stoke Mandeville Hospital 36 13
Sunderland Royal Hospital 19 6
Tameside General Hospital 1 0
Torbay Hospital 40 4
Ulster Hospital (Belfast) 37 18
University Hospital Coventry 57 32
University Hospital Lewisham (London) 11 5
Warrington Hospital – 8
Warwick Hospital 6 5
West Middlesex University Hospital (Isleworth) 38 17
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The number of reasons for screening failures are reported in Table 42.
TABLE 41 Numbers of patients screened and randomised at each site (continued )
Site
Patients (n)
Screened Randomised
Wexham Park Hospital (Slough) 11 5
Whipps Cross University Hospital (London) 7 4
Withybush General Hospital (Haverfordwest) 6 3
Wrexham Maelor Hospital 36 18
Wycombe Hospital (High Wycombe) 23 10
Wythenshawe Hospital (Manchester) 19 11
Total 2183 977
TABLE 42 Reasons for screening failure
Reason for screening failure n %
Declined, no reason given 278 23
Declined, too much going on 88 7
Not eligible/out of time window 290 24
Clinical decision 101 8
Location (e.g. moving to a new hospital) 36 3
Medication (e.g. did not want to take any more tablets or did not want to
take antibiotics when did not have an infection, etc.)
49 4
Did not want to participate in a clinical trial/already on another clinical trial 79 6.5
Inability to consent (e.g. language barrier/confusion) 44 4
Did not want to/could not take samples 21 2
Died 9 1
Not known 211 17.5
Total 1206 100
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Appendix 2 Details of serious adverse events
reported
TABLE 43 Summary of CTACE category of all SAEs reported, by treatment arm
System Organ Class ID/CTCAE category
Treatment arm, n (%)
Total, n (%)Levofloxacin Placebo
Missing System Organ Class ID/CTCAE 1 (0.2) 1 (0.2) 2 (0.2)
Infections and infestations 96 (18) 125 (26) 221 (21)
General disorders and administration site conditions 87 (16) 75 (15) 162 (16)
Gastrointestinal disorders 79 (15) 56 (11) 135 (13)
Respiratory, thoracic and mediastinal disorders 42 (8) 34 (7) 76 (7)
Cardiac disorders 32 (6) 31 (6) 63 (6)
Vascular disorders 28 (5) 24 (5) 52 (5)
Nervous system disorders 30 (6) 19 (4) 49 (5)
Musculoskeletal and connective tissue disorders 30 (6) 17 (3) 47 (5)
Renal and urinary disorders 29 (5) 16 (3) 45 (4)
Skin and subcutaneous tissue disorders 20 (4) 17 (3) 37 (4)
Metabolism and nutrition disorders 17 (3) 16 (3) 33 (3)
Blood and lymphatic system disorders 16 (3) 15 (3) 31 (3)
Investigations 17 (3) 13 (3) 30 (3)
Injury, poisoning and procedural complications 6 (1) 6 (1) 12 (1)
Psychiatric disorders 5 (1) 7 (1) 12 (1)
Immune system disorders 5 (1) 5 (1) 10 (1)
Ear and labyrinth disorders 2 (0.4) 2 (0.4) 4 (0.4)
Eye disorders 1 (0.2) 3 (0.6) 4 (0.4)
Hepatobiliary disorders 0 (0) 2 (0.4) 2 (0.2)
Endocrine disorders 0 (0) 1 (0.2) 1 (0.1)
Neoplasms benign, malignant and unspecified
(including cysts and polyps)
0 (0) 1 (0.2) 1 (0.1)
Reproductive system and breast disorders 0 (0) 1 (0.2) 1 (0.1)
Social circumstances 0 (0) 1 (0.2) 1 (0.1)
Surgical and medical procedures 1 (0.2) 0 (0.0) 1 (0.1)
Total 544 (100) 488 (100) 1032 (100)
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TABLE 44 Common Terminology Criteria for Adverse Events category and CTCAE term of all SAEs, by treatment arm
System Organ Class ID/CTCAE category
Treatment arm, n (%)
Total, n (%)Levofloxacin Placebo
Missing CTCAE 1 (0.2) 1 (0.2) 2 (0.2)
Infections and infestations 96 (18) 125 (26) 221 (21)
Lung infection 36 58 94
Infections and infestations – other, specify 19 26 45
Sepsis 19 19 38
Urinary tract infection 4 8 12
Bronchial infection 2 2 4
Soft tissue infection 1 3 4
Upper respiratory infection 2 2 4
Pharyngitis 2 1 3
Skin infection 2 1 3
Device-related infection 1 1 2
Phlebitis infective 1 1 2
Bladder infection 1 0 1
Endocarditis infective 0 1 1
Enterocolitis infectious 1 0 1
Joint infection 1 0 1
Kidney infection 1 0 1
Papulopustular rash 1 0 1
Pleural infection 0 1 1
Rash pustular 0 1 1
Small intestine infection 1 0 1
Tooth infection 1 0 1
General disorders and administration site conditions 87 (16) 75 (15) 162 (16)
Fever 53 56 109
Fatigue 6 6 12
Chills 5 4 9
Pain 5 4 9
Oedema limbs 6 1 7
Malaise 3 2 5
Non-cardiac chest pain 3 1 4
Flu-like symptoms 2 0 2
Oedema face 0 1 1
Oedema trunk 1 0 1
Infusion-related reaction 1 0 1
Localised oedema 1 0 1
Multiorgan failure 1 0 1
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TABLE 44 Common Terminology Criteria for Adverse Events category and CTCAE term of all SAEs, by treatment arm
(continued )
System Organ Class ID/CTCAE category
Treatment arm, n (%)
Total, n (%)Levofloxacin Placebo
Gastrointestinal disorders 79 (15) 56 (11) 135 (13)
Diarrhoea 17 20 37
Vomiting 14 11 25
Constipation 12 6 18
Nausea 14 3 17
Abdominal pain 3 9 12
Colonic perforation 5 0 5
Abdominal distension 2 2 4
Dysphagia 1 2 3
Gastrointestinal disorders – other, specify 1 2 3
Oral pain 2 0 2
Dental caries 1 0 1
Duodenal haemorrhage 1 0 1
Duodenal perforation 1 0 1
Duodenal ulcer 1 0 1
Faecal incontinence 1 0 1
Mucositis oral 1 0 1
Obstruction gastric 1 0 1
Rectal haemorrhage 0 1 1
Upper gastrointestinal haemorrhage 1 0 1
Respiratory, thoracic and mediastinal disorders 42 (8) 34 (7) 76 (7)
Dyspnoea 22 12 34
Cough 11 9 20
Hypoxia 1 3 4
Pleural effusion 3 1 4
Productive cough 0 4 4
Respiratory, thoracic and mediastinal disorders –
other, specify
1 2 3
Pulmonary oedema 0 2 2
Aspiration 1 0 1
Bronchospasm 1 0 1
Laryngeal inflammation 1 0 1
Pneumothorax 0 1 1
Respiratory failure 1 0 1
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TABLE 44 Common Terminology Criteria for Adverse Events category and CTCAE term of all SAEs, by treatment arm
(continued)
System Organ Class ID/CTCAE category
Treatment arm, n (%)
Total, n (%)Levofloxacin Placebo
Cardiac disorders 32 (6) 31 (6) 63 (6)
AF 11 10 21
Chest pain – cardiac 2 5 7
Cardiac arrest 2 3 5
Sinus bradycardia 3 2 5
Cardiac disorders – other, specify 1 3 4
Heart failure 4 0 4
Myocardial infarction 1 3 4
Acute coronary syndrome 1 2 3
Supraventricular tachycardia 3 0 3
Sinus tachycardia 1 1 2
Asystole 0 1 1
Atrial flutter 1 0 1
Atrioventricular block first degree 1 0 1
Palpitations 1 0 1
Ventricular arrhythmia 0 1 1
Vascular disorders 28 (5) 24 (5) 52 (5)
Thromboembolic event 14 18 32
Hypotension 13 4 17
Haematoma 0 1 1
Hypertension 1 0 1
Vascular disorders – other, specify 0 1 1
Nervous system disorders 30 (6) 19 (4) 49 (5)
Dizziness 6 6 12
Syncope 5 1 6
Nervous system disorders – other, specify 3 1 4
Vasovagal reaction 4 0 4
Depressed level of consciousness 1 2 3
Peripheral sensory neuropathy 3 0 3
Seizure 1 2 3
Headache 1 1 2
Lethargy 2 0 2
Peripheral motor neuropathy 1 1 2
Stroke 2 0 2
Ataxia 0 1 1
Dysphasia 0 1 1
Encephalopathy 0 1 1
Ischaemia cerebrovascular 0 1 1
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TABLE 44 Common Terminology Criteria for Adverse Events category and CTCAE term of all SAEs, by treatment arm
(continued )
System Organ Class ID/CTCAE category
Treatment arm, n (%)
Total, n (%)Levofloxacin Placebo
Paraesthesia 0 1 1
Tremor 1 0 1
Musculoskeletal and connective tissue disorders 30 (6) 17 (3) 47 (5)
Back pain 9 8 17
Musculoskeletal and connective tissue disorder –
other, specify
5 3 8
Bone pain 3 0 3
Chest wall pain 1 2 3
Generalised muscle weakness 2 1 3
Pain in extremity 2 1 3
Arthritis 2 0 2
Muscle weakness lower limb 2 0 2
Myalgia 2 0 2
Flank pain 1 0 1
Joint range of motion decreased cervical spine 0 1 1
Muscle weakness right-sided 0 1 1
Neck pain 1 0 1
Renal and urinary disorders 29 (5) 16 (3) 45 (4)
Acute kidney injury 20 13 33
Urinary retention 4 1 5
Chronic kidney disease 1 1 2
Cystitis non-infective 1 0 1
Renal and urinary disorders – other, specify 0 1 1
Urinary frequency 1 0 1
Urinary incontinence 1 0 1
Urinary tract pain 1 0 1
Skin and subcutaneous tissue disorders 20 (4) 17 (3) 37 (4)
Rash maculopapular 13 10 23
Skin and subcutaneous tissue disorders – other,
specify
3 1 4
Erythroderma 1 1 2
Pruritus 2 0 2
Stevens–Johnson syndrome 0 2 2
Dry skin 1 0 1
Palmar–plantar erythrodysaesthesia syndrome 0 1 1
Skin ulceration 0 1 1
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TABLE 44 Common Terminology Criteria for Adverse Events category and CTCAE term of all SAEs, by treatment arm
(continued)
System Organ Class ID/CTCAE category
Treatment arm, n (%)
Total, n (%)Levofloxacin Placebo
Metabolism and nutrition disorders 17 (3) 16 (3) 33 (3)
Dehydration 1 6 7
Hyponatraemia 3 3 6
Hypocalcaemia 2 3 5
Hyperkalaemia 2 1 3
Acidosis 2 0 2
Anorexia 1 1 2
Hyperglyacemia 2 0 2
Hypokalaemia 2 0 2
Hypercalcaemia 1 0 1
Hypernatraemia 0 1 1
Hypoglycaemia 0 1 1
Hypomagnesaemia 1 0 1
Blood and lymphatic system disorders 16 (3) 15 (3) 31 (3)
Anaemia 13 8 21
Febrile neutropenia 2 6 8
Blood and lymphatic system disorders – other, specify 1 1 2
Investigations 17 (3) 13 (3) 30 (3)
Neutrophil count decreased 4 4 8
Creatinine increased 5 2 7
Alanine aminotransferase increased 3 2 5
Alkaline phosphatase increased 2 1 3
Investigations – other, specify 2 1 3
Cardiac troponin I increased 0 2 2
Electrocardiogram QT corrected interval prolonged 0 1 1
Platelet count decreased 1 0 1
Injury, poisoning and procedural complications 6 (1) 6 (1) 12 (1)
Fall 2 5 7
Fracture 3 1 4
Vascular access complication 1 0 1
Psychiatric disorders 5 (1) 7 (1) 12 (1)
Confusion 2 5 7
Delirium 1 1 2
Hallucinations 1 0 1
Restlessness 0 1 1
Suicide attempt 1 0 1
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Table 45 shows all SARs that were reported to the trial office. A total of 106 symptoms (69 for patients on
levofloxacin and 37 for patients on placebo) were reported for the 60 SARs (38 events on levofloxacin and
22 events on placebo) between the start of treatment and up to 30 days post treatment.
TABLE 44 Common Terminology Criteria for Adverse Events category and CTCAE term of all SAEs, by treatment arm
(continued )
System Organ Class ID/CTCAE category
Treatment arm, n (%)
Total, n (%)Levofloxacin Placebo
Immune system disorders 5 (1) 5 (1) 10 (1)
Allergic reaction 5 5 10
Ear and labyrinth disorders 2 (0.4) 2 (0.4) 4 (0.4)
Vertigo 1 1 2
Ear and labyrinth disorders – other, specify 0 1 1
Ear pain 1 0 1
Eye disorders 1 (0.2) 3 (0.6) 4 (0.4)
Eye disorders – other, specify 1 2 3
Retinal vascular disorder 0 1 1
Hepatobiliary disorders 0 (0) 2 (0.4) 2 (0.2)
Hepatic failure 0 1 1
Hepatobiliary disorders – other, specify 0 1 1
Endocrine disorders 0 (0) 1 (0.2) 1 (0.1)
Endocrine disorders – other, specify 0 1 1
Neoplasms benign, malignant and unspecified
(including cysts and polyps)
0 (0) 1 (0.2) 1 (0.1)
Neoplasms benign, malignant and unspecified
(including cysts and polyps) – other, specify
0 1 1
Reproductive system and breast disorders 0 (0) 1 (0.2) 1 (0.1)
Testicular pain 0 1 1
Social circumstances 0 (0) 1 (0.2) 1 (0.1)
Social circumstances – other, specify 0 1 1
Surgical and medical procedures 1 (0.2) 0 (0.0) 1 (0.1)
Surgical and medical procedures – other, specify 1 0 1
Total 544 (100) 488 (100) 1032 (100)
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TABLE 45 Common Terminology Criteria for Adverse Events category for SARs, by treatment arm
System Organ Class ID/CTCAE category
Treatment arm, n (%)
Total, n (%)Levofloxacin Placebo
Missing System Organ Class ID/CTCAE 0 (0) 1 (3) 1 (1)
Gastrointestinal disorders 15 (22) 12 (32) 27 (25)
Skin and subcutaneous tissue disorders 9 (13) 5 (14) 14 (13)
General disorders and administration site conditions 6 (9) 5 (14) 11 (10)
Infections and infestations 7 (10) 2 (5) 9 (8)
Musculoskeletal and connective tissue disorders 7 (10) 1 (3) 8 (8)
Renal and urinary disorders 5 (7) 2 (5) 7 (7)
Blood and lymphatic system disorders 5 (7) 0 (0) 5 (5)
Cardiac disorders 3 (4) 1 (3) 4 (4)
Investigations 3 (4) 1 (3) 4 (4)
Metabolism and nutrition disorders 1 (1) 3 (8) 4 (4)
Nervous system disorders 3 (4) 0 (0) 3 (3)
Immune system disorders 1 (1) 1 (3) 2 (2)
Psychiatric disorders 2 (3) 0 (0) 2 (2)
Vascular disorders 1 (1) 1 (3) 2 (2)
Ear and labyrinth disorders 0 (0) 1 (3) 1 (1)
Injury, poisoning and procedural complications 1 (1) 0 (0) 1 (1)
Respiratory, thoracic and mediastinal disorders 0 (0) 1 (3) 1 (1)
Total 69 (100) 37 (100) 106 (100)
TABLE 46 Common Terminology Criteria for Adverse Events category and CTCAE terms for SARs, by treatment arm
System Organ Class ID/CTCAE category
Treatment arm, n (%)
Total, n (%)Levofloxacin Placebo
Missing System Organ Class ID/CTCAE 0 (0) 1 (3) 1 (1)
Gastrointestinal disorders 15 (22) 12 (32) 27 (25)
Diarrhoea 5 9 14
Vomiting 4 1 5
Nausea 4 0 4
Abdominal distension 1 0 1
Abdominal pain 0 1 1
Gastrointestinal disorders – other, specify 0 1 1
Obstruction gastric 1 0 1
Skin and subcutaneous tissue disorders 9 (13) 5 (14) 14 (13)
Missing CTCAE term 0 1 1
Rash maculopapular 6 1 7
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TABLE 46 Common Terminology Criteria for Adverse Events category and CTCAE terms for SARs, by treatment arm
(continued )
System Organ Class ID/CTCAE category
Treatment arm, n (%)
Total, n (%)Levofloxacin Placebo
Skin and subcutaneous tissue disorders – other, specify 2 0 2
Erythroderma 0 1 1
Pruritus 1 0 1
Skin ulceration 0 1 1
Stevens–Johnson syndrome 0 1 1
General disorders and administration site conditions 6 (9) 5 (14) 11 (10)
Fever 5 5 10
Chills 1 0 1
Infections and infestations 7 (10) 2 (5) 9 (8)
Sepsis 2 1 3
Lung infection 2 0 2
Bladder infection 1 0 1
Enterocolitis infectious 1 0 1
Rash pustular 0 1 1
Small intestine infection 1 0 1
Musculoskeletal and connective tissue disorders 7 (10) 1 (3) 8 (8)
Musculoskeletal and connective tissue disorder –
other, specify
4 0 4
Chest wall pain 0 1 1
Myalgia 1 0 1
Neck pain 1 0 1
Pain in extremity 1 0 1
Renal and urinary disorders 5 (7) 2 (5) 7 (7)
Acute kidney injury 4 2 6
Chronic kidney disease 1 0 1
Blood and lymphatic system disorders 5 (7) 0 (0) 5 (5)
Anaemia 4 0 4
Febrile neutropenia 1 0 1
Cardiac disorders 3 (4) 1 (3) 4 (4)
AF 2 0 2
Sinus bradycardia 1 1 2
Investigations 3 (4) 1 (3) 4 (4)
Alanine aminotransferase increased 1 1 2
Creatinine increased 1 0 1
Neutrophil count decreased 1 0 1
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TABLE 46 Common Terminology Criteria for Adverse Events category and CTCAE terms for SARs, by treatment arm
(continued )
System Organ Class ID/CTCAE category
Treatment arm, n (%)
Total, n (%)Levofloxacin Placebo
Metabolism and nutrition disorders 1 (1) 3 (8) 4 (4)
Anorexia 1 0 1
Dehydration 1 0 1
Hypernatraemia 1 0 1
Hyponatraemia 0 1 1
Nervous system disorders 3 (4) 0 (0) 3 (3)
Dizziness 1 0 1
Peripheral sensory neuropathy 1 0 1
Vasovagal reaction 1 0 1
Immune system disorders 1 (1) 1 (3) 2 (2)
Allergic reaction 1 1 2
Psychiatric disorders 2 (3) 0 (0) 2 (2)
Confusion 1 0 1
Delirium 1 0 1
Vascular disorders 1 (1) 1 (3) 2 (2)
Hypotension 1 1 2
Ear and labyrinth disorders 0 (0) 1 (3) 1 (1)
Vertigo 0 1 1
Injury, poisoning and procedural complications 1 (1) 0 (0) 1 (1)
Vascular access complication 1 0 1
Respiratory, thoracic and mediastinal disorders 0 (0) 1 (3) 1 (1)
Hypoxia 0 1 1
Total 69 (100) 37 (100) 106 (100)
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Appendix 3 Health economic tables
TABLE 47 Unit costs
Resource item Unit cost (£) Source Details
Trial medication
Levofloxacin 250 mg 11.57
(per 10-tablet pack)
BNF 2017 Normal dose: two tablets per day
Moderate renal failure: one tablet per
day
Severe renal failure: half tablet per day
Levofloxacin 500 mg 11.40
(per 10-tablet pack)
BNF 2017
Community health and social services
GP visit, surgery 36.00 (per visit) PSSRU 2016, p. 14545 Per patient contact lasting 9.22 minutes,
including direct care staff costs
GP visit, home 82.76 (per visit) PSSRU 2016, p. 14545 Per patient contact lasting 9.22 minutes
(plus an average 12-minute travel time)
× £3.90/minute
Telephone GP 14.60 PSSRU 2016, p. 14745 Telephone triage, GP led, per clinician
consultation lasting 4 minutes
District nurse visit 38.00 (per visit) NHS Reference Costs
2015 to 201646
District nurse, adult, face to face.
CC: N02AF; SC: NURS
Practice nurse visit 12.14 (per visit) PSSRU 2015, p. 17443
PSSRU 2016, p. 14345
Per 15.5-minute consultation,43 based
on £43.00 per hour45
Home help or care worker
visit
24.00 (per visit) PSSRU 2016, p. 16045 Face-to-face 1-hour weekday session
Acupuncture 120 NHS Reference Costs
2015 to 201646
General medicine: acupuncture for pain
management CC: AB23Z; SC: 300
Telephone call with research/
specialist nurse
7.90 PSSRU 2016, p. 14745 Telephone triage, nurse led, per
telephone consultation lasting
6.56 minutes
Chiropodist/podiatrist 32.00 PSSRU 2016, p. 135–745 Chiropodist/podiatrist band 5, face to
face, 1 hour
Specialist nurse 44.00 PSSRU 2016, p. 186–845 Nurse specialist band 6, 1 hour
Counsellor 42.00 PSSRU 2016, p. 135–745 Counsellor band 6, face to face,
1 hour
Day care 61.00 PSSRU 2016, p. 2845 Local authority provision day care per
client attendance
Occupational therapist 32.00 PSSRU 2016, p. 135–745 Occupational therapist band 5, face to
face, 1 hour
Physiotherapy 32.00 PSSRU 2016, p. 135–745 Physiotherapist band 5, face to face,
1 hour
Psychologist 52.00 PSSRU 2016, p. 135–745 Clinical psychologist band 7, face to
face, 1 hour
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TABLE 47 Unit costs (continued )
Resource item Unit cost (£) Source Details
Phlebotomy 61.00
(58.00 + 3.00)
NHS Reference Costs
2015 to 201646
PSSRU 2015, p. 16943
Phlebotomy DAPS08 and community
nurse (1 hour)
Palliative care nurse 136.00 NHS Reference Costs
2015 to 201646
Medical specialist palliative care SD04A
Palliative care
(non-medical)
69.00 NHS Reference Costs
2015 to 201646
Non-medical specialist palliative care
(other)
Telephone occupational
therapist
18.00 NHS Reference Costs
2015 to 201646
Occupational therapy, consultant led,
not admitted, non-face to face, first
Social worker 55.00 PSSRU 2016, p. 15645 Social worker per hour of client-related
work
Health visitor – postnatal 68.55 NHS Reference Costs
2015 to 201646
Community midwife, post-natal visit
N01P
Rapid response 79.00 PSSRU 2016, p. 10145 Per hour of service
Dentist (band 1) 51.75 PSSRU 2015, p. 18143 Dentist 15 minutes at £207.00 per
patient hour
Dentist (band 2) 207.00 PSSRU 2015, p. 18143 Per patient hour
Hearing centre 63.00 NHS Reference Costs
2015 to 201646
Audiometry or hearing assessment,
≥ 19 years CC: CA37A
Telephone 111 8.00 www.bbc.co.uk/news/
health-22370621
(accessed 22 May 2017)
£7.50–8.50 per call
Blood test 15.14
(12.14 + 3.00)
NHS Reference Costs
2015 to 201646
15.5-minute consultation with practice
nurse (PSSRU 201543) at £43.00 per
hour plus blood test at £3.00
Directly accessed pathology services –
haematology CC: DAPS05
Hospital based or residential care services
Hospital inpatient 298.41 (per day) NHS Reference Costs
2015 to 201646
Total Healthcare Resource Groups,
average of all non-elective inpatient
excess bed-days
Hospital critical/intensive
care unit
521.00 (per day) NHS Reference Costs
2015 to 201646
Medical adult patients (unspecified
speciality), adult critical care, zero
organs supported, CC: XC07Z;
SC: CCU03
Hospital short stay
(hospital stay of 1 day)
478.00 NHS Reference Costs
2015 to 201646
Non-elective short stay, malignant
disorders of lymphatic or
haematological systems
Hospital long stay
(hospital stay of 2–5 days)
4850.00 NHS Reference Costs
2015 to 201646
Non-elective long stay, malignant
disorders of lymphatic or
haematological systems
Hospital excess bed-days
(cost per day after first
5 days)
338.00 (per day) NHS Reference Costs
2015 to 201646
Non-elective excess bed-days,
malignant disorders of lymphatic or
haematological systems
Hospital outpatient 135.00 (per visit) PSSRU 2016, p. 9545 Weighted average of all outpatient
attendances
A&E 137.74 (per visit) NHS Reference Costs
2015 to 201646
Emergency medicine, average unit
costs of all emergency medicine
attendances
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TABLE 47 Unit costs (continued )
Resource item Unit cost (£) Source Details
Residential home 90.00 (per day) PSSRU 2016, p. 2645 Private sector residential home cost per
permanent resident day
Paramedic 181.00 NHS Reference Costs
2015 to 201646
Ambulance: see and treat or refer
ASS01
Ambulance 236.00 NHS Reference Costs
2015 to 201646
Ambulance: see, treat and convey
ASS02
Dialysis 133.36 NHS Reference Costs
2015 to 201646
Renal dialysis
Mammogram 30.00 NHS Reference Costs
2015 to 201646
Direct access plain film
Chest radiograph 30.00 NHS Reference Costs
2015 to 201646
Direct access plain film
A&E, accident and emergency; CC, currency code; SC, service code.
TABLE 48 Average resource use per patient in each treatment arm
Resource use,
mean (SD)
Treatment arm
Levofloxacin Placebo
Week 4 Week 8 Week 12 Week 16 Week 4 Week 8 Week 12 Week 16
Resources use data from resource use questionnaire only
n valid (missing) 450
(39)
412
(77)
394
(95)
374
(115)
437
(51)
405
(83)
385
(103)
368
(120)
GP 0.38
(0.76)
0.32
(0.73)
0.23
(0.59)
0.22
(0.54)
0.31
(0.62)
0.32
(0.9)
0.32
(0.74)
0.31
(0.69)
Nurse 0.88
(3.0)
1.03
(3.72)
0.81
(3.44)
0.71
(3.3)
0.84
(3.26)
0.78
(3.43)
0.79
(3.49)
0.58
(2.62)
Care worker 0.51
(3.24)
0.71
(5.52)
0.45
(3.02)
0.66
(1.20)
0.49
(3.52)
0.45
(2.94)
0.39
(3.04)
0.5
(4.07)
Hospital outpatient 2.88
(2.70)
3.14
(2.96)
2.99
(2.74)
2.78
(2.66)
2.79
(2.64)
2.92
(2.84)
2.76
(2.80)
2.82
(3.01)
Hospital A&E 0.29
(0.65)
0.15
(0.42)
0.12
(0.43)
0.12
(0.81)
0.23
(0.49)
0.13
(0.39)
0.12
(0.36)
0.11
(0.41)
Residential care 0.12
(1.28)
0.14
(1.91)
0.03
(0.61)
0.08
(1.45)
0.14
(1.97)
0.02
(0.36)
0.09
(1.48)
0.09
(1.58)
Resource use data combined from resource use questionnaire and hospital data
n valid (missing) 458
(31)
446
(43)
440
(49)
423
(66)
444
(44)
428
(60)
421
(67)
414
(74)
Hospital inpatient days 3.10
(6.02)
1.83
(5.5)
1.59
(5.28)
0.84
(3.61)
3.02
(6.54)
1.40
(5.61)
0.71
(2.58)
1.0
(4.26)
Resource use data from hospital data onlya
n 3 1 0 0 4 2 2 0
Hospital ICU days 5.33
(4.04)
9 (–) – – 14.75
(15.63)
19
(12.73)
2.5
(0.71)
–
A&E, accident and emergency; ICU, intensive care unit.
a As ICU admissions were from hospital data, the study reports only for those patients who experienced an ICU admission.
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TABLE 49 Average health-care costs, by treatment arm
Total costs (£),
mean (SD)
Treatment arm
Levofloxacin Placebo
Week 4 Week 8 Week 12 Week 16 Week 4 Week 8 Week 12 Week 16
Community health and social services
GP 13.68
(27.4)
11.62
(26.22)
8.41
(21.22)
7.89
(19.55)
11.12
(22.43)
11.38
(28.41)
11.10
(26.48)
11.05
(24.67)
Nurse 33.52
(113.91)
39.2
(141.55)
30.86
(130.74)
26.82
(125.43)
32.09
(123.93)
29.56
(130.49)
30.2
(132.5)
21.89
(99.53)
Care worker 12.16
(77.69)
17.01
(132.57)
10.72
(72.37)
15.72
(100.87)
11.81
(84.6)
10.79
(70.58)
9.29
(73.03)
12
(97.64)
Other community
health and social
services
7.76
(75.28)
6.08
(30.98)
7.21
(44.75)
9.11
(67.84)
6.73
(35.0)
2.85
(27.39)
4.48
(30.98)
1.82
(11.25)
Total community
health and social
services
67.12
(171.06)
73.91
(225.25)
57.20
(171.32)
59.55
(201.11)
61.74
(159.69)
54.57
(160.64)
55.47
(172.5)
46.77
(157.83)
Hospital and residential care services
Hospital outpatient 388.2
(365.05)
424.0
(399.76)
404.31
(369.62)
375.76
(359.66)
376.58
(355.81)
394
(383.04)
372.04
(378.16)
380.42
(406.21)
Hospital A&E 39.49
(90.08)
20.06
(57.35)
16.78
(59.02)
16.20
(111.14)
31.20
(66.81)
17.35
(53.34)
16.46
(49.95)
15.35
(55.89)
Residential care 10.4
(115.01)
12.23
(172.3)
2.97
(54.59)
6.98
(130.38)
12.15
(177.56)
2.22
(32.21)
8.42
(133.48)
8.32
(141.94)
Hospital inpatient 926.50
(1797.03)
544.63
(1640.47)
474.07
(1577.02)
249.73
(1076.89)
899.93
(1951.76)
419.03
(1675.11)
212.64
(770.52)
296.97
(1271.14)
Hospital ICU 2778.67
(2105.60)
4689 (–) – – 7684.75
(8142.45)
9899
(6631.25)
1302.50
(368.40)
–
Total hospital and
residential care
services
1376.39
(1831.68)
980.11
(1776.04)
853.86
(1598.18)
602.47
(1155.14)
1382.89
(2301.84)
860.36
(1828.71)
582.30
(864.11)
660.02
(1327.55)
n valid (missing) 458 (31) 446 (43) 440 (49) 423 (66) 444 (44) 428 (60) 421 (67) 414 (74)
Trial medication 54.49
(21.46)
56.25
(28.32)
53.41
(31.42)
– 0 (0) 0 (0) 0 (0) –
n valid (missing) 469 (20) 469 (20) 469 (20) – 461 (27) 461 (27) 461 (27) –
Total NHS cost 1463.01
(1831.86)
1053.22
(1776.57)
902.53
(1579.09)
655.11
(1171.37)
1390.42
(2279.26)
846.71
(1789.82)
578.11
(867.72)
701.59
(1332.62)
A&E, accident and emergency; ICU, intensive care unit.
APPENDIX 3
NIHR Journals Library www.journalslibrary.nihr.ac.uk
94

EME
HS&DR
HTA
PGfAR
PHR
Part of the NIHR Journals Library
www.journalslibrary.nihr.ac.uk
This report presents independent research funded by the National Institute for Health Research (NIHR).  
The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the  
Department of Health and Social Care
Published by the NIHR Journals Library
